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Endocrine organs play a critical role in physiology, growth, and metabolism 
through secretion of hormones. For example, the hypothalamus controls 
production of hormones from the pituitary gland to regulate homeostasis, the 
pancreas produces insulin and glucagon to control blood glucose levels, and 
the placenta produces hormones necessary for the establishment and 
maintenance of pregnancy. These organs require a vascular network for 
hormone secretion in addition to supplying oxygen and nutrients and removing 
metabolic wastes. Epidermal growth factor like domain 7 (Egfl7) is a secreted 
angiogenic factor important for vascular development. In this thesis, I have 
analyzed a role for Egfl7 in the development of two endocrine organs, the 
pancreas and placenta.  
 
The first set of studies elucidates a role for Egfl7 in pancreatic development. 
Endothelial specific overexpression of Egfl7 using a transgenic mouse model 
resulted in increased pancreatic progenitor cell proliferation and decreased 
differentiation toward insulin-positive endocrine cells. These results were 
concomitant with collaborative studies demonstrating the stage dependent role 
of EGFL7 in maintaining pancreatic progenitor self-renewal during directed 
differentiation of human embryonic stem cells (hESC) along the pancreatic cell 
lineage, a promising protocol to treat pancreas-associated disorders.   
 
The second set of studies elucidates a role for Egfl7 in normal and pathological 
placental development. Analysis of pathological placentation revealed that 
Egfl7 is downregulated in human preeclamptic term placentas, and in 
placentas of a mouse model of preeclampsia (PE), prior to the onset of clinical 
signs of the disease. In addition to placental endothelial cells, Egfl7 expression 
was uncovered in the trophoblast cell lineage. Analysis of Egfl7 loss-of-function 
placentas demonstrated a critical role for Egfl7 in patterning of the fetoplacental 
vasculature, resulting in reduced placental perfusion.  
 
Collectively, these studies have elucidated novel roles for Egfl7 during 
organogenesis of the pancreas and placenta. The stage dependent role of 
EGFL7 in hESC differentiation may enhance strategies used for treatment of 
diabetes mellitus, the seventh leading cause of death in the United States. The 
functional role of Egfl7 in placental development and its early downregulation in 
PE suggest that it could be a potential novel diagnostic tool and/or therapeutic 
target for treating PE.  
 iii	  
BIOGRAPHICAL SKETCH 
 
Lauretta Ann Lacko was born and raised in suburban Chicago, and 
graduated from Amos Alonzo Stagg High School in June 2004. Lauretta 
attended the University of Illinois at Urbana-Champaign, where was awarded 
the Jonathon Baldwin Turner Scholarship and honored as a James Scholar 
and an American Society of Animal Science Scholar. She earned her Bachelor 
of Science in Animal Sciences with a minor in Chemistry with honors in May 
2008. She was honored with the Bronze Tablet Award for graduating in the top 
3% of her class.   
Lauretta has an extensive and diverse research background in 
reproductive physiology. Her undergraduate thesis work involved optimizing 
artificial insemination and estrus resynchronization protocols in beef cattle. 
Lauretta was an ANSC-USDA Research intern at the Research Centre Foulum 
in Viborg, Denmark in 2006, where she examined lying behavior and its relation 
to early detection of lameness in dairy cattle under Dr. Lene Munksgaard, as 
well as studying thermoregulation mechanisms in mink kits. In addition to her 
studies, Lauretta was actively involved in working with faculty on maximizing 
study abroad experiences as a Learning Abroad and Global Awareness 
Program Leader. She aided in the establishment an exchange program 
between the University of Illinois and the National Taiwan University. 
Following her undergraduate studies, Lauretta was awarded a 
prestigious Fulbright Postgraduate Fellowship to study the role of progesterone 
receptors in breast cancer using a novel 3D in vitro model system in the 
laboratory of a leading breast cancer biologist, Dr. Christine Clarke, at the 
 iv	  
Westmead Institute for Cancer Research at the University of Sydney in 
Australia, from July 2008 through August 2009.  
In September of 2009, Lauretta entered the Physiology, Biophysics, and 
Systems Biology graduate program at Weill Cornell Graduate School of 
Medical Sciences. The following July, Lauretta became a member of the 
laboratory of Dr. Heidi Stuhlmann, and began her thesis research investigating 
the role of Epidermal Growth Factor Like Domain 7 (Egfl7) in pancreatic and 
placental development. She has presented her work annually at the Vincent 
DuVigneaud Graduate School Symposium at Weill Cornell, as well as at 
national and international conferences, including the North American Vascular 
Biology Organization (NAVBO) and the International Federation of Placenta 
Associations (IFPA). Lauretta has been awarded three best poster presentation 
awards as well as a best oral presentation award at local and national 
conferences. She was awarded the NIH T32 Developmental Biology training 
fellowship from 2011-2013. Lauretta has mentored two undergraduate summer 
students and two first-year rotation students, and has worked as a teaching 
assistant in the Summer Academy in Molecular Biology program for high 
school students.  
Lauretta’s Ph.D. work has resulted in three publications and a fourth in 
preparation. Following completion of her Ph.D., Lauretta plans to continue her 
training in scientific research in the field of reproductive physiology.  
 v 
This work is dedicated to my parents, Shirley and Tony Lacko,  
for their endless love and support, and their tireless encouragement of their 
little girl to dream big and keep asking ‘why’.  
 vi	  
ACKNOWLEDGMENTS 
 
I want to take this opportunity to express my gratitude, as I am truly 
lucky to have received a tremendous amount of support as I endeavored to 
complete my Ph.D.  
Firstly, I wish to thank my thesis advisor, Dr. Heidi Stuhlmann, for her 
guidance, support, and continuous encouragement. I am grateful for your 
mentorship and the opportunity to pursue a project outside of the current focus 
of the lab. Your constant reassuring words and mentoring and your enthusiasm 
for science provided a foundation for me to grow and mature as a scientist. 
Thank you. And thank you for always encouraging me to pursue ideas for new 
experiments. I also wish to thank my thesis committee members and faculty 
members at WCMC. I would like to thank Dr. Doris Herzlinger for the honorary 
membership in her lab, for constantly stimulating scientific discussion, and for 
her guidance and support throughout my graduate school career. I am grateful 
to Drs. Carl Blobel and Robin Davisson for their careful attention to my work 
and their guidance. I would like to acknowledge my committee chairperson and 
collaborator, Dr. Shuibing Chen, for allowing me to work on an exciting project 
with her lab and for her complimentary words. I would like to thank the PBSB 
chairperson, Dr. Harel Weinstein, for providing me the confidence to pursue my 
Ph.D. and for demonstrating a true passion for science and education.  
I am grateful for professors of my undergraduate education, Dr. Walter 
Hurley, Dr. White, and Dr. Katzenellenbogen, for taking the time to guide me as 
I ventured into a scientific career. I want to thank Drs. Dinny Graham and 
Christine Clarke, for their gracious mentoring and support throughout my 
 vii	  
Fulbright fellowship and showing me my true potential as a scientist. My time in 
your lab was life-changing. 
 Also deserving recognition are the past and present members of the 
Stuhlmann Laboratory, including Dr. Kathryn Bambino, Samantha Hinds, 
Abhijeet Sharma, Dr. Donna Nichol, and Dr. Pauline Ocaya. I owe many thanks 
to Dr. Kathryn Bambino for her constant moral support, scientific discussions, 
and for being a great friend and colleague. I want to thank Samantha Hinds for 
keeping a positive and organized atmosphere in the lab, and for her 
encouragement and ability to put our accomplishments into the big picture.   
Much of the work in my thesis could not have been done without the 
support of the core facilities at WCMC and MSKCC. I want to thank the 
MSKCC Transgenic Core Facility, Dr. Jason McCormack at the WCMC Cell 
Sorting Core, Drs. Jenny Xiang and Tuo Zhang at the WCMC Genomics Core 
Facility, and Lee Cohen-Gould and her team at the WCMC Electron 
Microscopy Core Facility. Furthermore, I would like to thank Nick Gale from 
Regeneron for the Egfl7 knockout ESCs. I would like to thank the funding 
sources for this work, including the NIH T32 Training Grant in developmental 
biology, March of Dimes (MOD #6-FY14-411), and the National Institutes of 
Health (R01 HL082098). I am also grateful for the friendships and support of 
my fellow PBSB students, including Peipei Guo and William Chang.  
 I would like to thank my parents for their unwavering support and for 
instilling in me the discipline and values needed to pursue higher education. I 
am forever grateful for their endless love and encouragement, and for all they 
sacrificed to give a better life to my brother and me. They are truly an 
inspiration. I owe endless gratitude to my brother, A.J., who has been a pillar in 
my education and in my life. I would like to thank my friends, Stephanie 
 viii	  
Richard, Megan Smyrniotis, Katie Rooney, and Sarah Blount, for their constant 
love and support.  
Finally, words cannot express the gratitude I have to my fiancé, Dr. 
Romulo Hurtado, without whom I could not have accomplished this work. I am 
eternally grateful for his support both scientifically and emotionally. I want to 
thank you for your mentorship, our scientific discussions, your technical advice, 
and our collaborative studies. I want to thank you for challenging me to my 
highest potential as a scientist and as a person. The confidence I’ve gained 
from your support has allowed me to achieve more than I’ve ever thought 
possible. Your patience is astounding. Dr. Romulo Hurtado: Thank you. I am 
truly lucky to have found you and cannot wait for the many scientific and life 
successes that are in our future.  
 
 ix	  
TABLE OF CONTENTS 
 
BIOGRAPHICAL SKETCH…………………………………………………………..iii 
DEDICATION………………………………………………………………………….v 
ACKNOWLEDGEMENTS……………………………………………………………vi 
TABLE OF CONTENTS……………………………………………………………..ix 
LIST OF FIGURES…………………………………………………………………..xii 
LIST OF TABLES……………………………………………………………………xiv 
LIST OF ABBREVIATIONS…………………………………………………………xv 
LIST OF SYMBOLS…………………………………………………………………xix 
 
CHAPTER 1: INTRODUCTION……………………………………………………..1 
1.1 Vasculogenesis and Angiogenesis……………………………………………..1 
1.2 Vascular lumen formation………………………………………………………..4 
1.3 Arterio-venous specification and vessel stabilization…………………………5 
1.4 Physiological and pathological angiogenesis………………………………….6 
1.5 Epidermal Growth Factor Like Domain 7………………………………………7 
1.6 Egfl7 expression and function…………………………………………………..8 
1.7 Egfl7 function in disease and vascular injury………………………………...11 
1.8 miR-126…………………………………………………………………………..13 
1.9 Egfl7 signaling pathways……………………………………………………….14 
1.10 Summary and significance……………………………………………………16 
Chapter 1 References……………………………………..………………………..18 
 
CHAPTER 2: ENDOTHELIAL CELLS CONTROL PANCREATIC CELL FATE 
AT DEFINED STAGES THROUGH EGFL7 SIGNALING (Kao D, Lacko 
LA, et al, Stem Cell Reports, 2015)………………………………………..24 
2.1 Rationale…………………………………………………………………………24 
2.2 Abstract…………………………………………………………………………..27 
2.3 Introduction………………………………………………………............……..27 
2.4 Results and discussion…………………………………………………………29 
2.4.1 Endothelial cells promote the proliferation of PDX1+ cells in the 
chemically defined environment…………………………………...29 
2.4.2 PDX1+ cells after co-culture with endothelial cells retain pancreatic 
progenitor signature gene expression…………………………….32 
2.4.3 Endothelial cells maintain human pancreatic progenitor self-
renewal by secreting EGFL7……..………………………..…..…..36  
2.4.4 Endothelial overexpression of Egfl7 in vivo increases proliferation 
of pancreatic progenitors……………………………………………41 
2.5 Materials and Methods…………………………………………………………58 
Chapter 2 References……………………………………..………………………..67 
 
 x	  
CHAPTER 3: NOVEL EXPRESSION OF EGFL7 IN PLACENTAL 
TROPHOBLAST AND ENDOTHELIAL CELLS AND ITS IMPLICATION 
IN PREECLAMPSIA (Lacko LA et al, Mechanisms of Development, 
2014)………………………………………………………………………….70 
3.1 Rationale…………………………………………………………………………70 
3.2 Abstract…………………………………………………………………………..72 
3.3 Introduction………………………………………………………............……..73 
3.4 Results……………………………………………………………………..........76 
3.4.1 Egfl7 is expressed by maternal and fetal endothelial cells in the 
mouse placenta throughout gestation…………………………….76 
3.4.2 Novel EGFL7 expression in placental trophoblast cells and the 
trophoblast cell lineage……………………………………………..77 
3.4.3 EGFL7 is expressed by fetal endothelial cells and trophoblast cells 
of human chorionic villi………………………..…..………………..82  
3.4.4 EGFL7 is downregulated in placentas of the BPH/5 mouse model 
of PE, prior to the onset of maternal signs of PE………………..84 
3.4.5 EGFL7 expression is significantly reduced in human preeclamptic 
placentas…………………………………………………………….86 
3.4.6 EGFL7 expression correlates with NOTCH signaling in normal and 
PE placentas……………………………………….………………..88 
3.5 Discussion…………………………………………………………………….....90 
3.6 Materials and Methods…………………………………………………………99 
Chapter 3 References……………………………………..………………………108 
 
CHAPTER 4: FETAL VASCULAR PATTERNING DEFECTS IN PLACENTAS 
WITH EGFL7 LOSS-OF-FUNCTION (Lacko LA et al, Developmental 
Biology, to be submitted)………………………………………………….114 
4.1 Rationale………………………………………………………………………..114 
4.2 Abstract…………………………………………………………………………116 
4.3 Introduction………………………………………………………............……117 
4.4 Results……………………………………………………………………........119 
4.4.1 Egfl7 loss-of-function results in reduced placental weights and 
embryonic lengths………………………………………………….119 
4.4.2 Egfl7 loss-of-function results in vascular patterning defects and 
reduced fetal blood space in the fetal labyrinth…………………123 
4.4.3 Altered vascular patterning results in reduced placental perfusion 
in Egfl7 loss-of-function placentas………………………..…..….126  
4.4.4 Egfl7 loss-of-function results in differential expression of genes 
involved in inflammatory response, extracellular matrix signaling 
and reproductive structure development………………………..128 
4.5 Discussion……………………………………………………………………...131 
4.6 Materials and Methods………………………………………………………..141 
Chapter 4 References……………………………………..………………………148 
 xi	  
 
CHAPTER 5: CONCLUSION AND FUTURE PERSPECTIVES……………..152 
5.1 Summary……………………………………………………………………….152 
5.2 Implications of Egfl7 signaling during pancreatic development…………..152 
5.3 Implications of Egfl7 signaling during placental development………….…153 
5.4 Conclusion……………………………………………………………………...156 
Chapter 5 References……………………………………..………………………158 
 
 
 xii	  
LIST OF FIGURES 
 
CHAPTER 1 
Figure 1.1 – Hallmarks of development of a functional vasculature…………….3 
 
CHAPTER 2 
Figure 2.1 – Role of endothelial cells in human pancreatic differentiation…...30 
Figure 2.2 – Cellular identity and differentiation potential of PDX1+ pancreatic 
progenitors expanded in endothelial cell niche…………………………………..34 
Figure 2.3 – Endothelial cells promote pancreatic progenitor proliferation by 
secretion of EGFL7………………………………………………………………….38 
Figure 2.4 – EGFL7 increases proliferation of pancreatic progenitors in both 
transgenic mice and explant cultures……………………………………………..42 
Supplemental Figure 2.1 – Endothelial cells play a stage-dependent role in 
pancreatic development…………………………………………………………….49 
Supplemental Figure 2.2 – Transcriptome analysis by RNA-seq…………….51 
Supplemental Figure 2.3 – Knockdown of EGFL7 in endothelial cells………53 
Supplemental Figure 2.4 – Effect of EGFL7 on endothelial cells in vitro and in 
vivo……………………………………………………………………………………55 
 
CHAPTER 3 
Figure 3.1 – Egfl7 is expressed by maternal and fetal endothelial cells in the 
mouse placenta…………………………………………………………………..….78 
Figure 3.2 – Egfl7 is expressed in the trophoblast cell lineage of the 
mouse…………………………………………………………………………………81 
Figure 3.3 – EGFL7 is expressed in endothelial cells and trophoblast cells of 
the human placenta………………………………………………………………....83 
Figure 3.4 – Egfl7 is downregulated in the placentas of the BPH/5 mouse 
model of preeclampsia……………………………………………………………...85 
Figure 3.5 – EGFL7 is significantly reduced in human preeclamptic 
placentas……………..………………………………………………………………87 
Figure 3.6 – Expression of NOTCH target genes and NOTCH receptors are 
downregulated in PE, concomitant with EGFL7……………………..…………..89 
Supplemental Figure 3.1 – Egfl7 transcript expression in E12.5 and E18.5 
mouse placentas…….………………………………………………………...…….96 
Supplemental Figure 3.2 – Egfl7 localizes to endothelial cells of E10.5 and 
E18.5 mouse placentas…….……………………………...…………………….....97 
Supplemental Figure 3.3 – Egfl7 expression in human placentas…….……..98 
 
CHAPTER 4 
Figure 4.1 – Egfl7 KO mice exhibit reduced placental weights and embryonic 
crown to rump lengths at E12.5………………………………………………….121 
 xiii	  
Figure 4.2 – Egfl7 KO placentas exhibit fetal labyrinth patterning defects and 
reduced fetal capillary blood space…………….……………………………….124 
Figure 4.3 – Egfl7 KO mice exhibit reduced perfusion of the placental fetal 
labyrinth…………………………………………………………………………….127 
Figure 4.4 – Transcriptional profiling of Egfl7 KO mouse placentas results in 
differential expression of genes related to immune function and extracellular 
matrix signaling…………………………………………………………………….130 
Supplemental Figure 4.1 – Egfl7 KO placentas do not exhibit defects in 
maternal decidua or junctional zone placental layer formation……………….136 
Supplemental Figure 4.2 – Egfl7 loss-of-function does not affect proliferation 
of placental cells…………………………………………………..……………….138 
Supplemental Figure 4.3 – Variable weights observed in late-stage Egfl7 KO 
embryos……….…………………………………………………..……………….139 
Supplemental Figure 4.4 – Transcriptional profiling of FACS sorted placental 
endothelial cells…………………………………………………..……………….140 
 
 
 
 
 
 
 
 
 
 xiv	  
LIST OF TABLES 
 
CHAPTER 2 
Supplemental Table 2.1 – List of genes highly expressed in MPECs……….56 
Supplemental Table 2.2 – Primer sequences used in pancreas study…..….57 
 
CHAPTER 3 
Supplemental Table 3.1 – Clinical characteristics of pregnancies for placentas 
studied………………………………………………………………………………..95 
 
CHAPTER 4 
Table 4.1 – Observed Mendelien ratios of Egfl7 intercross matings..…….…122 
Supplemental Table 4.1 – Real Time RT-PCR primers used in placental 
study…………………………………………………………………………………147 
 
 xv	  
LIST OF ABBREVIATIONS 
 
Akt Protein Kinase B 
Akt-HUVEC-CM Conditioned Medium from Akt-HUVECs 
Akt-HUVECs AKT-activated Human Umbilical Vein Endothelial Cells 
ANG1 Angiopoietin-1 
ANGPT2 Angiopoietin-2 
BJ human skin fibroblast cells 
bp base pairs 
BPH/5 Blood pressure high strain 5 
CASZ1 Castor zinc finger 1 
CCL13 Chemokine (C-C motif) Ligand 13 
CD31/PECAM1 Cluster of Differentiation 31/Platelet Endothelial Cell 
Adhesion Molecule 1 
CDX2 Caudal-type homeobox  2 
CK Cytokeratin 
CM Conditioned medium 
CNS Central nervous system 
COUP-TFII Chicken ovalbumin upstream promoter-transcription 
factor II 
Csf1 Colony stimulating factor 1 
DAPT N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (γ-secretase inhibitor) 
DE Definitive endoderm 
Dll4 Delta like protein 4 
DSL Delta, Serrate, Lag-2 
E Embryonic Day 
EC Endothelial Cell(s) 
ECM Extracellular matrix 
EdU 5-ethynyl-2’-deoxyuridine 
EGF Epidermal growth factor 
Egfl7 Epidermal growth factor like domain 7 
EGFP enhanced green fluorescent protein 
EGFR EGF receptor 
 xvi	  
ERG ETS related gene 
ERK Extracellular signal related kinase 
ESC Embryonic stem cells 
ETS E-twenty-six 
FACS Fluorescence activated cell sorting 
FAK Focal Adhesion Kinase 
FE Foregut endoderm 
FGF10 Fibroblast Growth Factor 10 
Fgf2 basic Fibroblast Growth Factor 
FOXA2 Forkhead box A2 
Fzd5 Frizzled class receptor 5 
GATA2 GATA binding protein 2 
Gcm1 Glial cells missing 1 
GFP Green fluorescent protein 
GO Gene Ontology 
GSIS Glucose Stimulated Insulin Secretion 
GTT Glucose Tolerance Test 
hESC Human embryonic stem cells 
Hey1/2 Hairy/enhancer of split related with YRPW motif 
protein 1/2 
HNF4α Hepatocyte Nuclear Factor 4 alpha 
HNF6 Hepatocyte Nuclear Factor 6 
HUVECs Human Umbilical Vein Endothelial Cells 
ICAM1 Intercellular adhesion molecule 1 
IL24 Interleukin-24 
iPSCs Induced pluripotent stem cells 
ISH In situ hybridization 
IUGR Intrauterine growth restriction 
kb Kilobase 
kDa KiloDalton 
Klf2a Kruppel like factor 2a 
KO Knockout 
MAPK Mitogen activated protein kinase 
MEF Mouse embryonic fibroblasts 
 xvii	  
mg milligram 
miR microRNA 
mL milliliter 
mm millimeter 
mm Hg Millimeters Mercury 
MPEC-CM Conditioned medium from MPECs 
MPECs Mouse pancreas islet endothelial cells 
mRNA messenger RNA 
NFκB Nuclear Factor Kappa-Light-Chain-Enhancer of 
activated B-Cells 
ng Nanogram 
NGN3 Neurogenin 3 
NKX6.1 NK6 homeobox 1 
p85β/PIK3R2 Phosphoinositide-3-Kinase Regulatory Subunit 2  
PDGF-BB Platelet derived growth factor homodimeric protein BB 
PDGFB Platelet derived growth factor B 
PDGFRβ Platelet derived growth factor receptor beta 
Pdx1 Pancreatic and duodenal homeobox 1 
PE Preeclampsia 
PI3K Phosphoinositide 3-kinase 
PLAU Plasminogen activator, Urokinase 
PlGF Placental growth factor 
PODXL Podocalyxin 
PP Pancreatic progenitor 
Prap1 Proline rich acidic protein 1 
Ptf1a Pancreas specific transcription factor 1a 
qRT-PCR Quantitative reverse transcription polymerase chain 
reaction 
Rasip1 Ras interacting protein 1 
RNA Ribonucleic acid 
RNA-Seq RNA sequencing 
ROCK Rho-associated protein kinase 
Rpbj Recombination Signal Binding Protein For 
Immunoglobulin Kappa J Region 
RT-PCR reverse transcription polymerase chain reaction 
 xviii	  
sEng Soluble Endoglin 
sFlt1 Soluble fms-like tyrosine kinase 1 
Shh Sonic Hedgehog 
shRNA Short hairpin RNA 
SOX17 Sex determining region Y (SRY)-box 17 
SOX9 Sex determining region Y (SRY)-box 9 
Spred1 Sprouty-related EVH1 domain containing 1 
TG Transgenic 
TGC Trophoblast giant cell 
TGFβ Transforming Growth Factor beta 
TIE2 Angiopoietin-1 Receptor/Tunica Interna Endothelial 
Cell Kinase 
Tmprss4 Transmembrane protease serine 4 
TSC Trophoblast stem cells 
VCAM1 Vascular cell adhesion molecule 1 
VEGF Vascular endothelial growth factor 
VEGF-A Vascular endothelial growth factor-A 
VEGFR2/KDR/Flk-1 VEGF Receptor 2/Kinase insert domain receptor/Fetal 
liver kinase-1 
WT Wild type 
  
 xix	  
LIST OF SYMBOLS 
 
α alpha or anti 
β beta 
γ gamma 
μ micro 
  
	  	   1	  
Chapter 1 – Introduction 
 
1.1 – Vasculogenesis and Angiogenesis 
 
Organogenesis requires a functional, arborized vascular network for proper 
development and homeostasis. The vasculature conducts blood in order to 
supply oxygen and nutrients to tissues while removing metabolic wastes, and is 
necessary for distant tissues to communicate. Abnormal vessel growth 
contributes to the pathology and progression of many diseases, such as cancer 
and myocardial infarction. Blood vessels form by two distinct processes, 
vasculogenesis and angiogenesis. Vasculogenesis, or the de novo formation of 
blood vessels during development, involves the differentiation of mesoderm-
derived angioblasts into endothelial cells that form a primitive vascular plexus 
(Figure 1.1) (1-3). Angiogenesis is the formation of blood vessels from pre-
existing vessels. Blood vessels are stabilized through recruitment of pericytes 
and smooth muscle cells to form a mature vascular network (Figure 1.1) (1-3).  
 
Blood vessel formation begins after gastrulation when mesodermal clusters of 
cells differentiate into angioblasts, or endothelial precursor cells, in the embryo. 
These cells proliferate, migrate to specified locations, and coalesce to form 
vascular cords (1-3). Vascular Endothelial Growth Factor-A (VEGF-A) is the 
predominant signaling molecule required for vascular development, and plays 
an important role in the migration of endothelial progenitor cells and the 
formation of the primitive vascular plexus (4). Indeed, loss of a single Vegfa 
allele results in embryonic lethality at midgestation (Embryonic Day 11.5-12.5) 
due to defective endothelial cell differentiation and irregular blood vessel 
development (5, 6). The importance of the VEGF signaling pathway during 
vascular development is further demonstrated by deficiency in VEGF-A’s two  
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predominant receptors, Flt-1/VEGFR1 and Flk-1/VEGFR2/KDR, resulting in the 
overgrowth or absence of a structured blood vessel network, respectively (7, 
8). 
 
The primitive vascular plexus expands and matures through branching and 
sprouting angiogenesis. Several elegant studies have elucidated the 
mechanism controlling angiogenesis (Reviewed in (2, 3, 9, 10)). In response to 
proangiogenic and chemotactic signaling molecules, certain endothelial cells 
acquire a tip cell phenotype, developing filopodia to sense environmental cues 
and becoming the leading migratory edge of a nascent vascular sprout (2, 9-
12). Tip cell expression of matrix metalloproteinases facilitates the degradation 
of the surrounding basement membrane proteins, allowing for the migration 
and invasion of endothelial cells (12). Adjacent to tip cells are endothelial stalk 
cells, which proliferate in order to elongate the vessel and also form lumens. 
Tip cells anastomose, often with the aid of macrophages, with neighboring 
vessel sprouts to build the branched, vascular network (1-3, 10, 11). Tip and 
stalk cell phenotypes are transient, and endothelial cells go through iterative 
cycles of sprouting and branching morphogenesis during vascular development 
(10, 13). Lateral inhibition and a negative feedback loop between VEGF 
signaling and NOTCH signaling are integrated to designate tip and stalk cell 
phenotypes (10). Notch signaling is an evolutionarily conserved pathway 
important for cell fate specification and branching morphogenesis, among other 
processes. Members of the Notch signaling pathway include five Delta-Serrate-
Lag2 (DSL) ligands (Jagged1, Jagged2, Delta-like1/3/4), as well as four 
transmembrane receptors (Notch1/2/3/4) (10). VEGF-A signaling through 
VEGFR2 induces Dll4 signaling in tip cells. Dll4/NOTCH signaling regulates 
tip/stalk cell fate specification as evidenced by increased number of tip cells 
and branching defects in Dll4-mutant mice (14). 
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FIGURE 1.1 Hallmarks of development of a functional vasculature. 
Borrowed from Potente et al, (2011) Cell 146(6): 873-887 
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1.2 – Vascular Lumen Formation 
 
Lumen formation is another important step required for normal vascular 
development, irrespective of the vessels arising from vasculogenesis or 
angiogenesis. Vascular lumen formation can occur by different mechanisms, 
which likely depend on the vascular bed, but require a few common, critical 
steps (3, 15, 16). The first step in vascular lumen formation is to establish 
apical-basal polarity in order to determine the luminal surface of the cells and 
then to rearrange their cell-cell junctions. In addition to several polarity and cell 
adhesion molecules, β1-integrin signaling plays an important role in this 
process, as β1-deficient mouse embryos have occluded lumens and 
mislocalized expression of the polarity molecule Par3, as well as the junctional 
molecule, VE-cadherin (17). Next, endothelial cell shape changes begin to 
establish a lumen. VEGF-A/VEGFR2 signaling activates Rho-associated 
protein kinase (ROCK) signaling, resulting in rearranging of non-muscle myosin 
II and F-actin fibers (16). Additionally, glycoproteins such as CD34 and 
Podocalyxin (PODXL) accumulate on the luminal side of the endothelial cells, 
and studies suggest they also recruit other proteins (Moesin and F-actin) to the 
apical surface and their repulsive charges facilitate tube formation (18). An 
endothelial specific regulator of GTPase signaling, Ras interacting protein 1 
(Rasip1), has been implicated tubulogenesis. Rasip1-deficient mice fail to form 
patent vascular lumens through dysregulation of cell polarity and cellular 
adhesion molecules (19). 
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1.3 Arterio-venous Specification and Vessel Stabilization 
 
The primitive vascular network must be specified into arteries and veins, which 
carry different hemodynamic loads. Arterial and venous endothelial cells are 
molecularly distinct, and the initial expression of arterial and venous markers 
occurs early during development (3, 20, 21). Eph-Ephrin signaling establishes 
arterio-venous boundaries. Analyses of Lacz knock-in mice demonstrated that 
Ephrin-B2 marks arterial endothelial cells while Eph-B4 is preferentially 
expressed by venous endothelial cells, prior to the onset of circulation (22). 
Ephrin-B2 and Eph-B4 may mark arterial and venous endothelial cells early. 
However, Eph-Ephrin signaling is not required for initial cell fate specification 
but arterio-venous maintenance and remodeling, as deficient mice exhibit 
defects in remodeling and not spatial localization of arteries and veins (21).  
 
Arterial endothelial cell specification is driven by a Sonic hedgehog (Shh)-
VEGF-Notch signaling pathway (21). Mutant mice of members of the Notch 
signaling pathway, including Dll4, Rpbj, and Hey1/Hey2 result in failed arterial 
differentiation and altered Ephrin-B2 and Eph-B4 expression (Reviewed in 
(21)). Venous specification requires nuclear receptor COUP-TFII (Chicken 
ovalbumin upstream promoter-transcription factor II) to repress Notch signaling. 
Furthermore, hemodynamic forces drive arterio-venous specification and 
maintenance (20). Arteries are covered by layers of vascular smooth muscle 
cells and carry a high-pressure gradient, while veins are low-pressure vessels 
encased by few smooth muscle cells.  
 
Blood vessels are stabilized via recruitment of vascular mural cells. Pericytes 
and smooth muscle cells interact with endothelial cells and engage in 
intercellular communication (23). Endothelial expressed Platelet-derived 
Growth Factor B (PDGFB) signals to its receptor, PDGFR-β, on vascular mural 
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cells, to stimulate their proliferation and recruitment to blood vessels (24). 
Indeed, PDGFB or PDGFR-β deficient mice exhibit hemorrhaging or embryonic 
lethality (24). Additionally, Angiopoeitin-1 (ANG1) activates its endothelial 
receptor, TIE2, to promote pericyte adhesion, stabilize vessels, and stimulate 
endothelial cell quiescence (25). Ang1 and Tie2 deficient mice exhibit reduced 
pericyte coverage, defective angiogenesis, and embryonic lethality (26, 27). 
 
Blood vessels mature through pruning and remodeling, in which the hierarchal, 
blood-conducting vascular system is formed and contains arteries, arterioles, 
capillaries, venules and veins. Tissue-specific phenotypes are further acquired 
to adapt to the specific requirements of that tissue, and endothelial cells 
become quiescent.  
 
1.4 – Physiological and Pathological Angiogenesis 
 
Although most endothelial cells in the adult are quiescent, they can become 
activated during physiological and pathological angiogenesis. Angiogenesis is 
required for normal physiologic processes such as the cyclic changes in the 
female reproductive tract, during wound healing, and in response to exercise 
(28-30). It is required for formation of the corpus luteum in the ovary, in the 
endometrium during the menstrual cycle, as well as in the uterus and placenta 
during pregnancy (28). New blood vessel formation is a critical requirement for 
wound repair and tissue regeneration (29). Increased vascularity in skeletal 
muscle is induced by exercise (30).  
 
Pathologic processes and diseases such as diabetic retinopathy, rheumatoid 
arthritis, and tumorigenesis also require angiogenesis. Abnormal retinal 
angiogenesis is implicated in diabetic patients, as diabetic retinopathy is one of 
the leading causes of blindness in the United States (31). Angiogenesis plays a 
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role in the invasiveness of the synovium and the development of rheumatoid 
arthritis (32). Furthermore, pathological angiogenesis in tumors has been 
shown to play a key role in tumor progression and metastasis, and has been a 
preferential target for therapeutic treatment (33).  
 
In addition to the signaling pathways mentioned above, many other factors play 
a role in regulating blood vessel development. Thus, it is important to elucidate 
the molecular mechanisms that control blood vessel formation during 
development, in order to understand pathological vascular development as well 
as to effectively treat patients in need of anti-angiogenic therapy.  
 
1.5 – Epidermal Growth Factor Like Domain 7  
 
Another angiogenic factor that has been implicated during vasculogenesis and 
angiogenesis is Epidermal Growth Factor Like Domain 7 (Egfl7), also known as 
VE-Statin, Zneu1, or Notch4-like protein. The Stuhlmann Lab identified Egfl7 
using a retroviral gene entrapment screen for genes with restricted expression 
during mouse embryogenesis and embryonic stem cell differentiation (34). 
Egfl7 was independently discovered by two other laboratories as a gene 
involved in early cardiovascular development (35, 36). EGFL7 is a unique 
angiogenic factor in that it is a secreted factor predominantly expressed by 
endothelial cells, while other secreted angiogenic factors, such as VEGF, are 
predominately expressed by non-endothelial cell types. The Egfl7 gene spans 
11.5kb on mouse chromosome 2 and human chromosome 9, and contains 11 
exons with the protein coding region extending from exon 3 to exon 10 (34, 35). 
A microRNA, miR-126, is embedded between exon 7 and exon 8 of Egfl7. The 
1.4kb Egfl7 transcript encodes a putative 278 amino acid, 29-kDa protein. The 
native EGFL7 protein runs at ~41kDa, suggesting posttranslational 
modifications of several potential N- and O-linked glycosylation sites (34, 35). 
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EGFL7 contains an N-terminal signal peptide, an EMI-like domain, and two 
centrally located EGF-like domains, one of which contains a region conserved 
in Notch ligands required for receptor binding, termed the DSL domain, and the 
second containing a calcium binding domain. Mouse EGFL7 is 73% identical to 
human, 88% identical to rat, and 45% identical to Xenopus laevis orthologs, 
including conservation of the signal peptide and EGF domains (34). 
 
The signal peptide domain within Egfl7 is common to many secreted proteins. 
When overexpressed in vitro, EGFL7 localizes to organelles of the secretory 
pathway, including the endoplasmic reticulum and the Golgi apparatus, and 
can be detected in conditioned medium from these cells (34, 35). Moreover, 
EGFL7 is found tightly associated with the extracellular matrix (ECM) (37). 
Fibronectin and type I collagen facilitate EGFL7 deposition into the ECM, 
supporting the notion that EGFL7 is associated with the ‘provisional matrix’, or 
the environment encountered by nascent blood vessels (38).   
 
1.6 – Egfl7 Expression and Function 
 
Egfl7 expression in largely restricted to actively proliferating endothelial cells, 
including endothelial cells undergoing vasculogenesis, physiological 
angiogenesis, and pathological angiogenesis. Egfl7 is also expressed in 
embryonic stem cells and neural stem cells, as well as in primordial germ cells, 
and pre- and peri-implantation embryos beginning at the 8-cell stage of 
development (34-36, 39, 40).  
 
Egfl7 is a marker of the endothelial cell lineage and their precursors, with an 
expression profile similar to, but preceding, Flk-1 (34, 41, 42). Egfl7 is 
expressed by endothelial progenitors of the developing embryo such as 
mesodermal cell clusters migrating from the posterior primitive streak, and of 
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extraembryonic tissues such as blood islands in the yolk sac (34-36, 41). Its 
expression becomes restricted to endothelial cells, peaking at E9.5 and 
becoming downregulated in the adult, quiescent endothelium (34, 36). Egfl7 is, 
however, expressed in the adult lung and kidney, albeit at low levels, as well as 
in both tip and stalk cells of the postnatal retina (38, 40, 41). 
 
Egfl7 is upregulated during physiological angiogenesis, such as in reproductive 
structures like the uterus, whose cyclic changes in angiogenesis supply the 
nutrients and hormones necessary for the establishment and maintenance of 
pregnancy (28, 36, 43). Egfl7 is also upregulated during pathological 
angiogenesis, such as in oxygen-induced retinopathy (41), vascular injury (43, 
44), and in several tumors (45-47). 
 
A role for EGFL7 has been demonstrated in key cellular processes involved in 
development and maturation of a stable, vascular network, such as 
proliferation, migration, adhesion, sprouting, and patterning (35, 36, 38, 40, 43, 
48). In vitro, knockdown of Egfl7 results in decreased proliferation of both 
embryonic stem cells (48) and Human Umbilical Vein Endothelial Cells 
(HUVECs) (40), and increased proliferation of neural stem cells (49). EGFL7 
affects migration by acting as a chemoattractant for endothelial cells (43) and 
inhibiting PDGF-BB induced aortic smooth muscle cell migration (35). Using in 
vitro angiogenesis assays, Egfl7 knockdown resulted in decreased migration of 
HUVECs, while overexpression and knockdown of Egfl7 resulted in aberrant or 
no capillary sprouting, respectively (40). 
 
Egfl7 functions to promote weak endothelial cell adhesion and a permissive 
environment for the migration and sprouting of endothelial cells (36, 37, 50, 
51). EGFL7 has been shown to bind to αVβ3 integrin on the ECM, but does not 
play a structural role in the matrix, resembling members of the ‘matricellular 
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proteins’ family (37, 52). EGFL7 promotes cell shape changes and mild 
adhesion of endothelial cells to the ECM via binding of αVβ3 integrin, activation 
of focal adhesion kinase (FAK), and upregulation of RhoA GTPase (36, 37, 50). 
In contrast to fibronectin and other traditional cell adhesion molecules that 
promote stress fiber formation and a non-migratory phenotype, EGFL7 
stimulates the development of filopodia, allowing endothelial cells to attach and 
migrate more efficiently. 
 
Additionally, EGFL7 has been shown to modulate ECM rigidity by blocking lysyl 
oxidase mediated conversion of tropoelastin to elastin through interaction with 
the enzyme’s catalytic site (51). Inhibition of elastin fiber deposition results in 
control of vascular elastogenesis, and provides a possible mechanism by 
which Egfl7 controls cell migration and invasion. In support, mature quiescent 
endothelial cells do not express Egfl7 but do accumulate elastin fibers, a 
mechanism in line with blood vessel development and maturation. 
 
In vivo studies in mice and zebrafish demonstrate that EGFL7 affects vascular 
patterning (36, 38, 40, 50). Endothelial specific overexpression of Egfl7 in mice 
results in abnormal vascular patterning and remodeling, including accumulation 
of endothelial cell aggregates, collapsed arterial vessels, hyperbranched and 
tortuous vessels in the head vasculature and postnatal retina, as well as 
aberrant positioning of endothelial and smooth muscle cells at branch points of 
the dorsal aorta (40). Egfl7 loss-of-function mice exhibited defects in the 
collective migration and spatial organization of endothelial cells, as well as 
hemorrhaging, vascular patterning, and partial embryonic lethality (36, 38). It is 
important to note, that studies involving Egfl7 knockout mice have been 
complicated by the presence of miR-126, which will be discussed in detail 
below. However, studies involving knockdown and overexpression of Egfl7  
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while maintaining miR-126 levels demonstrate that Egfl7 plays an important 
role during formation of a functioning vasculature (40, 48).  
 
Furthermore, Egfl7 has been shown to play a role in tubulogenesis and lumen 
formation (36, 50, 53). Egfl7 knockdown in zebrafish and Xenopus laevis 
results in defective reorganization of junctional proteins and failed lumen 
formation (36, 50, 53). 
 
1.7 – Egfl7 function in disease and vascular injury 
 
In addition to a role for Egfl7 during vascular development, Egfl7 has been 
implicated to function in response to vascular injury and disease. EGFL7 
expression is transiently upregulated in the endothelium of two models of 
arterial injury, and high levels are detected in human atherosclerotic plaques 
(43). 
 
Egfl7 plays a protective role in pathologic hypoxic or hyperoxic tissues. 
Upregulation of Egfl7 in response to hypoxia is seen in cultured endothelial 
cells, the immature rat brain, and in the mouse retina (41, 44, 54). In human 
coronary artery endothelial cells, Egfl7 exhibits anti-inflammatory 
characteristics by repressing ICAM1 expression and NFκB activation in 
response to hypoxia-reoxygenation injury or calcineurin-inhibition induced 
injury (44, 55). Egfl7 protects endothelial cells in vitro from hyperoxia-induced 
cell death via prevention of cytochrome c release, therefore inhibiting activation 
of the caspase cascade (56).  
 
In cancer, EGFL7 has been shown to promote cell motility and metastasis, as 
well as tumor growth. In hepatocellular carcinoma, EGFL7 stimulates focal 
adhesion kinase phosphorylation and subsequent tumor cell migration (57). 
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Furthermore, EGFL7 promotes tumor progression by reducing the expression 
of endothelial molecules that mediate leukocyte adhesion and infiltration of 
immune cells, including ICAM1 and VCAM1 (58, 59).  
 
The role of Egfl7 in cancer has been further corroborated. Expression of Egfl7 
is elevated in many tumors and cancer cell lines. A recent study found that 
EGFL7 is overexpressed in ten human epithelial tumors, including lung, breast, 
prostate, ovarian, renal, colorectal, gastric, and esophageal cancers, as well as 
hepatocellular carcinoma, and malignant glioma (45). Additionally, Egfl7 is 
widely expressed in pancreatic cancer cell lines (60), as well as in the serum of 
many cancer patients (45). High levels of EGFL7 correlate with higher tumor 
grade, poor prognosis, and higher metastatic score (57, 60-62). Therefore, 
Egfl7 may be a useful, novel predictive factor for progression of certain 
cancers, including ovarian cancer, gastric carcinoma, malignant glioma, 
laryngeal squamous cell carcinoma, and pancreatic cancer (60-64).  
 
Based on the knowledge of the functional role of Egfl7 during vascular 
development, vascular injury, and cancer, efforts are underway to explore the 
use of anti-EGFL7 therapy. Preclinical trials using anti-EGFL7 monoclonal 
antibodies in combination with anti-VEGF therapy showed promising results 
regarding inhibition of tumor growth in human cancer xenograft mouse models 
and genetically engineered mouse models, when compared to anti-VEGF 
therapy alone (65). Phase II clinical trials for anti-EGFL7 therapy 
(Parsatuzumab) are currently in progress to determine the effect of this therapy 
in treatment on progression-free survival and tumor growth in patients with 
certain cancers, including non-small cell lung cancer (Genentech; 
MEGF0444A, RG7414; Roche; 
http://sigma.larvol.com/merge/sigma/product.php?e1=69&tab=newstrac).  
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1.8 – miR-126 
 
As mentioned previously, determining the role of Egfl7 during mammalian 
vascular development has been complicated by the presence of a microRNA, 
miR-126, located between exon 7 and exon 8 of the Egfl7 transcript (66, 67). 
However, several studies have demonstrated an integral role for Egfl7 in 
vascular development without altering miR-126 expression (37, 40, 48, 50). 
Several groups have demonstrated Egfl7-specific functions during pathological 
development, such as oxygen-induced-retinopathy (41) and in cancer cells. 
 
Several possible explanations are considered to reconcile these seemingly 
conflicting results. The lack of phenotype seen by Kuhnert et al in the Egfl7-
specific knockout mice could be due to compensatory factors or to the mixed 
genetic background in which the studies were performed (66). It is important to 
note that while EGFL7 is secreted and found associated with the extracellular 
matrix, miR-126 exerts its function within the cell (34, 36, 37, 67, 68).  
 
MicroRNAs are a family of small non-coding RNAs (~20-25nt) that regulate 
expression of target mRNAs through destabilization and degradation or 
translation inhibition (69). The first studies using two different Egfl7 loss-of-
function mice demonstrated vascular defects and partial embryonic lethality, 
however, the levels of miR-126 were never measured (38). A later study 
demonstrated that Egfl7 loss-of-function mice that maintained miR-126 
expression did not exhibit any overt vascular defects (66). In contrast, a miR-
126-specific knockout mouse that maintained Egfl7 expression resulted in a 
vascular phenotype similar to the one described for the original Egfl7 knockout 
in Schmidt et al (38, 66), suggesting that the mutant phenotype was due to the 
loss of miR-126 rather than the loss of Egfl7.  
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Egfl7 and miR-126 share a 5.4kb regulatory promoter region that controls their 
vascular specific expression profile during development (67). Additionally, 
Klf2a, a transcription factor upregulated in response to hemodynamic forces, 
has been shown to upregulate miR-126 in zebrafish (70). miR-126 knockout in 
mice results in partial embryonic lethality, leaky vessels, and hemorrhaging, as 
well as aberrant endothelial cell proliferation and migration (67). miR-126 loss-
of-function mice and zebrafish exhibit impaired angiogenesis and defective 
vascular integrity via de-repression of angiogenic signaling pathways. 
Specifically, miR-126 directly targets Spred1 and p85β/PIK3R2, both inhibitors 
of the VEGF signaling pathway (67, 68). Two reports also indicate that miR-126 
can regulate Egfl7 expression directly or indirectly, in non-small cell lung 
cancer cells (71) or in HUVECs, respectively (68). 
 
Collectively, several groups have demonstrated an important role for both Egfl7 
and miR-126 during formation of a functional vasculature, and it is plausible 
that both cooperate to achieve this result. 
 
1.9 – Egfl7 signaling pathways 
 
Egfl7 has been shown to be directly regulated by GATA2 and ERG in 
endothelial cells through GATA and ETS- binding sites located in the proximal 
promoter region (72). Both binding sites are common to many genes of early 
blood and endothelial development (73). Two evolutionarily conserved ETS 
binding sites are located in the 5.4kb promoter region upstream of the Egfl7 
transcriptional start site, the minimal region demonstrated as sufficient to drive 
expression of Egfl7 during embryogenesis (67). The Egfl7 promoter also 
contains a GATA2 consensus binding site (72). A recent study has elucidated 
that the zinc transcription factor, CASZ1, directly regulates and activates Egfl7 
in vitro and in Xenopus embryos to control tubulogenesis (50).  
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Downstream, Egfl7 executes its role in blood vessel development through 
modulation of the Notch signaling pathway (40, 49). Notch signaling is 
important for vascular development, specifically playing a role in sprouting, 
branching, and proliferation (10). EGFL7 interacts with NOTCH1 and NOTCH4, 
as well as their ligand, DLL4, suggesting that EGFL7 can block NOTCH ligand-
receptor binding. EGFL7 modulates Notch signaling differentially, depending on 
the vascular bed. Egfl7 acts as a Notch agonist in developing embryos (40). On 
the other hand, overexpression of Egfl7 in endothelial cells in vitro represses 
Notch reporter activity and inhibits Jagged1/Jagged2-mediated Notch activation 
(40, 49). Furthermore, endothelial overexpression of Egfl7 in the postnatal 
retina results in reduction of Notch target gene expression, or actions as a 
Notch antagonist (40). The phenotype observed in the postnatal retina of Egfl7 
gain-of-function mice mildly, yet incompletely, recapitulates Notch loss-of-
function (40). These results suggest that Egfl7 refines Notch signaling and may 
act, at least in part, through additional signaling pathways to exert an important 
function during blood vessel development.  
 
Several studies have demonstrated that Egfl7 promotes cell migration and 
invasion through activation of the Epidermal Growth Factor Receptor (EGFR) 
signaling pathway in cancer cells (57, 74). In hepatocellular carcinoma, EGFL7 
promotes EGFR-mediated FAK activation, while EGFL7 in gastric cancer cells 
stimulates EGFR-AKT signaling and thus epithelial-mesenchymal transition 
(57, 74).  
 
EGFL7 may function through autocrine or paracrine pathways, or both. EGFL7 
is tightly associated with the ECM and known to affect the spatial organization 
of endothelial cells. This could result from EGFL7 secretion affecting signaling 
on the same cell, neighboring endothelial cells, or both. Additionally, EGFL7’s 
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modulation of NOTCH signaling involves interaction with the transmembrane 
bound ligands and receptors. However, EGFL7’s association with the ECM 
would not provide enough force to activate Notch signaling itself, therefore it 
has been suggested that EGFL7 may block the interaction of Notch ligands and 
receptors that either activate or repress Notch receptor signaling (40, 49), and 
this can be performed on cells that secreted EGFL7 or on neighboring cells.  
 
1.10 – Summary and Significance 
 
EGFL7 plays a critical role in the development of a functional, hierarchal 
vascular system, particularly during embryogenesis and during physiological 
and pathological angiogenesis. Dysregulated and abnormal vascularization 
contributes to the development and progression of many diseases, including 
tumorigenesis. Irregularly patterned vessels impair perfusion and thus oxygen 
and nutrient delivery to tissues. Despite numerous efforts to elucidate the 
mechanisms controlling developmental and pathological blood vessel 
formation, the detailed molecular mechanisms and regulatory factors remain 
incomplete. 
 
The function of the endocrine system is to produce and secrete hormones, and 
thus requires a well-defined vascular network. Two endocrine organs that 
require tightly regulated vascular patterning and development are the pancreas 
and the placenta. Disruptions in the signaling pathways involved in their 
organogenesis may result in pathologies such as diabetes mellitus or 
preeclampsia. It is important to elucidate the molecular mechanisms controlling 
normal development in order to better understand the pathophysiology and 
potential treatments of disease states. 
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Due to the functional role of Egfl7 during developmental and physiological 
angiogenesis, and the important role of the vasculature in the pancreas and the 
placenta, we hypothesized that Egfl7 plays an important role in their 
development. To test this, I utilized Egfl7 gain- and loss-of-function mice, as 
well as a mouse model of PE. In this dissertation, I describe the effect of 
modulation of Egfl7 on the development of both the pancreas and the placenta, 
and investigate the significance and implications of alterations of Egfl7 during 
development of these vascular organs. Importantly, to address the complication 
of the embedded microRNA within the Egfl7 transcript, miR-126 levels are 
unchanged in all models used for these studies.  
 
Secreted factors from the endothelium have been shown to support and induce 
pancreatic organogenesis (75, 76). In chapter two, I will demonstrate the effect 
of endothelial-specific overexpression of Egfl7 on pancreatic development in 
the mouse. Using confocal microscopy imaging techniques, I will reveal a 
functional role for endothelial EGFL7 in pancreatic progenitor cells in the 
mouse embryo.   
 
Furthermore, placental development requires formation of a dense fetal 
capillary network bathed in maternal blood delivered by remodeled maternal 
spiral arteries. Tightly regulated angiogenic signaling is required for these 
processes. Indeed, dysregulated angiogenic signaling and aberrantly 
vascularized placentas have been implicated in placental pathologies, such as 
preeclampsia (PE). In chapters 3 and 4, I will demonstrate a role for EGFL7 in 
normal and pathological placental development. Using a mouse model of PE 
and a global Egfl7-knockout mouse, I will reveal the spatiotemporal expression 
profile of Egfl7 in normal and PE placentas, and define the function of EGFL7 
in formation of the densely patterned fetal vasculature.   
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Chapter 2 – Endothelial Cells Control Pancreatic Cell Fate at Defined 
Stages through EGFL7 Signaling*† 
 
2.1 – Rationale  
 
The mammalian pancreas regulates blood glucose homeostasis and arises 
from the fusion of ventral and dorsal buds. Signaling from blood vessels directs 
growth, morphogenesis, and differentiation throughout pancreatic 
organogenesis (1). Step-wise inductive events occur to pattern and differentiate 
the pancreas. The pancreas develops from Pdx1-positive foregut endoderm, 
initiated at the contact site between the notochord and the dorsal endoderm at 
embryonic day (E)9.0 (2, 3). Pdx1, or Pancreatic and Duodenal Homeobox 
gene-1, is essential for pancreatic morphogenesis, as evidenced by 
apancreatic Pbx1-null mice (3, 4). Following fusion of the dorsal aortae and 
contact with the Pdx1-positive foregut endoderm, pancreatic buds begin to 
evaginate, and endocrine cell differentiation initiates (1). The splanchnic 
mesoderm containing small vessels then separates the dorsal aorta from the 
foregut endoderm. Insulin expression is upregulated at contact sites with the 
portal vein at E10.5 (1). At E11.5, the gut tube begins to rotate, bringing the 
dorsal and ventral pancreatic buds in close proximity for fusion (5). Subsequent 
branching morphogenesis and remodeling processes in addition to 
differentiation along the three pancreatic lineages occurs to form an arborized, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*	  Kao D, Lacko LA, Ding B, Huang C, Phung K, Gu G,  Rafii S, Stuhlmann H, and Chen S. 
Endothelial Cells Control Pancreatic Cell Fate at Defined Stages through EGFL7 Signaling. 
Stem Cell Reports, 4(2):181-9 (2015).	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  NOTE: Human studies, in vitro studies, and explant studies were performed by Kao D, Ding B, 
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mature pancreas (5). The mature pancreatic endocrine cells make up the Islets 
of Langerhans, which are established after birth and are tightly associated with 
blood vessels (1, 6).  
 
Early seminal studies demonstrate the critical role of blood vessel signaling 
during pancreatic organogenesis. First, insulin expression and epithelial buds 
were induced by recombined aortic endothelium but not by the notochord in 
pre-patterned dorsal endoderm (1). Next, removal of the aorta from Xenopus 
embryos fails to induce endocrine gene expression. Moreover, ectopic insulin 
expressing cells and epithelial buds were found in the posterior stomach 
epithelium, adjacent to ectopic endothelial cells of mice expressing VEGF-A 
under control of the Pdx1 promoter (1). Several animal studies have since 
begun to elucidate the precise mechanism by which endothelial cells control 
pancreatic development. For example, interaction of aortic endothelial cells 
with the dorsal pancreatic bud stimulates Ptf1a expression and early pancreatic 
growth (7). Endothelial cell ablation and forced hypervascularization 
experiments demonstrate a role for blood vessels in controlling pancreas size 
via branching morphogenesis and differentiation of early endocrine progenitor 
cells, in part through modulation of the Notch signaling pathway (8).  
 
Understanding the diverse, instructive steps required for pancreatic 
organogenesis in the mouse will have implications for translation to humans in 
order to study the mechanism of disease progression and to develop functional 
pancreatic endocrine cells for transplantation treatment of pancreatic diseases 
such as diabetes. Diabetes is characterized by chronic hyperglycemia resulting 
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from defects in production or action of insulin, which over time can seriously 
damage other tissues in the body (9). Its prevalence is predicted to double by 
the year 2030, resulting in the classification as a potential epidemic (10). Thus, 
the need for models of disease progression and the development of successful 
therapeutic treatments is essential. Dissecting the cellular biological and 
molecular mechanisms of pancreatic development in the mouse has 
contributed to the development of cell replacement therapies. Specifically, 
researchers have established controlled conditions in vitro to differentiate 
human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSCs) 
into functional, insulin-producing beta cells (11), but strategies remain 
inefficient.  
 
The laboratory of Dr. Shuibing Chen established that secreted factors from 
endothelial cells affect pancreatic progenitor cell self-renewal during directed 
differentiation of hESCs into beta cells (12). Indeed, they discovered that 
EGFL7 was the only factor that could alone promote pancreatic progenitor cell 
proliferation (12). In this chapter, I will demonstrate a stage-dependent role for 
Epidermal growth factor like domain 7 (Egfl7) in pancreatic growth and 
development in vivo, using a transgenic mouse overexpressing Egfl7 under the 
control of the Tie2 promoter. Results of these studies and those of Kao et al 
demonstrate that Egfl7 controls pancreatic cell fate at the progenitor cell stage 
both in vivo and in vitro, and can be used to increase the efficiency of 
producing large numbers of pancreatic endocrine cells, which can potentially 
be applied to future transplantation studies (12). 
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2.2 – Abstract 
 
Although endothelial cells have been shown to affect mouse pancreatic 
development, their precise function in human development remains unclear. 
Using a co-culture system containing human embryonic stem cell (hESC)-
derived progenitors and endothelial cells, we found that endothelial cells play a 
stage-dependent role in pancreatic development, in which they maintain 
pancreatic progenitor (PP) self-renewal and impair further differentiation into 
hormone-expressing cells. The mechanistic studies suggest that the 
endothelial cells act through the secretion of EGFL7. Consistently, endothelial 
overexpression of EGFL7 in vivo using a transgenic mouse model resulted in 
an increase of PP proliferation rate and a decrease of differentiation toward 
endocrine cells. These studies not only identified the novel role of EGFL7 as 
the molecular handle involved in the crosstalk between endothelium and 
pancreatic epithelium, but also provide a paradigm for using hESC stepwise 
differentiation to dissect the stage-dependent roles of signals controlling 
organogenesis.  
 
2.3 – Introduction 
 
During embryonic development, cell fate is determined by both intrinsic 
programs and the external cell niche. The animal studies suggested that the 
endothelial cell niche provides both supportive and inductive roles throughout 
pancreas development (6). Early studies showed that signals from endothelial 
cells are essential for the induction of pancreatic organogenesis (1). 
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Endothelial cells specifically promote early dorsal pancreas development by 
inducing Ptf1a+ pancreatic progenitors (PPs) by activating FGF10 signaling (7) 
(13). Interestingly, some groups recently reported that the endothelial cell niche 
could restrain epithelium branching and endocrine development. One group 
showed that blood vessel ablation results in increased pancreatic organ size 
(14). Another group showed that elimination of endothelial cells increases the 
size of pancreatic buds (8). Similarly, another group showed that over-
expressing VEGF-A increases embryonic endothelial cell populations and 
perturbs pancreatic endocrine differentiation (15). However, a complete 
understanding of the role of endothelial cells in human pancreatic development 
is still missing. 
 
Human embryonic stem cells (hESCs) provide an in vitro platform to study 
human development. To better understand the signaling from the endothelial 
cell niche in pancreatic differentiation, we have developed a co-culture system 
of endothelial cells with hESC-derived progenitors under serum-free, 
chemically-defined conditions. By using the co-culture system, we found that 
endothelial cells maintain PP self-renewal and impair further differentiation into 
hormone-expressing cells by secreting EGFL7. 
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2.4 – Results and Discussion 
 
2.4.1 – Endothelial cells promote the proliferation of PDX1+ cells in the 
chemically defined environment. 
 
To systematically probe the role of an endothelial cell niche in human 
pancreatic development, we set up a co-culture system using endothelial cells 
and hESC-derived progenitors. The co-culture system is established in a 
chemically defined culture condition to mimic the serum-free environment 
during embryonic development. The endothelial cells used in this study were 
AKT-HUVECs (AKT-activated human umbilical vein endothelial cells) (16) or 
MPECs (mouse pancreas islet endothelial cells). BJ cells, which are human 
skin fibroblasts, were used as a control for cell type specificity. To explore the 
stage-dependent effect of endothelial cells, HUES8 cells were differentiated 
into three different stages: definitive endoderm (DE), foregut endoderm (FE), or 
PP populations, using a previously established strategy (17). The hESC-
derived populations were cultured together with MPECs or AKT-HUVECs at 
different ratios and examined for their capacities to self-renew or differentiate 
(Figure 2.1A). The self-renewal ability was determined by immunostaining with 
antibodies against a proliferation marker (Ki67) and stage dependent self-
renewal markers, including SOX17 for DE, HNF4α for FE, and PDX1 for PPs. 
The differentiation ability was determined by immunostaining with antibodies 
against differentiation markers, including HNF4α for DE, PDX1 for FE, and 
insulin/glucagon/somatostatin for PPs.  
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Figure 2.1 The Role of Endothelial Cells in Human Pancreatic 
Differentiation. (A) Scheme of co-culture between endothelial cells and hESC-
derived progenitors. (B) Cell number per mm2 after HUES8-derived FE 
population were co-cultured with BJ cells, MPECs, or AKT-HUVECs at 
indicated ratios (n = 3). (C) Cell number per mm2 (n = 3) and representative 
images after HUES8-derived PP population were co-cultured with BJ cells, 
MPECs or AKT-HUVECs. The left scale bar represents 50 μm. The right scale 
bar represents 10 μm. Data presented mean ± standard deviation in each 
independent experiment, and *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001. 
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In the co-culture condition of MPECs or AKT-HUVECs with the hESC-derived 
DE population, neither the number of SOX17+/Ki67+ cells nor the number of 
HNF4α+ cells changed significantly (Supplemental Figure 2.1A), suggesting 
that endothelial cells do not affect either self-renewal or differentiation of DE. In 
the co-culture condition with the hESC-derived FE population, the number of 
PDX1+ cells was significantly increased in the presence of MPECs and AKT-
HUVECs, but not BJ cells (Figure 2.1B). In addition, when the hESC-derived 
PP population was cultured with MPECs and AKT-HUVECs, the number of 
PDX1+ cells was significantly elevated as compared to BJ cells (Figure 2.1C). 
The results suggest that endothelial cells, not fibroblasts, promote the 
generation of PDX1+ cells at the FE and PP stages.  
 
Next, we asked if the generation of PDX1+ cells is due to cell proliferation, by 
examining the proliferation marker Ki67. In co-cultures using the HUES8-
derived PP population, the number of PDX1+/Ki67+ cells is significantly higher 
in the presence of MEPCs and AKT-HUVECs than control conditions (Figure 
2.1C). To further validate that endothelial cells promote PP proliferation, we 
generated a transgenic Pdx1-EGFP HUES8 cell line, which contains the mouse 
Pdx1 promoter driving expression of EGFP. The Pdx1-EGFP HUES8 cell line 
was validated by Flow Cytometry. After 14 days of differentiation, about 45% of 
cells were EGFP+, most of which were positively stained by PDX1 antibody 
(Supplemental Figure 2.1B). Pdx1-EGFP+ cells were sorted and co-cultured 
with MPECs, AKT-HUVECs, or BJ cells (Supplemental Figure 2.1C). The 
result confirmed that endothelial cells can support the isolated PDX1+ cell 
proliferation. Interestingly, when we co-cultured the PP population with 
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endothelial cells, we observed that the differentiation of PPs to hormone-
expressing cells was impaired (Supplemental Figures 2.1D, E). In addition, 
endothelial cells show similar capacities to increase the number of PDX1+ cells 
and PDX1+/Ki67+ cells when co-cultured with H1-derived PP population 
(Supplemental Figure 2.1F), suggesting that the effect of endothelial cells is 
not hESC line dependent. These data together suggest that endothelial cells 
provide a niche to maintain proliferation and impair differentiation of PDX1+ 
cells toward hormone-expressing cells. 
 
2.4.2 – PDX1+ cells after co-culture with endothelial cells retain PP 
signature gene expression. 
 
To determine the cellular identity of PDX1+ cells after co-culture with 
endothelial cells, cells were stained with other antibodies against progenitor 
markers. Immunocytochemistry suggested that most PDX1+ cells grew in the 
presence of endothelial cells expressed PP markers, HNF6, SOX9 and FOXA2 
and endocrine marker, NKX6.1 (Figure 2.2A). The quantified results suggest 
that the number of PDX1+/NKX6.1+ cells, PDX1+/FOXA2+ cells, PDX1+/HNF6+ 
cells and PDX1+/SOX9+ cells were higher in the endothelial cell co-culture 
conditions than in control cells (Figure 2.2B).We further tested the mRNA 
expression of PP markers (FOXA2, HNF6, and SOX9) and endocrine 
progenitor markers (NKX6.1, NKX2.2 and NGN3) in the purified Pdx1-GFP+ 
cells. qRT-PCR suggested that the expression of PP markers (FOXA2, HNF6, 
and SOX9, Supplemental Figure 2.2B, D, E) and endocrine progenitor 
markers (NKX6.1, Supplemental Figure 2.2C) in sorted Pdx1-EGFP+ cells  
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Figure 2.2 The Cellular Identity of PDX1+ PPs Expanded in Endothelial 
Cell Niche. (A) Representative figures of PDX1+ cells co-stained with another 
PP marker, FOXA2, HNF6, or SOX9 and endocrine progenitor marker, NKX6.1 
under co-culture conditions. Scale bar represents 50 μm. (B) Relative cell 
number of PDX1+ cells co-stained with another progenitor marker (n = 3). The 
relative cell number normalized to control (none) as one. (C) Quantified results 
of the relative cell numbers of PDX1+/Ki67+ cells co-stained with another 
progenitor marker (n = 3). (D) Transcriptome analysis by RNA-seq of Pdx1-
EGFP+ cells before and after co-cultured with endothelial cells. The scatter plot 
showed mRNA expression level in sorted Pdx1-EGFP+ cells before co-culture 
versus after co-culture with AKT-HUVECs (left) or after co-culture with BJ cells 
versus after co-culture with AKT-HUVECs (right). Data were presented as 
mean ± SD. 
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was elevated in MPEC co-culture condition; but the expression of endocrine 
progenitor markers (NGN3 and NKX2.2, Supplemental Figure 2.2F-G) did not 
significantly differ between BJ and MPEC co-culture conditions (Supplemental 
Figure 2.2F, at day 4, P=0.1274 for none versus MPEC; P=0.8968 for BJ 
versus MPEC). It suggested that PDX1+ cells after co-culture with endothelial 
cells bias to endocrine fate, but have not expressed the endocrine progenitor 
markers yet. Next, we investigated whether the increased PP population under 
co-culture conditions was due to cell proliferation by measuring the number of 
PDX1+/Ki67 cells that are also positive for other PP markers (Figure 2.2C). 
When co-cultured with MPECs and AKT-HUVECs, the number of proliferating 
PPs increased about 5-fold and 6-8 fold, respectively, compared to none co-
culture conditions. Sometimes, the number of the proliferating PPs in the 
presence of BJ cells was lower than none co-culture condition. This might be 
due to the high cell density in the co-culture condition, which might affect PP 
proliferation.   
 
Transcriptome profiling provides a way to systematically compare gene 
expression in different cell populations. PPs before or after co-culture with 
endothelial cells were profiled by RNA-seq. To purify the PDX1+ PPs, EGFP+ 
cells were sorted from the Pdx1-EGFP HUES8 cell-derived cells before or after 
co-culture with MPECs or AKT-HUVECs. The global gene expression of PPs 
before and after co-culture with endothelial cells showed very high similarity 
(R2=0.9611 in the presence of AKT-HUVECs, Figure 2.2D left; and R2=0.9378 
in the presence of MPECs, Supplemental Figure 2.2A). In addition, the global 
gene expression pattern of PPs expanded in the presence of either AKT-
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HUVECs or BJ cells showed high similarity (R2=0.9692, Figure 2.2D right). 
These data confirm that PPs maintain cellular identity after expansion by 
endothelial cells. 
 
2.4.3 – Endothelial cells maintain human PP self-renewal by secreting 
EGFL7. 
 
In the co-culture system, endothelial cells might function through a secreted 
factor(s) or by direct cell-cell contact. To test these possibilities, HUES8 cell-
derived PP populations were treated with conditioned medium (18) collected 
from MPECs (MPEC-CM) or from AKT-HUVECs (AKT-HUVEC-CM). CM 
retained similar, but slightly lower activity compared to intact cells for promoting 
PP self-renewal (Figure 2.3A). This data suggests that endothelial cells 
function, at least in part, through a secreted factor(s). We further analyzed the 
gene expression profiles of AKT-HUVECs, MPECs and BJ cells to identify 
candidate secreted factors (Figure 2.3B and Supplemental Figure 2.3A). 
Genes encoding secreted proteins, whose expression in endothelial cells is at 
least 30-fold higher than in the BJ cells, were selected for further analysis. 
Among the genes encoding secreted molecules (Supplemental Table 2.1), we 
tested the abilities of recombinant proteins ANGPT2, EGFL7, CCL13, IL24, 
PLAU, DHH, and PDGFB to expand human PPs (Figure 2.3C). Only EGFL7 
was able to promote PP proliferation (Figure 2.3C, D, E). To determine 
whether EGFL7 was required for the endothelial cell effect, we used shRNA to 
knockdown EGFL7 expression in AKT-HUVECs. EGFL7 mRNA expression 
level was decreased by about 63.5% in AKT-HUVECs infected with EGFL7  
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Figure 2.3 Endothelial Cells Promote PP Proliferation by Secretion of 
EGFL7. (A) Cell number per mm2 4 days after HUES8-derived PPs were co-
cultured with endothelial cells or treated with CM (n = 3). (B) Transcriptome 
analysis of gene expression in BJ cells and AKT-HUVECs by RNA-seq. The 
blue line indicates the cutoff line of a 30-fold increase in gene expression in 
AKT-HUVECs as compared with BJ cells. The red dot indicates EGFL7. (C) 
Number of PDX1+ cells per mm2 4 days after hESC-derived PPs were treated 
with different recombinant proteins (300 ng/ml) (n = 3). (D) PDX1+ (left) or 
PDX1+/Ki67+ cell number per mm2 (right) 4 days after HUES8-derived PPs 
were treated with CM or 300 ng/ml EGFL7 (n = 3). (E) Representative images 
of (D). (F) PDX1+/Ki67+ cell number per mm2 4 days after HUES8-derived PPs 
were co-cultured with AKT-HUVECs carrying shRNA targeting EGFL7 (shRNA-
EGFL7) or AKT-HUVECs carrying scrambled control shRNA (scrambled) (n = 
3). (G) Representative images of (F). Data were presented as mean ± SD. 
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shRNA lentivirus as compared to a scrambled control lentivirus (Supplemental 
Figure 2.3B). When co-cultured with EGFL7-shRNA treated AKT-HUVECs, 
hESC-derived PPs showed significantly lower proliferation activity as compared 
to those co-cultured with untreated (P=0.0324) and scrambled-shRNA treated 
AKT-HUVECs (P= 0.0387, Figure 2.3F, G). These results indicate that EGFL7 
is both sufficient and necessary for endothelial cells to maintain PP self-
renewal.  
 
Since EGFL7 has been shown to modulate the NOTCH pathway (19), we 
tested whether the NOTCH pathway is involved in endothelial cell-dependent 
PP expansion. HUES8-derived PP populations were treated with five different 
NOTCH inhibitors, including DAPT, XX, compound E, III-31-C, and Sulindac  
sulfide. The NOTCH inhibitors did not mimic the effect of EGFL7 to promote PP 
proliferation (Supplemental Figure 2.3C). In addition, qRT-PCR analysis 
showed that EGFL7 treatment did not alter the expression of NOTCH target 
genes, such as Hes-1 and Hey-1, in Pdx1-GFP+ cells (Supplemental Figure 
2.3D).  
 
Recent studies suggested that EGFL7 might also activate the EGF receptor 
pathway (20, 21). Several experiments were performed to determine whether 
EGF receptor is a downstream signal of EGFL7. Immunocytochemistry 
suggests that the EGF receptor is expressed in hESC-derived PDX1+ PPs 
(Supplemental Figure 2.3E). In addition, microscale thermophoresis binding 
assay suggested that EGFL7 directly binds to the EGF receptor in vitro 
(Kd=384±76.5 nM, Supplemental Figure 2.3F). Furthermore, we found that 
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addition of an EGFR inhibitor (EGFRi) blocks the effect of endothelial cells and 
EGFL7 to expand PDX1+ PPs (Supplemental Figure 2.3G). Finally, we found 
that mRNA expression level for EGF is much lower in AKT-HUVECs 
(0.09±0.02) and MPECs (0.09±0.02) than BJ fibroblasts (0.6±0.1), as 
determined by RNA-seq (Supplemental Figure 2.3H). Since endothelial cells, 
but not BJ fibroblasts, promote PP self-renewal, this suggests that endothelial 
cells do not promote PP proliferation by secreting EGF. Together, these results 
indicate that endothelial cells promote PP self-renewal through the secretion of 
EGFL7 and through activation of the EGF receptor signaling pathway.  
 
To determine if EGFL7 treatment is capable to promote PP proliferation in long-
term cultures, we tested the expansion and differentiation capacity of PDX1+ 
PPs to the endocrine lineage following the pulsed expansion with recombinant 
EGFL7. HUES8-derived PP populations were treated with EGFL7 for different 
periods of time. One set of samples was fixed and stained with PDX1 and Ki67 
antibodies to determine cell proliferation rates. The other set of samples were 
further differentiated in the absence of EGFL7 for additional 7 days and stained 
with antibodies against endocrine markers to determine the differentiation 
potential. The percentage of PDX1+/Ki67+ cells increased during the first week 
of EGFL7 treatment (Supplemental Figure 2.3I). After one week, the 
percentage of PDX1+/Ki67+ cells started decreasing in all conditions no matter 
whether EGFL7 was present or not. However, the percentages of PDX1+/Ki67+ 
cells treated with EGFL7 are higher than those of under control conditions at all 
time points (Supplemental Figure 2.3I). Consistent with the increase in cell 
proliferation, the percentage of insulin+, C-peptide+ and somatostatin+ cells 
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increased in PPs cultured under EGFL7 treatment, and peaked at one week. 
The percentage of hormone-expressing cells under EGFL7-treated conditions 
is higher than that under control conditions at all time points (Supplemental 
Figure 2.3J-L). Together, these results suggest that one week of EGFL7 
treatment can expand PDX1+ PPs in vitro, resulting in significantly increased 
differentiation efficiency toward the endocrine cell lineages.  
 
2.4.4 – Endothelial overexpression of Egfl7 in vivo increases proliferation 
of PPs. 
 
To determine the effect of EGFL7 on the PP cell population in vivo, we 
analyzed pancreatic development in a transgenic mouse model, Tie2:Egfl7. In 
this strain, the Egfl7 transgene is under the control of the endothelial specific 
Tie2 promoter, resulting in a 2-3 fold overexpression of EGFL7 (19). Whole 
mount immunofluorescent staining was performed on E9.5 and E10.5 embryos 
from C57BL/6 wild type (WT) mice and Tie2:Egfl7-transgenic mice (TG) 
(Figure 2.4A, D). A CD31-positive capillary plexus surrounds the developing 
pancreatic bud in vivo, demonstrating the proximity of endothelial cells and 
implicating them as a potential source of EGFL7 to signal to the PDX1+ PP 
population (Supplemental Figure 2.4A). Quantification of the vascular 
coverage at E10.5 demonstrated no significant difference in blood vessel 
density surrounding the developing pancreatic bud between WT and TG mice 
(Supplemental Figure 2.4B, P=0.299).  
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Figure 2.4 EGFL7 Increases Proliferation of PPs in Both TG and Explant 
Cultures. (A and D) Representative collapsed z stack confocal image of (A) 
E9.5 and (D) E10.5 mouse pancreatic buds costained for DAPI, PP marker 
PDX1, and endothelial cell marker, CD31. (B, C, E, and F) Representative 
collapsed z stack confocal images of E9.5 and E10.5 pancreatic buds from WT 
and TG mice stained for PDX1. (G and H) Representative Images of E10.5 
mouse pancreatic bud sections from (G) WT and (H) TG mice, costained for 
PP marker, PDX1, and proliferation marker, EdU. (I) Quantification of the 
percentage of EdU+/PDX1+ cells of E10.5 WT and TG mice (n = 3). (J) 
Representative images of E11.5 WT pancreatic bud explants treated with or 
without 1 μg/ml recombinant mouse EGFL7 and costained for DAPI, Pdx1, and 
BrdU. (K) Quantification of the percentage of BrdU+/Pdx1+ cells of E11.5 WT 
pancreatic buds treated with or without recombinant EGFL7 (n = 6). (L) 
Representative images of E15.5 dorsal and ventral pancreatic buds from WT 
and TG mice, costained for PP marker, PDX1, and insulin. (M) Quantification of 
the ratio of insulin+ cells over PDX1+ cells of E15.5 pancreatic buds from WT 
and TG mice (n = 5). (N) Glucose-stimulated insulin secretion (GSIS) test of 
WT control (n = 3) and TG (n = 4) mice. (O) GTT of WT (n = 2) and TG (n = 4) 
mice. Data were presented as mean ± SEM.  
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At E9.5 and E10.5, the pancreatic buds of TG mice appear larger with less 
defined edges as compared to WT mice (Figure 2.4B-F). To determine if the 
larger pancreatic buds in the TG embryos resulted from increased proliferation 
of PDX1+ cells, we performed EdU injections of pregnant E10.5 WT and TG 
mice (Figure 2.4G, H). We analyzed the percentage of EdU+ PP (PDX1+) cells 
in sections of pancreatic buds (Figure 2.4I). The percentage of proliferating 
PPs (EdU+/PDX1+) in TG mice is significantly higher than WT mice (P*<0.05, 
Figure 2.4I). In addition, the PDX1+ area in TG mice is significantly increased 
compared to WT mice (P*=0.031 in Supplemental Figure 2.4C and P*=0.032 
in Supplemental Figure 2.4D). The number of PDX1+ cells in TG mice shows 
the same trend toward increase as the PDX1+ area, although it does not reach 
significance (P=0.1144 in Supplemental Figure 2.4E, P=0.065 in 
Supplemental Figure 2.4F). The increased of the number of PDX1+ cells in 
TG mice is more pronounced at E15.5 (Supplemental Figure 2.4G, H, 
P***<0.001). Together, these data suggest that PP proliferation was stimulated 
by endothelial-specific overexpression of EGFL7 in vivo. 
 
In addition, WT E11.5 pancreatic buds were isolated from surrounding 
mesenchyme and cultured in vitro in the presence or absence of recombinant 
mouse EGFL7 for two days. The explants were pulsed for 4 hours with BrdU 
prior to fixation. The percentage of proliferating PPs (BrdU+/PDX1+ cells) out of 
the total number of PPs (PDX1+ cells) was significantly increased in the 
presence of mouse recombinant EGFL7 (P**<0.01, Figure 2.4J, K). 
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To determine the effect of EGFL7 in vivo on differentiation into hormonal-
expressing cells, we analyzed the percentage of insulin+ cells and PDX1+ cells 
in E15.5 pancreatic buds (Figure 2.4L). The percentage of insulin+ cells over 
PDX1+ cells in E15.5 pancreatic buds is significantly decreased in TG mice 
(P*<0.05, Figure 2.4M). Consistently, the ratio of insulin+ area over E-
cadherin+ area in E15.5 TG pancreatic buds shows a trend toward decrease 
compared with WT controls (Supplemental Figure 2.4G, I, P=0.396) although 
it does not reach significance. We also examined the total number of PDX1+ 
cells and the percentages of PDX1+/NKX6.1+ cells, PDX1+/SOX9+ cells and 
PDX1+/NKX6.1+/SOX9+ cells in total PDX1+ cells at E15.5. Consistent with our 
results for E9.5 and E10.5 embryos, the total number of PDX1+ cells in E15.5 
TG pancreatic buds is significantly higher than that of WT controls 
(Supplemental Figure 2.4H, P***<0.001). The ratios of PDX1+/NKX6.1+ cells 
(P=0.385), PDX1+/SOX9+ cells (P=0.200) and PDX1+/NKX6.1+/SOX9+ cells 
(P=0.495) in PDX1+ cells did not differ significantly between TG and WT 
pancreatic buds (Supplemental Figure 2.4J, K). Importantly, less than 6% of 
total PDX1+ cells coexpress NGN3 in both WT and TG pancreatic buds 
(Supplemental Figure 2.4L, M, P=0.053), suggesting that these PPs have not 
yet fully committed to endocrine progenitors. Together, these data suggest that 
EGFL7 suppresses PP differentiation into pancreatic endocrine cells, which is 
consistent with our results using hESC-derived cells (Supplemental Figure 
2.1D, E).  
 
To determine the effect of EGFL7 overexpression in adult beta cell function, we 
performed a glucose-stimulated insulin secretion (GSIS) test and a glucose 
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tolerance test (GTT) in 8-week old male TG and WT mice. Strikingly, all four 
TG mice showed significantly less insulin secretion at both fasting and after 
glucose stimulation, compared to WT controls (fasting: P*=0.048; after glucose 
stimulation: P*=0.027, Figure 2.4N). Furthermore, the TG mice showed 
consistently impaired glucose tolerance (Figure 2.4O). The data suggests that 
adult TG mice have less functional beta cells than WT control mice. 
 
Stepwise differentiation of hESCs provides a useful platform to study human 
development. Using a stepwise pancreatic differentiation system, we found that 
an endothelial cell niche plays a stage-dependent role in human pancreatic 
development, promoting PP self-renewal and impairing differentiation from PPs 
towards hormone-expressing cells. Our finding could explain the results from 
previous animal studies: removing endothelial cells before the PP stage blocks 
pancreatic development (1), while forced hypervascularization at the PP stage 
negatively impacts the later endocrine differentiation (8, 14, 15). During 
pancreatic development, the endothelium pattern changes dramatically over 
time, which might affect the local concentration of paracrine factors, such as 
EGFL7, which will contribute to the cell fate decision. On the other hand, a 
recent study proposed that the endothelial cell niche could stimulate PPs to 
differentiate into insulin-secreting cells (22). In contrast to our co-culture 
conditions, in which MPECs and AKT-HUVECs survive well after 4 days of co-
culture (Supplemental Figure 2.4N), the rat microvascular endothelial cells in 
that study do not survive well in differentiation conditions, and could not be 
detected after 6 days in culture (22). Although increased insulin expression was 
detected in the co-cultures, we can speculate that the rat microvascular 
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endothelial cells might provide a transient amplifying signal to expand PPs. If 
the endothelial cells start to die, the block on differentiation of PPs would be 
relieved. To test this hypothesis, we cultured hESC-derived PPs in endothelial 
cell CM for 4 days. The medium was then removed to induce spontaneous 
differentiation. Consistent with our hypothesis, the hESC-derived cells treated 
with CM show better differentiation toward insulin-expressing cells 
(Supplemental Figure 2.4O).  
 
EGFL7 is a secreted protein that acts as a chemoattractant for endothelial cells, 
binds to the extracellular matrix, and promotes endothelial cell adhesion (23). 
Here, we identified the novel role of EGFL7 as the molecular handle involved in 
the crosstalk between endothelium and pancreatic epithelium, which plays as a 
gatekeeper to maintain PP self-renewal. In this context, it is interesting to note 
that the developmental stage of pancreatic bud formation (E9.0-E11.5) 
coincides with the peak in EGFL7 expression in the embryonic vasculature (24). 
Our data also suggested that EGFL7 might function through the EGF signaling 
pathway. Consistently, it has been shown that activation of EGF signaling 
facilitates the PDX1+ cell expansion (25). Although our data strongly support 
our conclusion that EGFL7 promotes PP proliferation, we cannot exclude the 
possibility that EGFL7 may also promote foregut epithelium differentiation. In 
addition, recombinant EGFL7 protein was less efficient for expansion of PDX1+ 
progenitors compared to co-culture with endothelial cells. To explain this 
discrepancy, we considered two possibilities. First, the recombinant EGFL7 
protein may lack post-translational modifications and might not be as 
functionally active as native EGFL7 secreted by endothelial cells. Second, we 
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cannot exclude the possibility that endothelial cells secrete additional factors 
that boost the effect of EGFL7. Finally, since the Egfl7 transgene is 
overexpressed in all endothelia, we cannot fully rule out the possibility of 
systemic effects. 
 
Pancreatic development is a highly dynamic process controlled by multiple 
pathways. Additional work is needed to unravel the dynamic interaction of 
pancreatic endoderm with endothelial and mesenchymal cell niches. A 
complete understanding of the underlying mechanism may lead to the 
development of more efficient strategies to differentiate hESCs/iPSCs into 
mature glucose-responding cells in vitro.  
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Supplemental Figure 2.1 (Corresponds to Figure 2.1): Endothelial cells 
play a stage-dependent role in pancreatic development. (a) Cell number of 
SOX17+ cells, SOX17+/Ki67+ cells, or HNF4α+ cells per mm2 after HUES8-
dervied definitive endoderm (SOX17+) population were co-cultured with BJ 
cells, MPECs, or AKT-HUVECs at indicated ratios (1/10, 1/3 or 1/1) (n=3); (b) A 
majority of EGFP+ pancreatic progenitors derived from Pdx1-EGFP HUES8 
remained PDX1+. Flow Cytometry of Pdx1-EGFP HUES8-derived pancreatic 
progenitors detected by secondary antibody only as a negative control (left) 
and in the presence of anti-GFP, anti-PDX1 and secondary antibody (right). 
Among 45.0% GFP+ cells, 40.6% of them were PDX1+. The data suggested 
that PDX1+ pancreatic progenitors can be enriched by sorting GFP+ cells in 
Pdx1-EGFP HUES8- derived pancreatic progenitors; (c) Pdx1-EGFP+ cells 
purified from Pdx1-EGFP HUES8 derived pancreatic progenitor population 
were cultured with BJ cells, MPECs or AKT-HUVECs for 4 days. Cell number 
of PDX1+ or PDX1+/Ki67+ cells per mm2 was quantified after 4 days co-culture 
(n=3); (d) Cell number of hormone-expressing cells, Insulin+ (INS), Glucagon+ 
(GCG), c-peptide+ (CP), or Somatostatin+ (SST) cells per mm2, after HUES8-
derived pancreatic progenitor (PDX1+) population were co-cultured with BJ 
cells, MPECs or AKT-HUVECs. Scale bar, 50 μm. Data represent the mean ± 
standard deviation (n=3); (e) HUES8-derived pancreatic progenitor population 
was co-cultured with mCherry labeled MPECs. 6 days later, HUES8-derived 
cells were purified by removing mCherry labeled MPECs with cell sorting and 
analyzed by qRT-PCR. The cells co-cultured with MPECs showed the 
decreased expression of insulin, glucagon and somatostatin (n=3); (f) The 
effect of endothelial cells on H1-derived pancreas progenitors. Cell number of 
PDX1+ or PDX1+/Ki67+ cells per mm2 after H1-derived PDX1+ pancreatic 
progenitors were co-cultured with BJ cells, MPECs, or AKT-HUVECs at the 
indicated ratio comparing to pancreatic progenitors without co-culture (none) 
(n=3). 
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Supplemental Figure 2.2 (Corresponds to Figure 2.2): (a) Transcriptome 
analysis by RNA-seq. The scatter plot showed mRNA expression level in 
sorted Pdx1-EGFP+ cells before co-culture versus after co-cultured with 
MPECs. The red line indicated identical gene expression levels between two 
samples. The mRNA expression level is very similar in sorted Pdx1-EGFP+ 
cells before co-culture versus after co-culture with MPEC (R=0.9378). (b-g) 
qPCR of sorted Pdx1-EGFP+ pancreatic progenitors after 2 or 4 days of co-
culture. RNA levels of (b) FOXA2, (c) NKX6.1, (d) HNF6, (e) SOX9, (f) NGN3, 
and (g) NKX2.2 were measured by qPCR in sorted Pdx1-EGFP+ cells after 2 
days or 4 days of co-culture in the absence (none) or presence of BJ cells and 
MPEC. All numbers were normalized to no co-culture of the same culture 
duration (in f, at day 4, P=0.1274 for none versus MPEC; P=0.8968 for BJ 
versus MPEC; Bonferroni). Data are presented as mean ± standard deviation 
(n=3). P*<0.05, P**<0.01, n.s. not significant.
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Supplemental Figure 2.3 (Corresponds to Figure 2.3): (a) Transcriptome 
analysis of gene expression in BJ cells and MPECs by RNA-seq (grey dots). 
Blue line indicates the cutoff line of a 30-fold increase in gene expression in 
MPECs as compared to BJ cells. Red dot indicates gene expression levels of 
EGFL7 in MPECs versus BJ cells; (b) Relative EGFL7 mRNA expression level 
in BJ cells, AKT-HUVECs expressing shRNA-EGFL7, or expressing scrambled 
shRNA comparing to AKT-HUVECs; (c) PDX1+ cell numbers per mm2 were 
measured after 4 days of treatment with DMSO or NOTCH inhibitors (DAPT, γ-
Secretase Inhibitor XX, Compound E, III-31-C, and Sulindac sulfide) (n=3); (d) 
HUES8 Pdx1-GFP cell-derived pancreatic progenitors were cultured in the 
absence or presence of endothelial cells for four days. qRT-PCR for NOTCH 
target genes, Hes-1 and Hey-1, was carried out on sorted Pdx1-EGFP+ cells; 
(e) Immunocytochemistry of EGF receptor (EGFR, green), PDX1 (red), and 
DAPI in HUES8 derived pancreatic progenitors; (f) Protein interaction between 
EGFR and EGFL7 was measured by microscale thermophoresis (MST). The 
dissociation constant (Kd= 387±76.5nM) of EGFL7 binding to EGFR was 
estimated by MST assay. (g) Effect of EGFRi on the relative number of 
PDX1+/Ki67+ HUES8-derived pancreatic progenitors after co-culture with 
MPECs, AKT-HUVECs, or treated with recombinant EGFL7 (n=3); (h) EGF 
mRNA expression levels in different cell types by RNA-seq; (i-l) proliferation (i, 
PDX1+/Ki67+) and differentiation ability of PDX1+ progenitors to endocrine 
lineage (j, Insulin; k, c-peptide; l, somatostatin) following pulsed expansion of 
progenitors with recombinant EGFL7 for 4 days, 1 week, 2 weeks or 4 weeks 
(n=3). 
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Supplemental Figure 2.4 (Corresponds to Figure 2.4 and discussion): (a,b) 
Representative collapsed z-stack confocal images and quantification of CD31+ 
area in E10.5 mouse pancreatic buds of C57BL/6 wild type and Tie2:Egfl7 
Transgenic mice, co-stained for pancreatic progenitor marker, PDX1 (red), and 
CD31 (green), showing that overall vascular coverage around the developing 
pancreatic bud is unchanged (P=0.299). Quantification of PDX1+ area in (c) 
E9.5 and (d) E10.5 pancreatic buds (P*=0.031 in c and P*=0.032 in d); 
Quantification of the number of PDX1+ cells in (e) E9.5 and (f) E10.5 
pancreatic buds (P=0.1144 in e and P=0.065 in f). (n=4-7) All data are 
represented as mean +/- SEM. (g) Immunocytochemistry analysis of E15.5 
pancreatic buds using PDX1, E-cadherin, and insulin antibodies; (h) The total 
number of PDX1+ cells in E15.5 wild type (WT) and Tie2:Egfl7 transgenic (TG) 
pancreatic buds (P***<0.001); (i) The ratio of insulin+ area over E-cadherin+ 
area in E15.5 pancreatic buds (P=0.396, n=3 for each genotype); (j) 
Immunocytochemistry analysis of E15.5 pancreatic buds using PDX1, NKX6.1 
and SOX9 antibodies; (k) The ratios of PDX1+/NKX6.1+ cells (P=0.385), 
PDX1+/SOX9+ cells (P=0.200), and PDX1+/NKX6.1+/SOX9+ (P=0.495) cells 
in total PDX1+ cells in E15.5 wild type (WT) and Tie2:Egfl7 transgenic (TG) 
pancreatic buds (n=3 for each genotype); (l) Immunocytochemistry analysis of 
E15.5 pancreatic buds using PDX1 and NGN3 antibodies; (m) The percentage 
of PDX1+/NGN3+ cells in total PDX1+ cells in E15.5 pancreatic buds (P=0.053, 
n=3 for each genotype); (n) Immunocytochemistry of CD31 (red) and PDX1 
(green) in HUES8-derived pancreatic progenitors alone (none) or co-culturing 
with MPECs or AKT-HUVECs at day 0 or day 4. (o) The HUES8-derived 
pancreatic progenitors were treated with MPEC-CM (conditioned medium) or 
AKT-HUVEC-CM treatment or without treatment (none) for 4 days and followed 
by 6 days spontaneous differentiation after the removal of treatments (P**<0.01, 
n=3). Cell number of insulin+ cells per mm2 were quantified using a Molecular 
Devices high-content screening system and analyzed by MetaXpress. (n.s.= 
not significant).
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Supplemental Table 2.1 (for Figure 2.3): The list of genes highly expressed 
in MPECs than in BJ cells (above the blue line in Figure 2.3B) and their 
subcellular protein localization (Olerud et al., 2009; Thorens, 2011). 
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Supplemental Table 2.2: Primer sequences used in this study were listed. 
 
	  
 
  
 
	  
	  
58	  
2.5 – Materials and Methods 
 
hESC culture and differentiation. HUES8 and H1 cells were routinely cultured 
on irradiated MEF feeders in DMEM/F12 (Cellgro) supplemented with 20% 
KnockOut Serum Replacement, 2 mM GlutaMAX, 1 mM nonessential amino 
acids, 1.1 mM β-merceptoethanol, 10 ng/ml bFGF (Invitrogen), 50 ng/ml 
normacin (InvivoGen). Cells were passaged every 5 or 6 days using 0.05% 
trypsin (Invitrogen). To differentiate to the pancreatic progenitor population, 
hESCs were cultured on feeders to 80-90% confluency, then treated with 3 μM 
CHIR99021 (CHIR, Stem-RD) and 100 ng/ml activin A (R&D systems) in RPMI 
(Cellgro) supplemented with 2 mM GlutaMAX and 100 U/ml Pen/Strep for one 
day, and then 100 ng/ml activin A in RPMI supplemented with 0.2% fetal 
bovine serum (FBS), 2 mM GlutaMAX and 100 U/ml Pen/Strep. At this stage, 
hESC-derived cells containing a high percentage of SOX17+/FOXA2+ cells 
were defined as the hESC-derived definitive endoderm population. The 
medium was changed 2 days later to 50 ng/ml FGF7 (PeproTech) in RPMI 
supplemented with 2 mM GlutaMAX, 100 U/ml Pen/Strep and 2% FBS, and 
maintained for an additional 2 days. At this stage, hESC-derived cells 
containing a high percentage of HNF4α+ cells were defined as the hESC-
derived foregut endoderm population. Cells were transferred to 300 nM 
LDN193189 (LDN, Axon), 2 μM retinoic acid (Sigma), and 0.25 μM SANT-1 
(Sigma) for the first 4 days and then to 300 nM LDN193189 (LDN, Axon), 20 
nM Phorbol 12,13-dibutyrate (PuBu, Sigma), and 1 μM ALK5i (Enzo) in DMEM 
supplemented with 2 mM GlutaMAX, 100 U/ml Pen/Strep, and 1x B27 
(Invitrogen) for an additional 4 days. At this stage, hESCs-derived cells 
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containing a high percentage PDX1+ cells are defined as the hESC-derived 
pancreatic progenitor population. 
 
Co-culture experiments. MPECs (MS1, mouse pancreatic islet endothelial cell 
line, ATCC), AKT-HUVECs (AKT activated human umbilical vein endothelial 
cells (16)) and BJ cells (human foreskin fibroblasts, ATCC) were used in the 
co-culture experiments. hESC-derived populations were trypsinized by 0.25% 
trypsin (Invitrogen), resuspended in DMEM supplemented with 2 mM 
GlutaMAX, 100 U/ml Pen/Strep, and 1x B27, and plated at a density of 0.8*103 
cells/mm2 in 96 well or 6 well plates. MPEC, AKT-HUVEC, or BJ cells were 
resuspended in the same medium and plated at a ratio of 1:1, 1:3 or 1:10 to 
hESC-derived pancreatic progenitors. One day after plating, medium was 
changed, and cells were maintained in the incubator for 4 days before fixation 
or further analysis. 
 
Immunocytochemistry. Cells were fixed in 10% (v/v) formalin for 20 min at room 
temperature. Non-specific antigen and antibody association were blocked in 
5% horse serum (Invitrogen), 0.3% Triton X in PBS for one hour at room 
temperature, followed by primary antibody incubation overnight. The following 
antibodies were used: goat anti-PDX1 (1:500, R&D systems, AF2419), rabbit 
anti-FOXA2 (1:1000, Millipore. 07-633), rabbit anti-HNF6 (1:200, Santa Cruz, 
sc-13050), mouse anti-NKX6.1 (1:500, U of Iowa Hybridoma bank, F55A12-c), 
guinea pig anti-insulin (1:1000, DAKO, A0564), mouse anti-C-peptide (1:1000, 
Millipore, 05-1109), rabbit anti-Amylase (1:1000, Sigma, A8273), rabbit anti-
Ki67 (1:1000, Thermo, RM-9106-S1), mouse anti-Glucagon (1:2000, Sigma, 
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G2654), rabbit anti-Somatostatin (1:2000, DAKO, A0566), and rabbit anti-
EGFR (1:50, Abcam, Ab2430). This was followed by incubation with species-
appropriate secondary antibodies.  
 
Data quantification. For cell number quantification, at least triplicates for each 
treatment in one experiment were carried out. Cells in the center 18 mm2 of 
each well (with density of 2*103 cells/mm2 in average) were imaged using a 
Molecular Devices high-content screening system and images were analyzed 
by MetaXpress. Quantification was done for three independent experiments. 
Data presented mean ± standard deviation as cell number per mm2 or relative 
cell number to none co-culture (none) in each independent experiment. 
 
RNA extraction and quantitative RT-PCR. Total RNA was isolated using 
Qiagen RNeasy mini kit according to manufacture’s instructions. RNA was 
reverse transcribed using superscript III reverse transcriptase and random 
primers (Invitrogen). Quantitative PCR with SYBR green detection was 
performed using LightCycler 480 system (Roche). Primer sequences were 
listed in supplementary material Supplemental Table 2.2. 
 
RNA-seq. The quality of RNA samples was analyzed, and cDNA libraries were 
synthesized and sequenced by Weill Cornell Genomics Core facility. In brief, 
the quality of RNA samples was examined by Agilent bioanalyzer (Agilent). 
cDNA libraries were generated using TruSeq RNA Sample Preparation 
(Illumina). Each library was sequenced using single-read in HiSeq2000/1000 
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(Illumina). Gene expression levels were analyzed with TopHat and Cufflinks by 
the Genomic Core facility.  
 
Accession numbers. RNA-seq data deposited in the GEO database can be 
accessed with GEO accession numbers GSE63840 and GSE63843. 
 
Generation of Pdx1-EGFP HUES8 line. Pdx1-eGFP-Rex-Neo was constructed 
by replacing the aMHC promoter on aMHC-eGFP-Rex-Neo (Addgene 21229) 
with the mouse Pdx1 promoter (Addgene 15085). To infect HUES8 cells, 
lentivirus carrying Pdx1-eGFP-Rex-Neo were generated in 293T cells. HUES8 
cells were plated on matrigel after removal of feeders. Lentiviruses were added 
to HUES8 cells supplemented with bFGF. After two days infection, HUES8 
were plated with NeoR MEFs and selected by Geneticin (Invitrogen) for 4 days. 
 
Mice. All animal protocols were approved by the Institutional Animal Care and 
Use Committee at Weill Cornell Medical College. Tie2:Egfl7 transgenic mice 
were from in-house colonies (19) and C57BL/6 mice were from Jackson 
Laboratories. For timed pregnancies, the date of visualization of a vaginal plug 
was designated as embryonic day 0.5 (E0.5). Mouse embryos (n=3-7 over 2-3 
litters for each genotype per time point) were isolated and fixed in 4% 
paraformaldehyde overnight. Embryos were further dissected for whole mount 
staining, removing the body wall as previously described (26) to expose the 
pancreatic buds for imaging. Whole pancreatic and gut tissues were isolated 
from E15.5 embryos and processed for immunostaining. Whole pancreatic and 
gut tissue was isolated from E15.5 embryos and either fixed in 4% 
 
	  
	  
62	  
paraformaldehyde overnight or fresh frozen in (2:1) OCT:30% sucrose mixture. 
Fixed pancreatic tissues were used for whole mount immunostaining or 
cryopreserved and embedded in (2:1) OCT:30% sucrose mixture for sectioning. 
 
Whole Mount Immunostaining. Processed embryos were washed and 
permeablized in PBS-0.4% Triton-X, then blocked in 10% donkey serum/0.4% 
Triton-X/PBS overnight at 4°C. Embryos were then incubated in primary 
antibodies in 5% donkey serum/0.4% Triton-X/PBS overnight at 4°C (PDX1, 
R&D Systems AF2419, 1:100 or 1:200; CD31, BD Biosciences #553370, 1:500; 
Insulin, DAKO A0564, 1:750; NKX6.1, U of Iowa Hybridoma bank F55A12, 
1:350; Sox9, Millipore AB5535, 1:2000; E-cadherin, BD 610181, 1:150), 
washed overnight, and incubated in secondary antibodies (594-donkey-anti-
goat, 1:500; 488-donkey-anti-rat, 1:200; 488-donkey-anti-guinea pig, 1:500; 
488-donkey-anti-goat, 1:1000; 647-donkey-anti-guinea pig, 1:500, Cy3-donkey-
anti-mouse, 1:500; Cy5-donkey-anti-rabbit, 1:500; Jackson Immunoresearch) 
overnight at 4°C. Embryos were washed, incubated in DAPI (1 µg/ml, 
Invitrogen), and mounted in Prolong Gold (Invitrogen) using Fastwell Spacers 
(Sigma-Aldrich). Images were acquired using an LSM Live 5 line scanner 
confocal microscope (Carl Zeiss) or Nikon TE200 microscope. Volume and 
total cell number quantifications were performed on z-stack confocal images, 
while area quantification was performed on collapsed z-stack confocal images 
(n=3-7). Four to five sections every 100µm were used for quantifications per 
embryo, and analyzed using Metamorph and Prism Software. 
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For NGN3 immunostaining, fresh frozen sections were dried on a heat block for 
20min and post-fixed in 4% paraformaldehyde for 15min. Sections were then 
washed and permeablized in 0.1%triton-X/0.1%tween-20 for 15min and 
blocked in 0.1%tween-20/1%BSA/0.5%donkey serum for 45min. Primary 
antibodies (PDX1, Abcam#Ab47308,1:1000; Ngn3, Abcam#Ab47383, 1:1000) 
were incubated in block overnight at 4°C. Sections were then washed, 
incubated with secondary antibodies (594-donkey-anti-goat at 1:1000 Jackson 
Immunoresearch) in block, and mounted with Prolong Gold + DAPI (Invitrogen). 
Four to five sections every 100µm were used for quantifications per embryo 
(n=3 per genotype), and analyzed using Metamorph and Prism software. 
 
Using EdU to monitor the pancreatic progenitor proliferation in vivo. 
Proliferating cells were labeled using the Click-iT EdU Imaging Kit (Life 
Technologies, C10339). Female C57BL/6 and Tie2:Egfl7-Transgenic mice 
were subject to intraperitoneal injection of EdU at 50 μg per gram of body 
weight at E10.5 of pregnancy. After 30 minutes, mice were euthanized and 
embryos were isolated, dissected to expose pancreatic buds as above, and 
fixed in 4% paraformaldehyde overnight. Tissue was cryopreserved, embedded 
in a 2:1 OCT:30% sucrose mixture, and sectioned for further processing. 
Sections were permeablized and EdU detection was carried out according to 
the manufacturer’s protocol. Antibody staining was then performed. Sections 
were blocked for 30 mins in 5% donkey serum/0.3% Triton-X/PBS, incubated in 
primary antibody (PDX1, R&D Systems AF2419, 1:500) in block overnight at 
4°C. Sections were washed and incubated in secondary antibody (488-donkey-
anti-goat, 1:1000; Jackson Immunoresearch). Sections were then washed, 
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incubated in DAPI (1 µg/ml, Invitrogen), and mounted in Prolong Gold 
(Invitrogen). Images were acquired using Axioplan 2 imaging microscope (Carl 
Zeiss). Approximately every 10th section was used, for a total of five sections 
per embryo (n=3 per genotype), and analyzed using ImageJ and Prism 
software.  
 
FACS (Fluorescence activated cell sorting). Cells were dissociated by accutase 
(Innovative Cell Technologies) and resuspended in sorting buffer (1% Fetal 
bovine serum, 1mM EDTA, 25mM HEPES in DMEM without phenol red). Cell 
sorting was performed using BD FASCvantage by the flow cytometry core 
facility at the Hospital of Special Surgery. 
 
Explant culture. Mouse embryonic bud cultures largely followed published 
protocols (27). Briefly, E11.5 pancreatic buds were dissected to strip most of 
the surrounding mesenchymal tissue and cultured on Millicell filters (Millipore) 
in DMEM supplemented with 2 mM GlutaMAX, 100 U/ml Pen/Strep, and 1x 
B27 with or without recombinant mouse EGFL7 protein (1 μg/ml). After 40-hour 
culture, fresh media with BrdU (50ng/ml) were utilized to label mitotic cells. 
Tissues were harvested 4 hours later for processing and staining. Guinea pig 
anti-Pdx1 is a gift from Dr. Chris Wright. Mouse anti-BrdU (G3G4) is from the 
Developmental Studies Hybridoma Bank. 
 
Chemicals. Recombinant mouse EGFL7 and human EGFL7 proteins were 
purchased from Sino Biological Inc. Recombinant Human Angiopoietin-2 
(ANGPT2), CCL13, u-Plasminogen Activator/Urokinase (PLAU), IL24, Desert 
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Hedgehog (DHH), and PDGF-BB (PDGFB) were purchased from R&D system. 
EGFRi (EGFR/ErbB-2/ErbB-4 Inhibitor) was purchased from Calbiochem.  
 
Microscale thermophoresis (MST). EGF receptor and EGFL7 were purchased 
from Sino biologics, 10001-H08H and 11979-H07B.  EGF receptor (20mM) was 
labeled by L001 Monolith protein labeling kit RED-NHS. Labeled EGF receptor 
was diluted to about 67.7 nM in the binding reaction to optimize the intensity 
and stability of fluorescence signal. In each binding reaction, EGFL7 was 
reconstituted and diluted in a titration series from 5500 nM to 0.17 nM. The 
interaction between EGF receptor and EGFL7 was performed in PBST buffer 
(DPBS, Corning 21-031-CM, plus 0.05% tween 20). MST was monitored by 
NanoTemper MST monolith 115 in High-Throughput and Spectroscopy 
Resource Center at Rockefeller University. 
 
Glucose stimulated insulin secretion. Glucose stimulated insulin secretion 
(GSIS) test of C57BL/6 control (WT, n=3) and Tie2:Egfl7-transgenic (TG, n=4) 
mice. Mice were starved for about 20 hours before the test. Blood samples 
were collected from mouse tail veins as the measurement of serum insulin level 
under fasting condition. 3g/kg glucose solution (300g/L) by mouse weight was 
injected. 15 minutes after injection, blood samples were collected again as the 
measurement of serum insulin level after glucose injection. 
 
Glucose tolerance test. Glucose tolerance test was tested in C57BL/6 wild type 
(WT, n=2) and Tie2:Egfl7-transgenic (TG, n=4) mice. Blood glucose level 
(mg/dL) in each animal was measured before and every 15 minutes in the first 
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hour, and every 30 minutes in the second hour after glucose injection using 
AlphaTrak2. 
 
Statistical Analysis. Unless otherwise stated in figure legends, P-values given 
are from t tests. Bonferroni correction was performed as a multiple comparison 
test. In all figures, data were presented as mean ± SD if not otherwise stated, 
and P* < 0.05, P** < 0.01, P*** < 0.001. N represents the number of 
independent experiments. 
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Chapter 3 – Novel expression of EGFL7 in placental trophoblast and 
endothelial cells and its implication in preeclampsia*† 
 
3.1 – Rationale  
 
The mammalian placenta is responsible for exchange of nutrients and gases 
between the mother and the fetus. It is a highly vascularized, transient organ 
that requires coordinated signaling to complete maternal vascular remodeling 
and fetal vasculogenesis and angiogenesis. Dysregulated placental 
development can result in placental pathologies, such as preeclampsia (PE), a 
disease that affects 2-8% of all pregnancies and accounts for 10-15% of 
maternal deaths each year (1). PE is characterized by the sudden onset of 
maternal hypertension and proteinuria after 20 weeks gestation. Despite being 
a leading cause of maternal and fetal morbidity and mortality, the only 
treatment for PE remains to be delivery of the placenta and fetus (2). 
Importantly, the resolution of maternal signs of PE after delivery of the placenta 
implicates this organ in the cause of the disease. 
 
The American College of Obstetrics and Gynecology diagnoses PE when a 
patient presents with blood pressure greater than 140/90 mm Hg occurring 
more than once, combined with urinary protein greater than 300 mg/day (3), 
however many studies show that these criteria are inadequate as patient 
symptom presentation is variable. Work is underway to improve the diagnostic 
criteria for the disease (4, 5). Global endothelial dysfunction underlies the 
maternal signs of hypertension and proteinuria in PE (6). Hypertension results 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	  Lacko LA, Massimiani M, Sones JL, Hurtado R, Salvi S, Ferazzani S, Davisson RL, 
Campagnolo L, and Stuhlmann H. Novel expression of EGFL7 in placental trophoblast and 
endothelial cells and its implication in preeclampsia. Mechanisms of Development, 133, 163-
176 (2014).	  †	  *NOTE: Human studies were performed by M. Massimiani, S. Salvi, S. Ferazzani and L. 
Campagnolo	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from peripheral vasoconstriction, while proteinuria results from glomerular 
endotheliosis. Despite a great deal of research and advancements into the 
cause of PE, the pathophysiology of the disease remains largely unknown and 
early predictive diagnostics are lacking (5, 7).  
 
PE is a multifactorial, multisystem disorder. Although the maternal signs 
present after 20-weeks, PE is thought to begin much earlier in gestation (8, 9). 
Furthermore, inadequate trophoblast cell invasion, dysregulated placental 
vascularization, and an altered immune response have been implicated in the 
pathophysiology of PE (2, 6, 10). Several groups have shown that an 
imbalance of pro- and anti- angiogenic growth factors underlies the cause of 
PE (2, 6). Under-perfused and under-vascularized placentas are predominantly 
seen in PE patients, which may result from dysregulated angiogenic signaling. 
Dysregulation of pro-angiogenic molecules Vascular Endothelial Growth Factor 
(VEGF), Placental Growth Factor (PlGF), and Transforming Growth Factor beta 
(TGFβ), as well as anti-angiogenic molecules soluble fms-like tyrosine kinase1 
(sFlt1) and soluble Endoglin (sEng), have been associated with PE (6). It will 
be critical to understand the pathophysiology of PE and to develop novel 
predictive markers to better treat and diagnose patients with PE. Thus far, the 
most promising predictive measurement in PE has been the ratio of sFlt1 and 
PlGF, however, much work is still needed (6, 11).  
 
Studies of placentation and placental pathologies have been limited by the lack 
of both the availability of human tissues early in gestation and animal models 
that faithfully recapitulate human placental development. Rodents and humans 
both exhibit hemochorial placentation, in which maternal blood comes in direct 
contact with the chorion. Primates are hemomonochorial and rodents are 
hemotrichorial, with one and three trophoblast cell layers separating maternal 
blood from the fetal endothelium (12). Mouse placentas are similar to humans 
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in their morphology, structure, and gene expression, and are also amenable to 
powerful genetic technologies, making them an attractive animal model for 
studying placentation (12-14). In this chapter, I will present a novel angiogenic 
factor that is dysregulated in preeclampsia in both the mouse and human, and 
define its spatiotemporal expression profile during placental development.  
 
3.2 – Abstract  
 
The mammalian placenta is the site of nutrient and gas exchange between the 
mother and fetus, and is comprised of two principal cell types, trophoblasts and 
endothelial cells. Proper placental development requires invasion and 
differentiation of trophoblast cells, together with coordinated fetal 
vasculogenesis and maternal vascular remodeling. Disruption in these 
processes can result in placental pathologies such as preeclampsia (PE), a 
disease characterized by late gestational hypertension and proteinuria. 
Epidermal Growth Factor Like Domain 7 (EGFL7) is a largely endothelial-
restricted secreted factor that is critical for embryonic vascular development, 
and functions by modulating the Notch signaling pathway. However, the role of 
EGFL7 in placental development remains unknown. In this study, we use 
mouse models and human placentas to begin to understand the role of EGFL7 
during normal and pathological placentation. We show that Egfl7 is expressed 
by the endothelium of both the maternal and fetal vasculature throughout 
placental development. Importantly, we uncovered a previously unknown site of 
EGFL7 expression in the trophoblast cell lineage, including the trophectoderm, 
trophoblast stem cells, and placental trophoblasts.  Our results demonstrate 
significantly reduced Egfl7 expression in human PE placentas, concurrent with 
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a downregulation of Notch target genes. Moreover, using the BPH/5 mouse 
model of PE, we show that the downregulation of Egfl7 in compromised 
placentas occurs prior to the onset of characteristic maternal signs of PE. 
Together, our results implicate Egfl7 as a possible factor in normal placental 
development and in the etiology of PE.  
 
3.3  – Introduction 
 
The placenta serves as the site of contact for the maternal and embryonic 
circulatory systems to enable nutrient and gas exchange, and contains two 
primary functional cell types, trophoblasts and endothelial cells. Proper 
placental development requires invasion and differentiation of trophoblast cells, 
as well as coordinated maternal vascular remodeling and fetal vasculogenesis 
(15). Any disruption in these processes can result in placental pathologies, 
including preeclampsia (PE). PE is a leading cause of maternal and fetal 
morbidity and mortality worldwide, and the only resolutive treatment is delivery 
of the baby and placenta. Although the pathophysiology of PE remains largely 
unknown, inadequate trophoblast cell invasion, endothelial cell dysfunction, 
dysregulated uteroplacental vascularization, and an imbalance of pro- and anti-
angiogenic growth factors have been implicated in the disease (2).  
 
Recent studies have implicated Notch signaling, an evolutionarily conserved 
pathway that is important for cell fate specification, proliferation, and patterning 
(16), in placental development and the pathogenesis of PE. Targeted mutations 
of Notch signaling components in the mouse result in placental defects, 
demonstrating their vital roles for proper placental development (17-20). In 
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addition, Notch pathway proteins are downregulated in trophoblast cells, 
endothelial cells, and stromal cells of third trimester placentas from human 
preeclamptic patients as compared to normal patients (21).  
Epidermal Growth Factor Like Domain 7 (EGFL7) is a secreted factor that is 
present in both soluble and extracellular matrix-bound forms (22). Egfl7 
expression in the developing embryo is largely restricted to endothelial 
progenitors and actively proliferating endothelium (22-24). However, it is also 
found in embryonic stem cells, pre- and peri-implantation embryos, primordial 
germ cells, and some CNS neurons (22, 24-27). EGFL7 is largely 
downregulated during late embryogenesis and in the quiescent endothelium of 
the adult mouse, and is upregulated during pathological and physiological 
angiogenesis, such as in the uterus (22-24). Egfl7 is upregulated in response 
to, and has a protective effect against, hypoxia (28-30). It acts as a 
chemoattractant for endothelial cells and plays an important role in their 
proliferation and migration (23, 31, 32). EGFL7 functions in vascular patterning, 
stratification, and tubulogenesis in vitro and in the mouse and zebrafish (23, 
26, 32, 33). EGFL7 has been shown to modulate the Notch signaling cascade 
by acting either as a Notch agonist, such as in the developing embryo, or as a 
Notch antagonist, such as in the postnatal retina and neural stem cells (27, 33).  
 
Despite its key role in early embryogenesis, vascular development, and 
modulation of Notch signaling, the expression pattern and function of EGFL7 in 
normal and PE placentas is poorly understood. In this study, we investigated 
the expression pattern of EGFL7 in normal murine and human placentas. 
Rodents and primates both undergo hemochorial placentation (34). Despite 
some structural differences, the trophoblast cell types and the molecular 
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pathways driving placental development are highly conserved between mouse 
and human (13, 14, 34, 35). Importantly, the labyrinth in the mouse placenta is 
analogous to the chorionic villi in human placentas, whereas the junctional 
zone in mice is analogous to the cytotrophoblast cell columns (14) or the basal 
plate in humans (13). 
 
In addition to examining the expression profile of Egfl7 during normal placental 
development, this study investigates a potential role for EGFL7 in preeclampsia 
by analyzing human PE placentas and compromised placentas from the BPH/5 
murine PE model. The BPH/5 mouse strain exhibits the characteristic PE signs 
of late-gestational hypertension, proteinuria, and endothelial dysfunction (36, 
37). BPH/5 mice also show fetoplacental defects such as impaired endothelial 
cell branching, maternal spiral artery remodeling, and reduced fetal labyrinth 
depth (37). Here we have described the spatiotemporal expression profile of 
Egfl7 in placental endothelial cells in the mouse and human. We uncovered a 
previously unknown site of EGFL7 localization in the non-endothelial 
trophoblast lineage, beginning at the blastocyst stage and becoming restricted 
to a subset of differentiated trophoblast cells. Furthermore, we provide 
evidence that a downregulation of EGFL7 is associated with human PE and the 
BPH/5 mouse model of PE, and this downregulation is concomitant with a 
decrease in Notch target gene expression. 
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3.4  –  Results 
 
3.4.1 –  EGFL7 is expressed by maternal and fetal endothelial cells in the 
mouse placenta throughout gestation   
 
To obtain a temporal and spatial expression profile for Egfl7 throughout 
pregnancy, we used the mouse as a model system. To localize expression of 
Egfl7 transcripts in the maternal and fetal placental vasculature, RNA in situ 
hybridization (ISH) was performed on 100µm thick vibratome sections of 
C57BL/6 mouse placentas using an Egfl7 specific riboprobe. Egfl7 transcripts 
were highly expressed at E10.5, and were localized to maternal vessels, 
including the spiral arteries of the decidua (Figure 3.1A,B), and the branching 
vascular structures in the fetal labyrinth (Figure 3.1A,C). Following ISH, 
specimens were embedded in paraffin, sectioned, and counterstained to 
analyze the cellular morphology of Egfl7 mRNA expression in the placenta. 
Results revealed Egfl7 transcript expression in cells lining the large lumen of 
maternal vessels in the decidua (Figure 3.1D) and in the narrow and highly 
branched capillaries of the fetal labyrinth (Figure 3.1E). Egfl7 transcript levels 
were dramatically reduced at E12.5 and nearly undetectable at E18.5 
(Supplemental Figure 3.1). Egfl7 sense controls (insets of Figure 3.1A, 
Supplemental Figure 3.1A,C) demonstrate specificity of the Egfl7 riboprobe.  
 
To determine the spatiotemporal expression profile of EGFL7 protein, we 
performed double immunofluorescent staining for EGFL7 and the pan-
endothelial marker, CD31, on C57BL/6 mouse placentas (Figure 3.1-F-M, 
Supplemental Figure 3.2). EGFL7 colocalized with CD31 in the maternal 
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decidua and the fetal labyrinth at every stage examined, confirming that EGFL7 
localized to maternal and fetal endothelial cells in the placenta.  
 
Together, the results demonstrate that Egfl7 transcript and protein expression 
was dynamic throughout gestation. Egfl7 expression is high during early stages 
of vascular development in the placenta, with transcript expression peaking at 
E10.5 (Figure 3.1A-E), as well as high protein expression at E10.5 and E12.5 
(Figure 3.1F-M, Supplemental Figure 3.2A). At E18.5, a time point with fewer 
newly forming nascent vessels, Egfl7 transcript expression is dramatically 
lower (Supplemental Figure 3.1D), while the protein expression persists 
(Supplemental Figure 3.2B). Our data are consistent with previously reported 
Egfl7 expression data during vascular development and physiological 
angiogenesis, where the highest expression levels of Egfl7 are detected in 
actively proliferating endothelial cells, such as during formation of the initial 
vascular plexus during early embryogenesis (22, 23, 25, 26, 31-33). 
 
3.4.2 – Novel EGFL7 expression in placental trophoblast cells and the 
trophoblast cell lineage 
 
In addition to demonstrating dynamic expression of EGFL7 in the placental 
endothelium, our in situ hybridization images at high magnification also 
uncovered a novel expression domain for Egfl7 in non-endothelial cells of the 
junctional zone of the mouse placenta, albeit at reduced levels (Figure 3.2A-
B). Images of Egfl7 ISH paraffin sections revealed clusters of EGFL7 positive 	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Figure 3.1 EGFL7 is expressed by maternal and fetal endothelial cells in 
the mouse placenta. In situ hybridization was performed to determine Egfl7 
mRNA localization, using an Egfl7 riboprobe on 100µm thick vibratome 
sections of E10.5 C57BL/6 placentas (A-E). Higher magnification images of 
boxes in (A) demonstrating Egfl7 transcript is highly expressed in the maternal 
decidua (B) and fetal labyrinth (C). Egfl7 sense controls (A inset) show 
specificity of Egfl7 riboprobe. Paraffin sections of the vibratome sections 
showing cellular morphology after Egfl7 riboprobe staining in the maternal 
decidua (D) and fetal labyrinth (E). To determine the cell types expressing 
EGFL7 protein in the placenta, double immunofluorescent staining was 
performed on E12.5 C57BL/6 placentas for EGFL7 (red), CD31 (green) and 
nuclear DAPI (blue) (F-M). EGFL7 colocalizes with the endothelial cell marker, 
CD31, in the maternal decidua (F-I) and the fetal labyrinth (J-M). Dec-Maternal 
Decidua, JZ-Junctional Zone, Lab-Fetal Labyrinth. Scale bar (F-M) = 20µm.   
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cells located in the junctional zone, between the fetal labyrinth and trophoblast 
giant cells (Figure 3.2B). Double immunofluorescent staining for EGFL7 and 
the pan-trophoblast marker CYTOKERATIN (CK), performed on mid-gestation 
mouse placentas confirmed EGFL7 localization to the trophoblast lineage 
(Figure 3.2C-F). This is the first evidence that EGFL7 localizes to trophoblast 
cells of the placenta. The newly uncovered expression of EGFL7 in placental 
trophoblast cells prompted us to examine its temporal expression pattern 
during trophoblast lineage development in mice. Differentiated trophoblast cells 
are derived from the outer cell layer of blastocysts, the trophectoderm (38). We 
have previously shown that Egfl7 mRNA was expressed by blastocysts and 
embryonic stem cells, however its spatial expression in pre-implantation 
embryos was not defined (23, 25). Here, we isolated embryos from C57BL/6 
mice at the blastocyst stage of development and performed whole-mount 
immunofluorescent staining for EGFL7 and the trophectoderm marker, CDX2. 
Both inner cell mass cells and trophectoderm cells expressed EGFL7 (Figure 
3.2G-J). Therefore, Egfl7 is expressed at the first step of trophoblast lineage 
development. 
 
To further establish EGFL7 expression in the trophoblast lineage, we assayed 
trophoblast stem cells (TSC), a model of in vitro trophoblast cell differentiation. 
Multipotent TSC are derived from the trophectoderm of blastocysts, and upon 
removal of exogenous Fibroblast Growth Factor, they recapitulate the defining 
characteristics of in vivo trophoblast cell differentiation (39). Semi-quantitative 
and Real Time RT-PCR analysis showed that TSC express Egfl7 mRNA at 
significantly higher levels than embryonic stem cells (ESC), whereas primary 
mouse embryonic fibroblasts (MEF) express very low levels of Egfl7 (Figure  
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Figure 3.2 EGFL7 is expressed in the trophoblast cell lineage of the 
mouse. In situ hybridization was performed to determine Egfl7 mRNA 
localization, using an Egfl7 riboprobe on 100µm thick vibratome sections of 
E10.5 C57BL/6 placentas (A). Shown is the junctional zone of the placenta (A). 
Paraffin sections of the vibratome section showing cellular morphology of Egfl7 
riboprobe staining in the junctional zone of the placenta (B). Arrows indicate 
positive Egfl7 transcript signal in the junctional zone trophoblast cells. 
(TGC=Trophoblast Giant Cell). To determine the cell type expressing EGFL7 
protein in the placenta, double immunofluorescent staining was performed on 
E10.5 C57BL/6 placentas (C-F) for the pan-trophoblast marker, 
CYTOKERATIN (CK, red), EGFL7 (green), and nuclear DAPI (blue). Cross-
section of E10.5 placenta showing the fetal labyrinth (Lab), junctional zone (JZ, 
demarked by white lines) and maternal decidua (Dec). High magnification 
images (D-F) of the junctional zone demonstrating colocalization of EGFL7 with 
CK in the JZ trophoblast cells (arrows). Whole mount immunofluorescent 
staining of blastocyst-stage C57BL/6 embryos (G-J) for DAPI (blue), EGFL7 
(red), and trophectoderm cell marker, CDX2 (green) reveals EGFL7 protein 
localization to both inner cell mass (ICM) cells and trophectoderm cells 
(arrowheads). Real Time RT-PCR data for Egfl7 transcript expression in 
trophoblast stem cells (TSC), embryonic stem cells (ESC), and mouse 
embryonic fibroblasts (MEF), shows a significantly higher level of Egfl7 
expression in TSC,**P<0.01 (K, top). Agarose gel with products of semi-
quantitative RT-PCR for TSC, ESC and MEFs are shown, using Egfl7 and β-
actin specific primers (K, bottom). RNA in situ hybridization analysis of Egfl7 
mRNA in TSC (L-O) defines Egfl7 transcript expression in TSC. Phase-contrast 
and bright-field images of TSC incubated with an Egfl7 sense control probe (L-
M), and an Egfl7 antisense probe (N-O). Double immunofluorescent staining of 
TSC (P-T) for DAPI, EGFL7, and CDX2 demonstrating EGFL7 protein 
localization to TSC. Phase-contrast image of TSC colony is shown in (P). Scale 
bars in D-F=25µm, G-J=20µm, C and L-T=100µm. 
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3.2K, P<0.01). RNA in situ hybridization on TSC revealed specific localization 
of Egfl7 mRNA in TSC (Figure 3.2L-O).  EGFL7 protein was detected on 
cultured TSC, as shown by colocalization of EGFL7 and CDX2 using double 
immunofluorescent staining (Figure 3.2P-T). Two additional antibodies that are 
directed against different regions of the EGFL7 protein gave comparable 
results (data not shown). Together, our results show that EGFL7 is expressed 
by the trophectoderm of blastocysts, in trophoblast stem cells, and a subset of 
differentiated trophoblast cells in the mid-gestation mouse placenta. 
 
3.4.3 – EGFL7 is expressed by fetal endothelial cells and trophoblast cells 
of human chorionic villi 
 
To determine if EGFL7 expression in endothelial and trophoblast cells is 
conserved in human placentas, chorionic villi samples were obtained from 
normal pregnant women with an average pregnancy duration of 39 weeks. 
Double immunofluorescent staining analysis revealed that EGFL7 was 
expressed on fetal vessels, where it colocalized with the pan-endothelial 
marker, CD31 (Figure 3.3A-D). Importantly, EGFL7 was also expressed on the 
syncytiotrophoblast layer of the villi, where it colocalized with the pan-
trophoblast marker CYTOKERATIN (Figure 3.3E-H). To confirm this 
observation, EGFL7 staining was performed using two antibodies directed 
against different regions of the EGFL7 protein, and both gave comparable 
results (Supplemental Figure 3.3). Of note, expression of Egfl7 was not 
detected in the analogous mouse syncytiotrophoblasts. To further determine if 
EGFL7 localized to trophoblast cells of the human placenta, we isolated  
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Figure 3.3 EGFL7 is expressed in endothelial cells and trophoblast cells 
of the human placenta. Double immunofluorescent staining of normal human 
placentas (A-D) for EGFL7 (red), CD31 (green), and nuclear DAPI (blue) 
showing localization of EGFL7 protein on endothelial cells. Double 
immunofluorescent staining of human chorionic villi from placentas at 40-weeks 
of gestation (E-H) for nuclear DAPI (blue), EGFL7 (red), and pan-trophoblast 
marker CYTOKERATIN (CK) (green) demonstrates EGFL7 protein localization 
to trophoblast cells (arrows-fetal vessels, arrowheads-trophoblasts). Control 
staining of a close-by section (insets, E-H) using IgG and secondary 
antibodies only and nuclear Hoechst (blue) shows specificity of the antibodies. 
Expression of EGFL7 protein is found in human cytotrophoblast cells isolated 
from term placentas (I-L). Cells were stained for Hoechst (blue), EGFL7 (red) 
and CYTOKERATIN (green) (I-L). Scale bars in E-H and insets =100µm, and I-
L=30µm.  
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cytotrophoblast cells from term placentas as previously described (40). Double 
immunofluorescent staining showed that EGFL7 and CYTOKERATIN 
colocalized to the isolated cytotrophoblast cell (Figure 3.3I-L). Thus, our data 
demonstrate that EGFL7 is expressed in endothelial cells and trophoblast cells 
in both mouse and human placentas. 
 
3.4.4 – EGFL7 is downregulated in placentas of the BPH/5 mouse model 
of PE, prior to the onset of maternal signs of PE 
 
To examine potential variations in the expression and spatial distribution of 
EGFL7 in PE, we first utilized the BPH/5 mouse model of preeclampsia. E10.5 
placentas from control C57BL/6 and compromised BPH/5 fetoplacental units 
(see Materials and Methods) were subjected to immunofluorescent staining for 
EGFL7 and CD31 (Figure 3.4B-I). Importantly, this time point is prior to the 
onset of the late-gestational signs of PE in BPH/5 mice (36). EGFL7 protein 
expression was reduced in the fetal labyrinth zone of the BPH/5 placentas 
compared to C57BL/6 (Figure 3.4C,G). Total levels of CD31 appear 
unchanged (Figure 3.4D-E,H-I), suggesting no overall reduction in placental 
vascular density. The pattern of the vessels, however, appears irregular in 
BPH/5 placentas. In fact, a previous study reported the anatomical appearance 
of attenuated and irregularly branched fetal vessels in isolectin B4-stained 
BPH/5 placentas (37). To provide quantitative evidence, we performed Real 
Time RT-PCR analysis of E10.5 placentas from C57BL/6 and affected BPH/5 
fetoplacental units for Egfl7. Results demonstrated that Egfl7 mRNA levels 
were significantly downregulated in BPH/5 placentas compared to C57BL/6 
(Figure 3.4A, *P<0.05).  
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Figure 3.4 EGFL7 is downregulated in the placentas of the BPH/5 mouse 
model of preeclampsia. Real Time RT-PCR data for Egfl7 transcript levels in 
E10.5 placentas from C57BL/6 (WT) and BPH/5 mice reveal a significant 
decrease in Egfl7 in BPH/5 mice *P<0.05 (A). Immunofluorescent staining for 
EGFL7 protein (red), CD31 (green), and nuclear DAPI (blue) on the fetal 
labyrinth of E10.5 placentas from C57BL/6 (B-E) and BPH/5 mice (F-I) 
demonstrating a decrease in EGFL7 in BPH/5 placentas. Scale bar=100µm. 
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3.4.5 – EGFL7 expression is significantly reduced in human preeclamptic 
placentas 
 
Our results in the mouse model of PE prompted us to investigate potential 
variations in the expression of EGFL7 in human PE placentas. Biopsies from 
normal and PE human placentas were obtained and analyzed. Clinical 
characteristics of patients in this study are shown in Table 3.1 (41). The study 
group consisted of ten early-onset preeclamptic patients with average 
pregnancy duration of 32 weeks. The control group consisted of ten healthy 
pregnant women with average pregnancy duration of 39 weeks. All patients 
underwent Caesarean sections. There were no differences in patient age at 
delivery, gravidity, or parity between the study and control groups. However, 
the study group exhibited lower neonatal birth weight and placental weight, 
higher systolic and diastolic pressure, and earlier gestational age, all of which 
are characteristic of PE patients.  
 
To examine the EGFL7 protein expression profile of normal and PE placentas, 
we performed immunofluorescent staining for EGFL7 and CD31 on human 
placental biopsies (Figure 3.5A-F). EGFL7 was immunodetected on the 
endothelium and trophoblast cells of the human placenta. When comparing 
immunofluorescent staining of normal and PE placentas, EGFL7 appeared 
lower in both endothelial and trophoblast cells of PE placentas (Figure 3.5A-
B), whereas no major differences were observed for CD31 (Figure 3.5C-D).  
 
To quantify this observation, we performed Real-Time RT-PCR analysis on 
normal and PE samples for EGFL7 (Figure 3.5G) and CD31 (Figure 3.5H).   
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Figure 3.5 EGFL7 is significantly reduced in human preeclamptic 
placentas. Double immunofluorescent staining of normal and preeclamptic 
(PE) human placentas (A-F) for EGFL7 protein  (red), CD31 (green), and 
nuclear Hoechst (blue) revealing a decrease in EGFL7 protein in PE placentas 
(arrows-fetal vessels, arrowheads-trophoblasts). Real Time RT-PCR data for 
EGFL7 (G), CD31 (H), and VEGF (I) on normal and preeclamptic (PE) human 
placentas demonstrating a significant decrease in EGFL7 transcript levels in 
PE placentas, even further than the known angiogenic factor, VEGF (n=10, 
*P<0.05). Scale bars = 50µm. 
 
  
 	  88 
EGFL7 mRNA expression was significantly decreased by more than 10-fold in 
PE when compared to normal placentas (*P<0.05).  In contrast, no significant 
difference in the level of CD31 mRNA was detected, suggesting the difference 
in EGFL7 transcript levels was not due to an overall reduced expression of 
endothelial-specific genes or a reduction in vascular density (33, 42-44). In our 
study, the reduction in EGFL7 levels in PE was more pronounced as compared 
to VEGF levels (Figure 3.5I), a growth factor whose implication in PE has been 
extensively studied by others, and found to be either decreased (45-47) or 
increased (48-50) in PE placentas. Thus, EGFL7 expression is significantly 
downregulated in both a mouse model of PE and human PE placentas.  
 
3.4.6 – EGFL7 expression correlates with NOTCH signaling in normal and 
PE placentas 
 
Previous studies demonstrated that EGFL7 interacts with and modulates 
NOTCH signaling in vitro and in vivo (27, 33). To examine if EGFL7 and the 
Notch signaling pathway are concomitantly dysregulated in PE, we performed 
Real-Time RT-PCR analysis of normal and human PE placentas for NOTCH 
pathway members and NOTCH target genes. Our results demonstrated a 
significant decrease in NOTCH1, NOTCH4, HEY2, HEY1, and HES1 mRNA 
expression (P<0.05), and a downward trend in NOTCH2 expression in PE 
samples when compared to normal placentas (Figure 3.6 A-F). In contrast, 
transcript levels for the Notch ligands DLL4 and JAGGED1 were unchanged 
(Figure 3.6 G-H). Additionally, double immunofluorescent staining of human 
placentas revealed that EGFL7 colocalized with NOTCH4 on the 
syncytiotrophoblast cells (Figure 3.6 I-K). Thus, downregulation of NOTCH   
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Figure 3.6 Expression of NOTCH target genes and NOTCH receptors are 
downregulated in PE, concomitant with EGFL7. Real Time RT-PCR data for 
NOTCH pathway members on normal and preeclamptic (PE) human placentas 
(A-H). Gene expression analysis for HES1 (A), HEY1 (B), and HEY2 (C) 
demonstrating a significant decrease in all NOTCH target gene transcripts in 
PE. Gene expression analysis for NOTCH receptors NOTCH1 (D), NOTCH2 
(E), and NOTCH4 (F) demonstrating a significant downregulation in NOTCH1 
and NOTCH4, and a downward trend in NOTCH2 in PE patients. Gene 
expression analysis indicating no change in NOTCH ligands DLL4 (G) and 
JAGGED1 (H). (n=3-7, *P<0.05). Immunofluorescent staining of a cross section 
of human villi (I-K) for EGFL7 (red), NOTCH4 (green), and Hoechst (blue) 
(arrowheads-trophoblasts) shows colocalization of EGFL7 protein and 
NOTCH4. (*P<0.05) Scale bars = 50µm.  
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signaling members and NOTCH target gene expression correlate with a 
downregulation of EGFL7 in PE placentas, suggesting that EGFL7 may 
possibly function through the Notch signaling pathway. 
 
3.5 – Discussion 
 
PE is a complex placental disease that occurs in approximately 2-7.5% of 
pregnancies worldwide (51, 52), yet the etiology of the disease remains 
unknown and early predictive biomarkers are lacking. Research on the human 
placenta has mostly been limited to studying the organ at late gestation and full 
term. To fully understand the early causes and progression of this placental 
disease, it is crucial to employ appropriate animal and in vitro models. Our 
results show that expression of EGFL7 is significantly reduced in compromised 
placentas from the BPH/5 mouse model of PE compared to control mice. 
These findings are corroborated by our results from human PE samples. 
Importantly, reduced EGFL7 expression in PE placentas did not correlate with 
reduced expression of the pan-endothelial marker CD31 or reduced density of 
CD31-positive vessels. This suggests that the change in EGFL7 was not a 
consequence of reduced vascular density. However, as a caveat, CD31 
transcript expression is an indirect indicator for endothelial cell content and 
therefore may vary from the total vascular density in the placenta.  
 
Of interest to this study, EGFL7 was identified in two recent microarray studies 
as one of the genes significantly reduced in human PE placentas compared to 
normal placentas, consistent with our data (53, 54). Importantly, PE is thought 
to begin much earlier in gestation than when the late-stage human placental 
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biopsies used in most studies are obtained (8, 9). Our results describe changes 
in EGFL7 expression in phenotypically abnormal placentas of a PE mouse 
model, prior to the onset of characteristic maternal signs of PE, suggesting 
EGFL7 may be an early biomarker for the disease. It would be of interest to 
determine whether EGFL7 is altered in phenotypically abnormal placentas of 
other placental pathologies.  
 
Moreover, we have shown that EGFL7 is downregulated in human placentas of 
early-onset PE patients. Formally, we cannot rule out the possibility that the 
difference in EGFL7 expression is due to a difference in gestational age (PE: 
week-32 versus Normal: average of 39-week gestation). However, analysis of a 
single placenta at week-34 of gestation from a normal pregnancy indicated that 
EGFL7 expression levels were similar to those in normal term placentas (data 
not shown). Furthermore, both early onset PE and intrauterine growth 
restriction (IUGR) are associated with abnormal placentation and changes in 
plasma levels of placental angiogenic factors, but IUGR does not present with 
the maternal signs of hypertension and proteinuria. A recent study 
demonstrated that isolated IUGR with no maternal disease is associated with 
the same changes in placental angiogenic factors and subclinical endothelial 
dysfunction as in PE (55), suggesting the only difference between these two 
diseases may be maternal manifestations of the disease. Early-onset PE, 
which manifests by maternal hypertension and proteinuria, and progresses to a 
systemic hypoperfusion of multiple maternal organs, is often accompanied by 
abnormal fetal growth (56), as in the cases of our study (9/10; 90%). Therefore, 
reduced EGFL7 expression correlates with abnormal placentation that may be 
associated with either early-onset PE or isolated IUGR. Contribution of 
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additional facilitating factors, possibly at the level of maternal predisposition, 
may influence the manifestation of maternal hypertension and proteinuria.  
 
Previously, EGFL7 expression was thought to be restricted to actively 
proliferating vascular endothelium and to embryonic stem cells (22, 25, 27). 
Our study has used multiple methods to uncover a novel and dynamic 
expression pattern for Egfl7 during murine placental development. Egfl7 is 
expressed highly in the fetal and maternal vasculature of the placenta. Its 
highly regulated expression pattern that correlates with expression during 
embryonic development suggests a potential angiogenic role in placental 
angiogenesis. Notably, in addition to its expression in the fetal and maternal 
vessels of the placenta, we showed, for the first time, that Egfl7 was also 
expressed in the trophoblast cell lineage, beginning at the blastocyst stage and 
becoming restricted to a subset of differentiated trophoblast cells in the mature 
placenta. Trophoblast cells are the principal non-endothelial cell populations at 
the fetal-maternal interface. Targeted mutations in genes important for 
trophoblast cell differentiation result in placental defects or complete loss of 
placenta formation (38). Interestingly, knockdown of Egfl7 in ESC decreases 
the proliferation rate of undifferentiated ESC and impairs endothelial cord 
formation in an embryoid body model of ESC differentiation (32). Determining 
the role of Egfl7 in TSC and trophoblasts will be crucial for understanding the 
molecular mechanisms that control trophoblast lineage development and 
formation of the placenta.  
 
EGFL7 has previously been shown to colocalize and functionally interact with 
NOTCH to modulate Notch signaling (27, 33). Notch signaling is a crucial 
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pathway for placental development that affects both trophoblast and vascular 
cell function. For example, mouse strains with targeted deletions in the Notch 
receptors Notch1/4, their ligand Dll4, Notch target genes Hey1/2, or the Notch 
nuclear co-activator RBPJκ show defects in chorioallantoic branching and fetal 
placental angiogenesis (17-19, 57-61). Mash2, a basic helix-loop-helix 
transcription factor that is thought to be repressed by the Notch target Hes1 
(61), is critical for trophoblast cell fate specification in the mouse (62). Notch2 
receptor function is crucial for formation of maternal blood sinuses and 
maternal spiral artery and arterial canal remodeling (20, 63). A recent study 
demonstrated that the Notch2 receptor is prominently expressed in the 
junctional zone trophoblast cells at E10.5 (64), as is EGFL7. It would be of 
interest to determine if EGFL7 functionally interacts with NOTCH2 in the 
placental junctional zone. Here we showed that NOTCH4 colocalized with 
EGFL7 in the placenta, and that downregulation of EGFL7 coincided with a 
reduction in Notch target gene expression in human PE placentas. Together, 
our results suggest EGFL7 may act, at least in part, as a NOTCH agonist in the 
placenta. Interestingly, whereas Egfl7 was found to act as an antagonist of 
Notch postnatally and in HUVECs (27, 33), embryonic overexpression of Egfl7 
significantly increased Hey1 and Hey2 transcript levels, consistent with acting 
as a Notch agonist during embryogenesis (33). It will be important to further 
explore the functional relationship between EGFL7 and the Notch signaling 
pathway during placental development, in addition to other pathways through 
which EGFL7 may be functioning.  
 
EGFL7 gain- and loss-of-function approaches will help to fully understand the 
role of EGFL7 in the placenta and in placentopathies, and to dissect the 
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underlying mechanism in both trophoblast cells and endothelial cells. It will be 
important to examine if endothelial and/or trophoblast-derived EGFL7 acts as 
an angiogenic factor in the placenta and if secreted EGFL7 acts in an autocrine 
or paracrine fashion, as has been suggested (65). Of interest, partial 
embryonic lethality at mid-gestation was reported in the EGFL7 mutant mice 
that either overexpress EGFL7 or are EGFL7 deficient (31, 33). It is plausible 
that the partial lethality is, at least in part, due to a dysfunction in placental 
development.  
 
In conclusion, our study has uncovered a novel expression domain for EGFL7 
in non-endothelial trophoblast cell types. Its novel and dynamic expression 
pattern suggests a potential role in the molecular mechanisms that regulate 
trophoblast cell proliferation, differentiation, and invasion during placental 
development. Our study also links a significant downregulation of EGFL7 
expression to PE placentas. We demonstrate that, in a PE mouse model, the 
change occurs in phenotypically abnormal placentas before the onset of the 
characteristic maternal signs of preeclampsia. It is tempting to speculate that 
EGFL7 could play a functional role in the pathophysiology of PE, and that 
EGFL7 could be an early biomarker of PE.  
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Table 3.1: Clinical characteristics of pregnancies for placentas studied. Data 
are presented as median ± standard deviation and analyzed using a student’s 
t-test.   
 
Table 3.1 
  
Clinical Characteristics of Pregnancies for Placentas Studied 
 
Parameter Preeclampsia (n=10) Control (n=10) Significance 
 
Parity 
 
 
0 ± 0.3 
 
0 
 
 
Gestational age 
(weeks) 
 
 
32 ± 2 
 
39 ± 0 
 
<0.0001 
 
Maternal age 
(years) 
 
 
34 ± 4 
 
35 ± 6 
 
0.54 
 
Gravidity 
  
 
2 ± 1 
 
2 ± 1 
 
0.59 
 
Birth Weight 
(grams) 
 
 
1235 ± 359 
 
3372 ± 354 
 
<0.001 
 
Birth Weight 
Percentile 
 
 
9 ± 3 
 
63 ± 18 
 
<0.001 
 
Placental Weight 
(grams) 
 
 
236 ± 65 
 
550 ± 55 
 
<0.001 
 
Systolic blood 
pressure at 
delivery (mm Hg) 
 
 
161 ± 11 
 
130 ± 5 
 
<0.001 
 
Diastolic blood 
pressure at 
delivery (mm Hg) 
 
 
109 ± 8 
 
82 ± 3 
 
<0.001 
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Supplemental Figure 3.1 Egfl7 transcript expression in E12.5 and E18.5 
mouse placentas. In situ hybridization was performed using an Egfl7 
riboprobe on 100µm thick vibratome sections of E12.5 (A-C) and E18.5 (D-E) 
C57BL/6 placentas. Higher magnification images of boxes in (A) demonstrating 
that Egfl7 transcript is expressed in the maternal decidua (B) and fetal labyrinth 
(C). Egfl7 transcript is largely downregulated at E18.5 (D), except in a few 
vascular structures resembling arterioles in the fetal labyrinth (E). Egfl7 sense 
controls (A, D insets) show specificity of Egfl7 riboprobe. Dec-Maternal 
Decidua, JZ-Junctional Zone, Lab-Fetal Labyrinth. 
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Supplemental Figure 3.2 EGFL7 localizes to endothelial cells of E10.5 
and E18.5 mouse placentas. Double immunofluorescent staining was 
performed on E10.5 (A) and E18.5 (B) C57BL/6 placentas for EGFL7 (red), 
CD31 (green) and nuclear DAPI (blue). Images are collapsed z-stack confocal 
images of the maternal decidua and fetal labyrinth placental zones. EGFL7 
colocalizes with the endothelial cell marker, CD31, in the maternal decidua and 
the fetal labyrinth. Scale bar=20µm. 
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Supplemental Figure 3.3 EGFL7 expression in human placentas.  (A) H&E 
staining of week-10 chorionic villi (left), and of week-40 chorionic villi (right) 
demonstrating morphology. Scale bars=50mm. (B) EGFL7 antibodies from 
different sources show similar staining patterns in trophoblasts. Depicted are 
staining of chorionic villi from placentas at week-10 of gestation for Hoechst 
(blue) and EGFL7 (red). Top row: EGFL7 antibody from R&D; middle row: Egfl7 
antibody from Santa Cruz; bottom row: IgG control on the same chorionic villi 
specimen. (*-syncytiotrophoblast cell layer; arrow-inner trophoblast cell layer). 
Scale bar=50mm.  
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3.6 – Materials and methods 
 
Mice and placental sampling  
All animal protocols were approved by the Institutional Animal Care and Use 
Committee at Weill Cornell Medical College and Cornell University. BPH/5 mice 
were from in-house colonies. C57BL/6 mice were obtained from Jackson 
Laboratories and served as a control for the BPH/5 strain (36).  For timed 
pregnancies, the day of visualization of a vaginal plug was designated 
embryonic day 0.5 (E0.5). Fetoplacental units of BPH/5 pregnancies are of 
varying status as assessed by ultrasonography in utero, ranging from normal to 
compromised to resorbed (36). A subset of placentas were dissected only from 
E10.5 BPH/5 fetoplacental units that were compromised, i.e. with reduced fetal 
size, heart rate, and blood flow as determined by ultrasound as described (36, 
37). Placentas from normal or resorbed BPH/5 fetoplacental units were not 
sampled.  
 
Human placenta sampling 
Biopsies of placentas from normal (n=10) and early-onset PE pregnancies 
(n=10) were obtained from the Catholic University of Rome. The study 
respected the principles expressed in the Declaration of Helsinki and was 
approved by the Bioethical Committee of the Catholic University of Rome. For 
the collection of samples, all patients provided written informed consent. 
Clinical criteria used to define preeclampsia in our study were in accordance 
with the definition of the International Society for the Study of Hypertension in 
Pregnancy (ISSHP). In short, a patient (previously normotensive) was defined 
as being affected by PE if she had at least two diastolic blood pressure 
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measurements of 90mmHg in 24 hours (≥4 hours apart), accompanied by 
proteinuria of at least 300 mg in a 24-hour collection of urine. Early-onset PE 
diagnosis was defined as the development of PE before the 34th week of 
gestation. All 10 PE patients displayed abnormal uterine artery Doppler 
velocimetry. Among PE patients, two had a normal umbilical artery Doppler 
velocimetry, and five patients showed altered umbilical artery Doppler data (two 
of which were associated with a brain sparing effect). No Doppler data were 
available for three PE patients. Nine out of ten (90%) of the early-onset PE 
pregnancies were associated with intrauterine growth restriction, defined as an 
estimated fetal weight below the 10th percentile for gestational age.  
 
Chorionic villus samples were obtained from 3 healthy patients during prenatal 
diagnosis on the 10th week of gestation, following standard biopsy procedures. 
Placental villi from the third trimester of gestation were collected from 10 
normotensive, healthy patients during cesarean section by multiple biopsies in 
the parasagittal plane with respect to the umbilical cord insertion. Similar 
procedures were followed for the collection of PE samples. Portions of all 
placental sample types were immediately frozen in liquid nitrogen or embedded 
in OCT. Clinical characteristics of patients in this study are shown in Table 3.1 
(41).  
 
Cell Culture 
Mouse trophoblast stem cells (TSC) were gifts from Dr. Kat Hadjantonakis 
(Memorial Sloan Kettering Institute, New York, NY) and Dr. Janet Rossant 
(Hospital for Sick Children, Toronto, Canada). TSC were cultured and 
maintained using published methods (39), on mouse embryonic fibroblasts 
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(MEF) or with 50% MEF preconditioned medium. Primary human 
cytotrophoblasts were isolated from term placentas of normal patients, using a 
published protocol (40). Cytotrophoblast cells were cultured on Matrigel-coated 
dishes in DMEM/H-21 medium (Gibco) supplemented with 2% Nutridoma 
(Roche). 
 
RT-PCR 
Placentas from C57BL/6 and BPH/5 mice were dissected and flash frozen in 
liquid nitrogen. TSC were grown on 60-mm plates for RNA extraction. For 
mouse and cell culture studies, RNA was isolated using Trizol (Invitrogen) and 
reverse transcribed using qScript cDNA Supermix (Quanta Biosciences). Gene 
expression was measured quantitatively using SYBR Green (Applied 
Biosciences) and specific primer sets for β-actin, Egfl7, CD31, Hes1, and 
Hey1/2 as described (33). Differences among target expression were quantified 
using the ∆∆CT method with normalization to β-actin. For semi-quantitative RT-
PCR, cDNA was amplified using the following primers:  
Egfl7 (forward) 5’-CCACAAAAAGAAGAAGGCTACCC-3’  
Egfl7 (reverse) 5’-TCCAAGAAGGACCCTGCTCACTC-3’ 
β-actin (forward) 5’-GTGGGCCGCTCTAGGCACCAA-3’ 
β-actin (reverse) 5’-CTCTTTGATGTCACGCACGATTTC-3’ 
 
Products were analyzed on agarose gels.    
 
DNAse-free RNA from human placental tissue was prepared using the RNeasy 
Mini Kit (Qiagen). RNA quality was examined by determining the presence of 
ribosomal RNA bands in agarose gels. RNA was reverse transcribed using 
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random primers and the Superscript First Strand Synthesis System (Invitrogen) 
following the manufacturer’s protocol. Specific intron-spanning primers for 
EGFL7, CD31 and VEGF were designed using Primer Express software 
(Applied Biosystems, sequences are listed below). Gene expression was 
measured using Real Master Mix SYBR ROX (Eppendorf) and normalized to 
GAPDH.  
 
EGFL7: 5’-TCGTGCAGCGTGTGTACCAG-3’  
5’-GCGGTAGGCGGTCCTATAGATG-3’ 
CD31: 5’-TAGCGCATGGCCTGGTTAGAG-3’ 
5’-GGCGGTGCTCCCAAGTAGTCT-3’ 
VEGF: 5’-ATGACGAGGGCCTGGAGTGTG-3’ 
5’-CCTATGTGCTGGCCTTGGTGAG-3’ 
GAPDH:   5’-TCGGAGTCAACGGATTTGGT-3’ 
5’-GAATTTGCCATGGGTGGAAT-3’ 
NOTCH1: 5’- GCGGGATCCACTGTGAGAA-3’ 
5’-CCGTTGAAGCAGGAGCTCTCT-3’ 
NOTCH2: 5’- AAAAATGGGGCCAACCGAGAC-3’ 
5’-TTCATCCAGAAGGCGCACAA-3’ 
NOTCH4: 5’- CGGGCCTCTCTGCAACCT-3’ 
5’-GACGTCTATGCCTTGGCTCAGT-3’ 
HES1: 5’-AAAGATAGCTCGCGGCATTC-3’  
5’-AGGTGCTTCACTGTCATTTCCA-3’ 
HEY1: 5’- CATCGAGGTGGAGAAGGAGAGT-3’ 
5’-GACATGGAACCTAGAGCCGAACT-3’ 
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HEY2: 5’- CGACCTCCGAGAGCGACAT-3’ 
5’-CTTTGCCCCGAGTAATTGTTCT-3’ 
JAGGED1: 5’-GGAGGCGTGGGATTCCA-3’ 
5’-CCGAGTGAGAAGCCTTTTCAATAAT-3’ 
DLL-4: 5’-CCAGCCAGATGGCAACTTGT-3’ 
5’-CCCGAAAGACAGATAGGCTGTT-3’ 
 
RNA in situ hybridization 
Egfl7 cDNA probes were generated by RT-PCR using the following primers: 
Egfl7 forward 5’-AGTTACTGGTGCCAGGGATG-3’ and Egfl7 reverse 5’-
TCCTCCAAGAAGGACACCTG-3’. Amplicons were subcloned into pCR-2.1 or 
pCRII-Topo-TA vectors (Invitrogen) and linearized with SpeI or EcoRV. All 
probes were synthesized using DIG-labeling mix (Roche) according to 
manufacturer’s instructions.  
 
In situ hybridization (ISH) was performed by modification of the protocol 
described by Hurtado et al (66). C57BL/6 placentas were isolated, fixed in 4% 
paraformaldehyde, and methanol dehydrated. Placentas were rehydrated, 
incubated in 5% low melt agarose (BioRad) at 42°C for 2hours, and embedded 
in 5% low melt agarose through solidification at room temperature. Blocks were 
cut at 100µm thickness. Agarose was removed; sections were washed in PBT 
(PBS-0.01%Tween20), and treated with Proteinase K (10µg/ml, Roche) for 
20min. After terminating proteinase K reaction with Glycine (2mg/ml) and 
postfixation with 4% paraformaldehyde-0.1% gluteraldehyde (40min), samples 
were washed with PBT, pre-incubated with hybridization buffer (50% 
Formamide, 200µg/ml Yeast RNA, 0.5% Chaps, 1.3X SSC, 5mM EDTA, 
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100µg/ml Heparin, 0.2% Tween20 in DEPC-H2O) for 1hour at 60°C, and 
incubated overnight with DIG-labeled RNA probes (1µg/ml) at 60°C. Samples 
were washed and blocked with 2% Boehringer Blocking Reagent (BBR) 
(Roche) in MABT for 1hour and 2%BBR-20%NGS in MABT for 1hour, then 
incubated with alkaline phosphatase conjugated anti-DIG (Roche) at 1:2000 
overnight at 4°C. Samples were washed with MABT then NTMT (100mM NaCl, 
100mM Tris-HCl pH9.5, 50mM MgCl2, 1% Tween20, 20µM Levamisole, in 
H2O). Signals were detected with NBT-BCIP (Roche) chromogenic substrate in 
NTMT at 4°C. Samples were post-fixed in 4% paraformaldehyde and imaged 
using a DKC-5000 (Sony) Digital Photo Camera.  
 
Specimens were processed for paraffin sectioning as described by Hurtado, et 
al (66). Briefly, after ISH specimens were post-fixed with 4% paraformaldehyde 
in PBS, rocking for 48 hours at room temperature, and then overnight at 4°C. 
Specimens were then dehydrated stepwise in ethanol/double distilled H2O 
solutions as follows: 70% ethanol for 10 min, 90% ethanol for 10 min, 95% 
ethanol for 10 min, 3 × 100% ethanol for 10 min, 1:1 of ethanol/Citrisolv 
(Sigma) for 15 min. Specimens were then incubated in paraffin at 65°C as 
follows: 1:1 of Citrisolv/paraffin for 15 min, 3 × paraffin for 1hour, paraffin 
overnight, 2 × paraffin for 1hour. Specimens were then embedded in paraffin in 
a sagittal orientation and sectioned at 10μm thickness. Sections were 
rehydrated through a series of ethanol washes (100%, 90%, 85%, 70%), 
counterstained with Nuclear Fast Red (Sigma-Aldrich), dehydrated through a 
series of ethanol washes (70%, 85%, 90%, 100%), and mounted with 
Permount (Fisher Scientific).  
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For TSC, in situ hybridization was performed as above with the following 
modifications: TSC were cultured on 8-chamber slides (BD Biosciences) for 2 
days prior to fixation and proteinase K incubation was carried out for 3min.    
 
Antibodies 
The following primary antibodies were used for all immunostaining: EGFL7 
(Santa Cruz, SC-34416, 2µg/ml; R&D Systems AF3089; 2µg/ml, In-house 
EGFL7 (22), 1:100), CD31 (BD Biosciences, 553370; 5µg/ml (mouse studies) 
or 0.78mg/ml (human studies)), CDX2 (Biogenex; CDX2-88; 25mg/ml), 
Cytokeratin (DakoCytomation; 53.5µg/ml (human studies)), Cytokeratin (DAKO 
Z0622; 12µg/ml (mouse studies)), and NOTCH4 (Santa Cruz, SC-5594; 
2mg/ml). The following secondary antibodies were used: Dylight 594-donkey-α-
goat (Jackson Immunoresearch, 1.5µg/ml), Alexa 488-donkey-α-goat (Jackson 
Immunoresearch, 1.5µg/ml) or Cy3-donkey-α-goat (Chemicon, 4µg/ml), 
Alexa488 donkey-α-rabbit (Jackson Immunoresearch, 1.5µg/ml) or FITC-
donkey-α-rabbit (Chemicon, 4µg/ml), Alexa488 donkey-α-mouse (Jackson 
Immunoresearch, 1.5µg/ml (mouse studies) or Invitrogen, 4µg/ml (human 
studies)).  
 
Immunofluorescence 
Mouse whole fetoplacental units or placentas alone were isolated and 
embedded in an OCT:30% sucrose (2:1) mixture. Sections were permeablized 
in 0.5% Triton-X/0.1% Saponin/PBS (TSP) and blocked with 1% donkey serum 
in 0.1% TSP/PBS (PBS-TSP). Primary antibodies (EGFL7, CD31, 
CYTOKERATIN) were incubated for 3 hours at 37°C in block, then secondary 
antibodies in block, and mounted with Prolong Gold +DAPI (Invitrogen).  
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TSC were grown on 8-chamber slides (BD Biosciences) for 2-4 days and fixed 
with cold methanol for 5 minutes. TSC were washed in PBS-TSP and blocked 
with 1% donkey serum in PBS. Primary antibodies (EGFL7, CDX2) were 
incubated overnight at 4°C or 2hrs at RT in block, then secondary antibodies in 
block, and mounted as above.  
 
For the human studies, sections were fixed in methanol for 5 minutes at -20°C 
and blocked in 10% donkey serum/PBS. Sections were incubated with primary 
antibodies (EGFL7, CD31, CYTOKERATIN, NOTCH4) in 0.1%BSA/PBS 
overnight at 4°C. Sections were incubated in secondary antibodies, stained 
with Hoechst33342 (Sigma-Aldrich), and mounted with Möwiol (Sigma-Aldrich).  
 
Primary human cytotrophoblasts were cultured overnight, fixed with ice-cold 
methanol for 5 min at -20oC, and immunostained with EGFL7 and 
CYTOKERATIN antibodies. 
 
All images were acquired using an Axioplan 2 imaging microscope (Carl Zeiss) 
or a LSM Live 5 line scanner confocal microscope (Carl Zeiss).  
  
Whole Mount Immunostaining  
Blastocyst-stage embryos were isolated by flushing uteri with M2 Medium 
(Sigma). Embryos were collected between E3.5 and E4.0, washed with M2 
medium, fixed in 2% paraformaldehyde, and permeablized with 0.25%Triton-
X/PBS. Embryos were blocked with 2.5% donkey serum/0.5%PBS-TSP/PBS, 
and incubated with primary antibodies (EGFL7, CDX2) overnight at 37°C in 
 	  107 
block. Blastocysts were incubated with secondary antibodies and mounted with 
Prolong Gold+DAPI using Fastwell spacers (Sigma-Aldrich).  
 
Statistics 
Data are represented as mean ± SEM. The data were analyzed using a 
student’s t-test with statistical significance defined as P < 0.05. 
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Chapter 4 – Fetal vascular patterning defects in placentas with Egfl7 loss-
of-function* 
 
4.1 – Rationale  
 
The pathophysiology of preeclampsia (PE) is believed to begin early during 
pregnancy, despite the presentation of symptoms in late gestation (1, 2). The 
resolution of symptoms upon delivery of the placenta, as well as the vascular 
defects and dysregulated pro- and anti-angiogenic signaling common to most 
PE pregnancies, point to defects in placental vascularization and development 
as a major contributing factor underlying the disease (3-5). It is important to 
dissect the tightly regulated molecular mechanisms controlling normal placental 
development to begin to understand the diseased state and to elucidate 
diagnostic and therapeutic treatments.  
 
Formation of the placenta begins when the blastocyst-staged embryo implants 
into the receptive uterus. Fetal trophoblast cells invade the uterine decidua and 
commence a series of events to form the fetal-maternal interface, a site in 
which the fetal and maternal circulatory systems come in close contact. The 
first step in fetal labyrinth development is chorioallantoic fusion, when the 
allantois makes contact with the chorionic trophoblast cells (6-8). One molecule 
implicated in this process, for example, is cell adhesion molecule VCAM-1. 
VCAM-1 mutant mice display defects in chorioallantoic fusion and subsequent 
embryonic lethality (9, 10). Following chorioallantoic fusion, branching 
morphogenesis is initiated at sites along the chorion where Gcm1 is 
upregulated (7, 8, 11). Indeed, chorions of Gcm1-null mice remain flat and fail 
to initiate branching (11). Invaginations form within the chorion into which blood 
vessels grow from the allantois (6). Branching morphogenesis continues to 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	  Lacko LA, Hurtado R, Hinds SG, Gale NW, Stuhlmann H. Fetal vascular patterning defects in 
placentas with Egfl7 loss-of-function. Developmental Biology. To be submitted. 2015	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form a dense, arborized vascular network. The maternal blood is brought 
through large central arteries where their endothelial cells are replaced by 
specialized trophoblast cells. The maternal blood bathes the fetal vessels in the 
fetal labyrinth compartment of the placenta for efficient fetal-maternal exchange 
of nutrients, gases, and wastes (6).  
 
It is important to dissect the primary defect when analyzing abnormal placental 
vascularization, as it has been shown that many are caused by a primary 
defect in the trophoblast compartment (7, 8). In fact, several mouse mutants 
with a small, underdeveloped labyrinth are of genes primarily expressed in the 
trophoblast compartment, including Fgf2 and Fzd5 (6). Determining factors with 
primary vascular defects will allow for insights into disease states and 
therapeutics that can be used. 
 
In the previous chapter, I have described a novel, secreted angiogenic factor 
dysregulated in human term PE placentas and in a mouse model of PE early in 
gestation. The spatiotemporal expression profile of EGFL7 in trophoblast and 
endothelial cells of the developing placenta, and the downregulation prior to the 
onset of maternal signs of the disease, suggest that EGFL7 may play a 
causative role in the pathophysiology of PE. In this chapter, I will describe the 
functional role of Egfl7 during placental development using a global Egfl7 loss-
of-function mouse. Mice and humans exhibit strong similarities in the vascular 
development and remodeling events that occur in the placenta (12), making it 
an excellent model to study fetal labyrinth formation.  
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4.2 – Abstract 
 
The placenta provides an interface between the maternal and fetal circulatory 
systems during mammalian development. Proper placental development 
requires branching morphogenesis to form the arborized vascular network of 
fetal blood vessels. The fetal labyrinth vessels are bathed by maternal blood 
brought to the fetal compartment of the placenta through remodeling of 
maternal spiral arteries. Defects in fetoplacental vascularization can result in 
placental pathologies such as preeclampsia (PE) and/or intrauterine growth 
restriction. Angiogenic signaling plays an important role in normal placental 
development, and has been implicated in the pathophysiology of PE.  We have 
recently shown that the secreted angiogenic factor, Epidermal Growth Factor 
Like Domain 7 (Egfl7) is expressed in the endothelium of the fetal labyrinth and 
in spongiotrophoblasts of the junctional zone. Egfl7 expression is 
downregulated in human PE placentas and in placentas of the BPH/5 mouse 
model of PE. In this study, we investigated the role of Egfl7 during placental 
vascularization using mice with global Egfl7 loss-of-function (Egfl7 KO). At 
midgestion, Egfl7 KO placentas have reduced weight and exhibit irregular 
vascular patterning in the fetal labyrinth, resulting in reduced fetal blood space 
and reduced placental perfusion. Transcriptome profiling of mutant placentas 
implicates a role for Egfl7 in inflammatory signaling and extracellular matrix 
formation. Results of this study demonstrate that Egfl7 plays an important role 
in normal placental development and suggest that it could be a potential novel 
diagnostic tool and/or therapeutic target for treating placentopathies, including 
PE.  
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4.3 – Introduction 
 
The placenta is a critical, transient organ, which provides an interface between 
the maternal and fetal circulatory systems during pregnancy. The placenta 
performs gas and nutrient exchange as well as immunological and endocrine 
functions necessary for proper development of the mammalian embryo.  The 
site of exchange occurs in the chorionic villi in humans and the analogous fetal 
labyrinth zone in mice, where the maternal and fetal circulations are brought in 
close contact. Proper development of the fetal labyrinth requires a series of 
morphogenetic events, including chorionic branching morphogenesis and 
subsequent blood vessel development (6). At embryonic day (E)8.5 in the 
mouse, chorioallantoic fusion occurs when the allantois, arising from the 
posterior embryonic mesoderm, makes contact with the chorionic trophoblast 
cells, which arise from the extraembryonic ectoderm (6, 7). Upregulation of 
Glial cells missing-1 (Gcm1) in clusters of trophoblast cells in the chorion 
marks the sites of initiation of branching morphogenesis (11, 13).  Chorion 
trophoblast differentiation and morphogenesis develop extensive folds of 
chorionic villi, into which blood vessels from the allantois invade and 
interdigitate (6, 7), resulting in the highly branched vascular network of the fetal 
labyrinth of the placenta.  
 
Defects in fetoplacental vascularization can result in intrauterine growth 
restriction or placental pathologies such as preeclampsia (PE), a disease 
clinically diagnosed by late gestational hypertension and proteinuria. Despite 
intense research, the only treatment for PE is to induce labor and deliver the 
fetus and placenta. A number of factors have been implicated in the 
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pathogenesis of PE. These include an imbalance in pro- and anti-angiogenic 
factors, including dysregulation of soluble Flt1 (sFlt1), Placental Growth Factor 
(PlGF), and soluble Endoglin (sEng) (reviewed in (3, 4, 14, 15). We and others 
have shown that Epidermal growth factor like domain 7 (Egfl7) encodes an 
angiogenic factor that functions during vascular development in mouse and 
zebrafish embryos. Egfl7 expression is downregulated in human preeclamptic 
placentas (16, 17), placentas of a mouse model of PE prior to the onset of 
clinical signs (16), and in sera of PE patients (18).  
 
EGFL7 is a partially secreted protein that is predominantly localized to the 
extracellular matrix. Egfl7 is expressed in pre- and peri-implantation embryos, 
in both the inner cell mass and trophectoderm, and later becomes restricted to 
actively proliferating endothelium of the developing embryo proper, as well as 
placental endothelial cells and spongiotrophoblast cells (16, 19-22). Egfl7 
regulates vascular patterning and tubulogenesis in mouse, zebrafish, and 
Xenopus embryos (21, 23, 24), and has been shown to be important for the 
migration of endothelial and trophoblast cells (24-26). Furthermore, endothelial-
specific overexpression of Egfl7 in mice results in partial embryonic lethality at 
mid-gestation (24). 
 
To understand the functional role of Egfl7 during placental development and to 
determine if Egfl7 may functionally contribute to the development of PE-like 
symptoms, we analyzed placental development and fetal labyrinth formation in 
mice with a global Egfl7 loss-of-function. Although the mouse placenta differs 
from the human placenta in some aspects, the key signaling and 
developmental pathways are conserved between the two species, making the 
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mouse a good model of placental development and disease (6, 27). We show 
here that placentas with global Egfl7 knockout exhibit vascular patterning 
defects resulting in poor placental perfusion. Transcriptome profiling of mutant 
placentas uncovered dysregulation of genes involved in a number of biological 
processes important during placentation and pregnancy. The results of this 
study demonstrate that Egfl7 plays an important role in regulating fetal labyrinth 
formation in the placenta. 
 
4.4 – Results 
 
4.4.1 – Egfl7 loss-of-function results in reduced placental weights and 
embryonic lengths 
 
Previous Egfl7 loss-of-function studies in mice have been complicated by the 
presence of an intronic microRNA, miR-126 (28). Original analysis of knockout 
mice suggested a role for Egfl7 in vascular morphogenesis, however, later 
studies demonstrated that exclusive loss of miR-126 phenocopied the original 
Egfl7 knockout (Egfl7 KO) (21, 28). These results suggested the mutant 
phenotype could be attributed to the loss of miR-126 rather than loss of Egfl7.  
 
To determine Egfl7 function during placental development, we generated global 
Egfl7 loss-of-function in mice that did not affect expression of miR-126 (Egfl7 
KO). An embryonic stem cell clone, Velocigene #1501 (Regeneron) that 
contains a targeted Egfl7 allele with a 12-base pair deletion of the N-terminal 
MQTM sequence of its coding sequence, including the two predicted 5’ ATG 
start codons and an insertion of a hygromycin cassette flanked by loxP sites 
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(Figure 4.1A) was used for blastocyst injections. Founder mice were 
backcrossed ten generations into the C57BL/6 congenic background and then 
crossed to global Cre-expressing mice (CAG-Cre) for excision of the 
hygromycin cassette. Egfl7 transcript expression was measured by Real Time 
RT-PCR using two sets of primers, one complimentary to sequences in exons 
8 and 9, and a second pair with one primer complimentary to a sequence in 
exon 4 and the other containing the 12bp sequence targeted for deletion in the 
Egfl7 KO mice. Results demonstrate that Egfl7 mRNA containing exon 8 and 9 
sequences is transcribed in both C57BL/6 control and Egfl7 KO placentas. 
However the Egfl7 transcript that was amplified with the primer complimentary 
to the sequence encoding the two translational start sites is detected at high 
levels in C57BL/6 control mice, but not in Egfl7 KO mice (Figure 4.1B). The 
specific deletion of the translational start sites of Egfl7 is predicted to not affect 
production of miR-126, which is embedded in intron 7. Indeed, Real Time RT-
PCR of E12.5 C57BL/6 control and Egfl7 KO placentas demonstrate no 
significant difference in miR-126 expression levels (Figure 4.1C).  Egfl7 KO 
mice are fertile, however, Egfl7-/- newborn pups are detected at a slightly lower 
than expected Mendelian ratio (Table 4.1). In addition, approximately 10-12% 
of Egfl7 KO mice die within the first two weeks of life. 
 
To analyze the effect of Egfl7 loss-of-function on placental development, we 
first analyzed the placental and embryonic weights at E12.5 from Egfl7 
heterozygous (Egfl7+/-) intercrosses. At E12.5, all three layers of the mature 
mouse placenta are formed, including the maternal decidua, junctional zone, 
and the fetal labyrinth. At approximately E13.5, a global molecular switch from 
placental-expressed genes with functions in developmental processes to a 
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FIGURE 4.1 Egfl7 KO mice exhibit reduced placental weights and 
embryonic crown-to-rump lengths at E12.5. (A) Schematic representation of 
the Egfl7 gene structure. Shaded regions represent protein coding exons. The 
positions of the microRNA miR-126 embedded in intron 7 and the 12-bp 
deletion in the mutant Egfl7 allele including the two ATG codons in exon 3 are 
depicted (not drawn to scale). (B) Real Time RT-PCR for unmodified Egfl7 
mRNA and modified Egfl7 mRNA containing the 12-bp deletion in E12.5 
placentas from C57BL/6 control (+/+) and Egfl7 KO (-/-) mice. (C) Real Time 
RT-PCR for miR-126 and miR-126* in E12.5 placentas from C57BL/6 (+/+) and 
Egfl7 KO (-/-) mice. (D-E) E12.5 placenta (D) and embryo (E) weights from 
Egfl7+/- intercrosses demonstrating a significant decrease in Egfl7+/- and 
Egfl7-/- placentas. (F) Representative images of an E12.5 C57BL/6 control 
(+/+) embryo and Egfl7 KO (-/-) embryo. Quantification of the crown-to-rump 
length of E12.5 embryos showing a significant reduction in Egfl7 KO (-/-) 
embryo lengths.  
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TABLE 4.1 Observed Mendelien ratios of Egfl7 intercross matings. 
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mature phase requiring genes that stimulate increased metabolic functions 
occurs (29). Coincidentally, endothelial-specific overexpression of Egfl7 results 
in partial embryonic lethality at E12.5 (24).  
 
Egfl7+/- and Egfl7-/- placentas exhibit significantly reduced placental weights at 
E12.5 (Figure 4.1D). Egfl7+/- and Egfl7-/- embryonic weights trend downward 
but do not reach significance at this stage, when compared to Egfl7+/+ 
embryos (Figure 4.1E). To determine if Egfl7 knockout affects the size of 
midgestation embryos, crown-to-rump measurements were taken at E12.5 of 
embryos from C57BL/6 control and Egfl7 KO matings. The lengths of Egfl7 KO 
embryos were approximately 1mm shorter than C57BL/6 control embryos 
(Figure 4.1E). The results reveal a significant growth restriction at midgestation 
of Egfl7 KO embryos.  
 
Together, Egfl7 loss-of-function while maintaining normal miR-126 expression 
results in reduced placental weights and embryonic lengths, suggesting a 
functional role for Egfl7 in placental development. 
 
4.4.2 – Egfl7 loss-of-function results in vascular patterning defects and 
reduced fetal blood space in the fetal labyrinth 
 
To examine the morphology of Egfl7-/- placentas, hematoxylin and eosin 
staining was performed on cross-sections of paraffin-embedded E12.5 
C57BL/6 control and Egfl7 KO placentas. No gross abnormalities of placental 
zone formation, including the maternal decidua, junctional zone, and fetal 
labyrinth were found (Supplemental Figure 4.1A-B). At higher magnification,  
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FIGURE 4.2 Egfl7 KO placentas exhibit fetal labyrinth patterning defects 
and reduced fetal capillary blood space. (A-B) Hematoxylin and eosin 
stained fetal labyrinth sections of E12.5 C57BL/6 control (+/+) (A) and Egfl7 KO 
(-/-) (B) placentas. (C-D) Double immunofluorescence staining for pan-
endothelial marker, CD31 (green) and pan-trophoblast marker, CYTOKERATIN 
(red), on placenta sections from E12.5 C57BL/6 (+/+; C) and Egfl7 KO (-/-; D) 
conceptuses. (E-G) Quantification of the area of fetal blood space in the fetal 
labyrinth of C57BL/6 (+/+; E) and Egfl7 KO (-/-; F) mice, demonstrating a 
significant decrease in the percentage of area (G) covered by fetal capillaries in 
the fetal labyrinth zone of Egfl7 KO placentas. 
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the fetal capillaries of the Egfl7 KO placentas displayed vascular patterning 
defects, including decreased fetal blood space area (Figure 4.2A-B). The 
maternal decidua and junctional zone of Egfl7 KO placentas displayed no 
abnormalities at high magnification (Supplemental Figure 4.1C-D). To further 
characterize the placental morphology, double immunofluorescent staining was 
performed on frozen sections of E12.5 placentas for the pan-endothelial 
marker, CD31, and the pan-trophoblast marker, CYTOKERATIN. Results 
revealed that endothelial cells surround the irregularly patterned and narrowed 
fetal capillaries, while trophoblast cells line the maternal blood spaces (Figure 
4.2C-D). To determine if the fetal blood space area was reduced in Egfl7-/- 
placentas, the area of fetal capillary lumens was quantified. Results reveal a 
significant reduction in fetal capillary blood space in the fetal labyrinth of Egfl7 
KO placentas (Figure 4.2E-G).  
 
To determine if the reduced placental weights and altered vascular patterning 
observed in the Egfl7 KO placentas was due to an alteration in the proliferation 
rates of placental cells, EdU was injected intraperitoneally into E12.5 pregnant 
females. Placentas were isolated after 45 minutes, processed for EdU 
detection and stained for endothelial and trophoblast markers, CD31 and 
CYTOKERATIN (Supplemental Figure 4.2A-B). To quantify the number of 
proliferating endothelial cells, placentas were processed for EdU detection and 
immunostained for nuclear ERG (Supplemental Figure 4.2E-F). In the fetal 
labyrinth zone of E12.5 placentas from C57BL/6 control and Egfl7 KO mice, 
ERG is an endothelial specific marker that colocalizes with CD31 
(Supplemental Figure 4.2C-D). No significant difference in the number and  
	   126	  
percentage of proliferating endothelial and non-endothelial cells was observed 
between Egfl7 KO and C57BL/6 control placentas (Supplemental Figure 
4.2G-H).  
 
Thus, our data demonstrate that Egfl7 loss-of-function results in abnormal 
vascularization of the placental fetal labyrinth, and this defect cannot be 
attributed to altered proliferation. 
 
4.4.3 – Altered vascular patterning results in reduced placental perfusion 
in Egfl7 loss-of-function placentas  
 
To determine if the reduced fetal capillary blood space in mutant placentas 
affects placental perfusion with fetal blood, C57BL/6 control and Egfl7 KO 
whole conceptuses were isolated at gestation day 12.5. Microangiography of 
each conceptus was performed by injecting a fluorescent-lectin solution into the 
umbilical artery in order to mark endothelial cells of perfused vessels in the 
fetal labyrinth. Vibratome sections (100µm) of perfused C57BL/6 control 
placentas revealed a dense, arborized vascular network. Large chorionic 
vessels at the base of the placenta branched into smaller vessels of the fetal 
labyrinth, and further into the dense capillary network that covers a large 
surface area. Perfusion was restricted to the fetal labyrinth zone of the control 
placentas (Figure 4.3A). In contrast, Egfl7 KO placentas exhibited locally 
restricted and reduced placental perfusion. The large chorionic vessels were 
well perfused in the Egfl7 KO placentas. However, sporadic areas of well-
perfused, smaller branched vessels were surrounded by areas of poorly 
perfused vessels (Figure 4.3B).   
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FIGURE 4.3 Egfl7 KO mice exhibit reduced perfusion of the placental 
fetal labyrinth. (A-B) Microangiography of placentas from E12.5 C57BL/6 (+/+; 
A) and Egfl7 KO (-/-; B) mice. Insets: high magnification of representative 
images of 100µm thick vibratome cross-section of placentas perfused with 
tomato-lectin showing areas of reduced placental perfusion in Egfl7 KO mice 
as compared to controls. (C-H) Three-dimensional reconstruction of z-stack 
confocal images of placentas perfused with tomato-lectin (red) and co-stained 
with CD31 (green). (C-E) C57BL/6 placentas exhibit evenly perfused vessels 
lined by CD31-positive endothelial cells, while (F-H) Egfl7 KO placentas exhibit 
areas with well-perfused vessels lined by CD31-positive endothelial cells 
adjacent to poorly perfused CD31-positive vessels. Arrows demarcate 
narrowed fetal capillaries and demonstrate areas where reduction in perfusion 
begins.   
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Immunofluoresence staining for CD31 was performed on vibratome sections to 
determine if the reduced perfusion resulted from narrowed fetal capillaries lined 
by endothelial cells and vascular patterning defects. Confocal imaging of the 
fetal labyrinth revealed a well-patterned, perfused fetal capillary network lined 
by CD31-positive endothelial cells in C57BL/6 control placentas (Figure 4.3C-
E). In contrast, Egfl7 KO fetal labyrinth capillaries were tortuous, and subsets 
of vessels were poorly perfused (Figure 4.3F-H). Microangiography results 
revealed that perfusion was reduced at the sites of small, narrowed or 
constricted fetal capillaries in Egfl7 KO placentas (Figure 4.3H).  
 
To determine if the observed reduced placental perfusion had a functional 
consequence and affected embryonic growth at term, we analyzed the weights 
of embryos from Egfl7+/- X Egfl7+/- intercrosses at E18.5. Results 
demonstrated a trend toward decreased embryonic weight in Egfl7-/- embryos 
(Supplemental Figure 4.3). Thus, Egfl7 loss-of-function results in poor 
placental perfusion at sites of narrowed fetal capillaries.  
 
4.4.4 – Egfl7 loss-of-function results in differential expression of genes 
involved in inflammatory response, extracellular matrix signaling, and 
reproductive structure development  
 
Egfl7 loss-of-function results in placental vascular patterning defects and 
reduced placental perfusion. To determine the molecular pathways regulated 
through Egfl7, RNA Sequencing (RNA-seq) analysis was performed on RNA 
isolated from E12.5 placentas of C57BL/6 control and Egfl7 KO mice (Figure 
4.4A-C). TopHat and Cufflinks software was used to align the RNA-seq reads 
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to a reference genome and to assemble the reads into transcripts. Differentially 
expressed transcripts were analyzed using in-house software at the Genomics 
Core Facility at WCMC.  
 
RNA-seq analysis revealed that expression of 219 genes were significantly 
upregulated with a fold change greater than two in Egfl7 KO placentas, while 
only 6 genes were downregulated (Figure 4.4A-B). The top ten genes 
upregulated in Egfl7 KO placentas include Prss29, Wfdc15b, Gm5294, Eif2s3y, 
Ddx3y, Uty, Slc13a1, Akr1b, Sult1d1, and Klk1, while the six downregulated 
genes include Btg3, Amd1, Rps27, Lcn4, Tex13, and RhD.   
 
To identify the biological processes affected by Egfl7 loss-of-function in the 
placenta, gene ontology (GO) analyses using DAVID functional annotation 
software (30) was performed. GO results indicated that processes associated 
with extracellular matrix signaling, inflammatory response, and reproductive 
structure development were upregulated in Egfl7 KO placentas (Figure 4.4C). 
Fewer genes, and therefore fewer biological processes, were downregulated in 
Egfl7 KO mice.  
 
Eleven upregulated genes and one downregulated gene were validated by 
Real Time RT-PCR, including Csf1, Emr1, Ccl20, Cxcl16, Prap1, Serpina1e, 
Apoa4, Tgfb2, MMP7, TMEM213, Tmprss4, and RhD (Figure 4.4D). 
Representative genes of GO categories were chosen for validation. For 
example, (i) Csf1 (Colony stimulating factor 1), an important signaling molecule 
for macrophage function, was chosen for inflammatory signaling; (ii) Prap1 
(Proline rich acidic protein 1), a factor suggested to be important in the uterus 
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FIGURE 4.4 Transcriptional profiling of Egfl7 KO mouse placentas results 
in differential expression of genes related to immune function and 
extracellular matrix signaling. (A) Scatterplot of transformed relative RPKM 
expression values in E12.5 placentas from C57BL/6 and Egfl7 KO mice. 
Differentially expressed genes with a fold change greater than 2 are marked in 
green. (B) The number of genes differentially expressed in E12.5 placentas 
from Egfl7 KO mice compared to C57BL/6 control. (C) Gene ontology 
enrichment analysis listing Gene Ontology terms upregulated in E12.5 Egfl7 
KO placentas. (D) Real Time RT-PCR of eleven upregulated (Csf1, Emr1, 
Ccl20, Cxcl16, Prap1, Serpina1e, Apoa4, Tgfb2, MMP7, TMEM213, Tmprss4) 
and 1 downregulated (RhD) genes validating RNA-seq transcriptome analysis.
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during pregnancy (31), was chosen for reproductive structure development; 
and (iii) Tmprss4 (Transmembrane protease serine 4) a transmembrane serine 
protease demonstrated to be involved with extracellular matrix modification, cell 
adhesion, and embryonic development was chosen for the gene ontology 
category of extracellular matrix signaling (Figure 4.4D).  
 
Furthermore, to dissect the molecular pathways regulated through Egfl7 
specifically in the endothelial cell lineage, we isolated E12.5 placental 
endothelial cells from C57BL/6 control and Egfl7 KO mice by fluorescence 
activated cell sorting (FACS) with an antibody against the pan-endothelial 
marker, CD31. RNA-seq analysis was performed on RNA isolated from the 
sorted placental endothelial cells and performed as above. RNA-seq analysis 
revealed that expression of 12 genes were significantly upregulated with a fold 
change greater than two in Egfl7 KO placentas, while 32 genes were 
downregulated (Supplemental Figure 4.4). The top ten genes upregulated in 
Egfl7 KO placentas include Hist1h4j, Kdm5d, Uty, Ddx3y, Eif2s3y, S100g, Ucn, 
Cd52, Ly6h, and Cd74, while the top ten downregulated genes include Amd1, 
Ear1, Guca2b, Fam162b, Prap1, Gkn2, Afp, Pet117, C3, and Psg16. Results 
revealed that Egfl7 loss-of-function in the placenta affects differential signaling 
pathways in placental endothelial cells as compared to whole placentas. 
 
4.5 – Discussion 
 
Disruptions in vascular development of the placenta can result in intrauterine 
growth restriction, fetal demise, or placental pathologies such as PE. Although 
several signaling pathways have been implicated in labyrinth development, 
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especially chorionic branching morphogenesis, the number of mouse mutants 
with a primary defect in placental vascularization is limited (7). Defects in fetal 
labyrinth development and vascularization can be classified as resulting either 
from defects in chorionic branching morphogenesis with secondary vascular 
defects, or primarily resulting from vascular-specific defects (7). In this study, 
we have revealed that Egfl7 KO mice exhibit patterning defects in the fetal 
labyrinth vasculature that results in reduced fetal blood space area and 
reduced perfusion. Many mouse mutants that exhibit vascular defects are 
primarily expressed in the trophoblast compartment. Egfl7, however, is 
primarily expressed and secreted by endothelial cells of the fetal labyrinth and 
not in labyrinthine trophoblasts. Egfl7 is, nevertheless, expressed in 
spongiotrophoblast cells of the junctional zone (16), a cell type that has been 
implicated to be important for vascular development in the fetal labyrinth. For 
example, HtrA-1 deficient mice exhibit irregularly patterned fetal labyrinth 
vessels at E14.5, although its expression is restricted to spongiotrophoblast 
cells (32). Furthermore, RNA-seq results revealed that Egfl7 loss-of-function 
affects different signaling pathways in placental endothelial cells as compared 
to whole placentas, suggesting that it may have distinct, non-overlapping roles 
in placental trophoblast and endothelial cells. Additionally, reciprocal 
communication between trophoblast and endothelial cells is important for 
branching morphogenesis in the fetal labyrinth (8). Consequently, a role for 
spongiotrophoblast expressed EGFL7 cannot be ruled out as our Egfl7 loss-of-
function mice exhibit global knockout of the Egfl7 gene.   
 
It will be important to determine the cell-type specific role of Egfl7 in placental 
trophoblast and endothelial cells through conditional knockout experiments. 
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EGFL7 has recently been shown to function in vitro in human trophoblast cells 
through activation of MAPK, PI3K, and NOTCH signaling (26). In these studies, 
overexpression of EGFL7 in human choriocarcinoma cells resulted in 
significantly increased cell migration and invasiveness, suggesting that 
trophoblast-derived EGFL7 may play an indirect role in the vascularization of 
the placenta. The ERK/MAPK pathways have been implicated in placental 
development and formation of the blood-placental barrier (33, 34), with 
functions in both endothelial cells and pericytes.  
 
Egfl7 expression is also upregulated in response to hypoxia and exerts a 
protective effect against ischemia (35-38). Furthermore, Egfl7 plays a critical 
role in vascular patterning and tubulogenesis in vitro and in mouse, zebrafish, 
and Xenopus embryos (21, 23, 24, 39, 40). It is possible that the hypoxic 
environment present during placental development may contribute to its 
upregulation, thereby regulating the patterning of the fetal labyrinth vasculature 
to ensure a large surface area for nutrient and gas exchange.  
 
Placental vascular defects in Egfl7 KO mice appear to be partially resolved at 
late gestation, as seen in the slight decrease in Mendelian ratios of embryos 
and lack of a significant difference in placental weights at E18.5. Since 
extensive vascular remodeling occurs after E12.5, it is conceivable that the 
overall size and extent of vascularization of the placenta can change to 
compensate for primary defects (7). Of interest, a switch in placental gene 
expression patterns from genes that are primarily involved in growth and 
development to genes predominantly involved in maturation and increased 
metabolic processes occurs at E13.5 (29). Egfl7 expression is downregulated 
	   134	  
in the placenta as gestation approaches completion (16). Vascular remodeling 
and additional compensatory factors could therefore correct, during late 
gestation, the defects observed in Egfl7 KO mice at E12.5.  
 
Several of the biological processes predicted to be dysregulated in the Egfl7 
KO placentas could contribute to the observed placental phenotype. Several 
genes identified in the transcriptome analysis are involved in inflammatory 
signaling, such as Csf1, Emr1 (F4/80), Ccl20, and Cxcl16. Additionally, genes 
involved in reproductive structure development were upregulated in Egfl7 KO 
placentas, including Prap1, several members of the Psg family (Psg17/18/27), 
Prl7a2, and Ctsq. TMPRSS4 plays a role in both cancer and embryonic 
development (41). Zebrafish knockdown of TMPRSS4 results in defects in 
vascular development, global organogenesis, and cell-cell adhesion (42). Thus, 
the upregulation of these genes and their involvement in vascular patterning of 
other vascular beds support the notion that these processes may also 
contribute to vascular patterning of the fetal labyrinth, and that they are 
regulated by Egfl7 signaling.  
 
Determining the specific role of Egfl7 during vasculogenesis and angiogenesis 
has been complicated by the presence of an intronic mircoRNA miR-126 (28). 
A previous study by Kuhnert et al. using an Egfl7 KO model that did not affect 
miR-126 expression reported no vascular defects and no lethality in developing 
embryos (28). It is important to note, however, that these studies were 
performed in a mixed genetic background, presenting the possibility that 
modifying factors could have compensated during vascular development. In 
this study, miR-126 levels are unchanged and the global Egfl7 KO mice were 
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bred into a C57BL/6 congenic background. Our results demonstrate that mice 
with Egfl7 loss-of-function exhibit defects in placental development, including 
altered vascular patterning, reduced fetal blood space, and poor placental 
perfusion resulting in embryos with reduced placental weights and reduced 
crown-to-rump lengths at midgestation. Egfl7 expression has been shown to be 
reduced in human PE placentas and placentas from a mouse model of PE (16). 
It will therefore be important to determine if the constriction of fetal vessels and 
reduction in placental perfusion in Egfl7 KO mice results in preeclampsia-like 
phenotypes. 
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SUPPLEMENTAL FIGURE 4.1 Egfl7 KO placentas do not exhibit defects 
in maternal decidua or junctional zone placental layer formation. (A-B) 
Hematoxylin and eosin stained cross sections of E12.5 C57BL/6 control (+/+) 
(A) and Egfl7 KO (-/-) (B) placentas, demonstrating no overt defects in 
placental zone formation. (C-D) High magnification images of the junctional 
zone demonstrating no over defects in Egfl7 KO (-/-; D) placentas as compared 
for C57BL/6 controls (+/+; C). Scale bars = 100µm. DEC-decidua, JZ-junctional 
zone, LAB-fetal labyrinth, TGC-trophoblast giant cell
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SUPPLEMENTAL FIGURE 4.2 Egfl7 loss-of-function does not affect 
proliferation of placental cells. (A-B) Triple immunfluorescent staining of 
E12.5 placentas from C57BL/6 (+/+; A) and Egfl7 KO (-/-; B) mice for the pan-
trophoblast marker, CYTOKERATIN (CK; red), pan-endothelial marker, CD31 
(green), and proliferation marker, EdU (white). (C-D) Double immunfluorescent 
staining of E12.5 placentas from C57BL/6 (+/+; C) and Egfl7 KO (-/-; D) mice 
for CD31 (green) and nuclear endothelial marker, ERG (red). (E-F) Double 
immunfluorescent staining of E12.5 placentas from C57BL/6 (+/+; E) and Egfl7 
KO (-/-; F) mice for ERG (green) and EdU (red). (G-H) Quantification of the 
percentage of proliferating endothelial and non-endothelial cells in C57BL/6 
(+/+) and Egfl7 KO (-/-) placentas. Scale bars = 100µm.
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SUPPLEMENTAL FIGURE 4.3 Variable weights observed in late-stage 
Egfl7 KO embryos. E12.5 embryonic weights from Egfl7+/- intercrosses 
demonstrating a variable, but trend to decreased weights in Egfl7-/- embryos. 
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SUPPLEMENTAL FIGURE 4.4 Transcriptional profiling of FACS sorted 
placental endothelial cells. Scatterplot of transformed relative RPKM 
expression values in isolated E12.5 placental endothelial cells from C57BL/6 
and Egfl7 KO mice. Differentially expressed genes with a fold change greater 
than 2 are marked in green. 
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4.6 – Materials and Methods 
 
Mice  
All animal protocols were approved and are in accordance with the Institutional 
Animal Care and Use Committee (IACUC) at Weill Cornell Medical College of 
Cornell University. C57Bl/6 mice were obtained from Jackson Laboratories and 
Egfl7-KO mice were derived at the Mouse Genetics Core at Memorial Sloan 
Kettering Cancer Center from embryonic stem cells of Velocigene clone #1501 
(Regeneron Pharmaceuticals, Inc), a generous gift from Dr. Nick Gale of 
Regeneron. Velocigene clone #1501 contains a 12-bp deletion of the N-
terminal MQTM sequence (including the two 5’ ATG start codons) and insertion 
of a hygromycin cassette flanked by loxP sites. Founder mice were 
backcrossed into the C57Bl/6 background for 10 generations to obtain 
congenic mice.  To remove the hygromycin cassette, Egfl7 knockout mice were 
bred to CAG-Cre transgenic mice (MSKCC Transgenic Core), a strain that 
retains Cre Recombinase activity in mature oocytes, irrespective of cre 
transgene transmission (43). Mice that were identified by PCR as positive for 
removal of the hygromycin cassette and negative for Cre were used for all 
further studies.  
 
Timed pregnancies were performed and date of visualization of the vaginal 
plug was designated embryonic day 0.5 (E0.5). Placentas and embryos were 
dissected, imaged on Zeiss Discovery.V20 stereoscope, and weighed after 
removal of excess fluid. Crown-to-rump lengths were measured using ImageJ 
software.  
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Immunohistochemistry  
Placentas were isolated, fixed in 4% paraformaldehyde, and embedded in an 
OCT:30% sucrose mixture in PBS (2:1). Cryosections were permeablized in 
0.5% Triton-X/0.1% Saponin/PBS (TSP) and blocked with 1% donkey serum in 
0.1% TSP/PBS (PBS–TSP). Primary antibodies (CD31, BD Biosciences, 
553370, 5µg/ml; CYTOKERATIN (DAKO Z0622, 12µg/ml; ERG, Abcam, 
ab110639, 0.17µg/ml) were incubated overnight at 4°C in block, followed by 
incubation with secondary antibodies in block (Alexa488-donkey-α-rat and 
Cy3-donkey-α-rabbit, Jackson Immunoresearch, 1.5 µg/ml), and mounted with 
Prolong Gold + DAPI (Invitrogen). Images were acquired using an Axioplan 2 
imaging microscope (Carl Zeiss).  
 
Hematoxylin and Eosin Staining  
Placentas were isolated, fixed in 4% paraformaldehyde, dehydrated through a 
series of alcohols, and embedded in paraffin. Sections were stained with 
hematoxylin and eosin, and mounted with Permount (Fisher Scientific). Images 
were acquired using an Axioplan 2 imaging microscope (Zeiss).  
 
EdU Labeling 
Proliferating cells were labeled using the Click-iT EdU Imaging Kit (Life 
Technologies, C10339). Female C57Bl/6 and Egfl7-KO mice were subjected to 
intraperitoneal injection of EdU at 50 μg per gram of body weight at day-12.5 of 
gestation. After 45 minutes, mice were euthanized and placentas were isolated 
and fixed in 4% paraformaldehyde overnight. Tissue was cryopreserved, 
embedded in a 2:1 OCT:30% sucrose mixture, and sectioned for further 
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processing. Sections were permeablized and EdU detection was carried out 
according to the manufacturer’s protocol. Antibody staining was then performed 
as described above. Approximately every 10th section was used for 
quantification of labeling, for a total of five sections per placenta (n=3 per 
genotype), and analyzed using ImageJ, Metamorph and Prism software.  
 
Quantifications 
Fetal blood space was analyzed on 9 images from the fetal labyrinth zone of 
n=3 placentas from at least two litters of C57Bl/6 and Egfl7-KO mice. Fetal 
blood space was identified by CD31-positive staining surrounding DAPI-
positive nucleated erythrocytes and traced using ImageJ software. The 
percentage of fetal blood space of the total area analyzed was quantified.  
 
Microangiography 
Females were sacrificed at day 12.5 of gestation by cervical dislocation, 
conceptuses were isolated in L15 medium (Invitrogen) and umbilical arteries 
exposed. A 40µl solution of tomato-lectin (Vector Labs, #DL-1177) in PBS 
containing heparin was injected into the umbilical artery. Each conceptus was 
incubated for 10minutes at 37°C in L15 medium (Corning), allowing the 
embryonic heart to circulate the injection throughout the feto-placental 
circulation. Placentas and embryos were then further dissected and fixed 
overnight at 4°C in 4% paraformaldehyde. Only conceptuses in which the 
fluorescent lectin had reached the embryo were kept for analysis. Placentas 
were incubated in 5% low melt agarose (Lonza) for 2hours at 42°C, and 
embedded in 5% low melt agarose through solidification at room temperature. 
Blocks were cut on a vibratome at 100µm thickness. Agarose was removed 
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and sections were either mounted in Prolong Gold (Life Technologies) using 
slide wells (Electron Microscopy Sciences) or processed for immunostaining.  
 
Placenta vibratome sections were blocked for 3hours in 10% donkey serum in 
TSP, incubated in CD31 primary antibody (BD #550274; 1µg/ml) in 5% donkey 
serum in TSP, overnight at 4°C.  Sections were washed in TSP, incubated in 
488-donkey-α-rat secondary antibody (JacksonImmuno #712-546-150; 1:500), 
washed in TSP, and mounted in Prolong Gold (Life Technologies) using slide 
wells.  
 
FACS analysis 
Placentas from C57BL/6 and Egfl7 KO timed pregnant females were isolated at 
E12.5. Pooled placentas were digested with Collagenase/Dispase (Roche) and 
DNAse I (Roche) at 37°C for 20minutes. Digested placentas were passed 
through a 40µm cell strainer to form a single cell suspension. Samples were 
then depleted using lineage cell depletion kit per manufacturer’s protocol 
(Miltenyi Biotec). Cells were resuspended in PBS+2%FBS and incubated in 
primary-conjugated antibody for CD31 (APC-CD31, BD Pharmingen) for 
30minutes at room temperature. Stained cells were washed in PBS-2%FBS, 
sorted using the BD FACSAriaII SORP high-speed cell sorter and analyzed 
using BD FACSDiva software (BD Biosciences) with the aid of Dr. Jason 
McCormick at the Weill Cornell Medical College Department of Pathology and 
Laboratory Medicine Flow Cytometry Core for FACS. 
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RNA-seq 
Total RNA was isolated from E12.5 placentas or isolated placental endothelial 
cells using Trizol Reagent. RNA was digested with DNase I (Zymo Research) 
and purified using the DNA-free RNA kit (Zymo Research). RNA quality was 
verified using an Agilent Technologies Bioanalyzer 2100 and samples were 
processed for next-generation sequencing by the Genomics Core Facility at 
Weill Cornell Medical College.  
 
RNA was converted into cDNA using the Illumina TruSeq sample preparation 
kit, and cDNA hybridization and cluster amplification was performed using a 
cBOT fluidic device, following protocols offered by Illumina, Inc. (San Diego, 
CA). Templates were then sequenced on the HiSeq2500 (Illumina) by 
performing single read clustering (51 cycle sequencing). Analysis of the reads 
was performed with the help of the Genomics Core Facility (Dr. Tuo Zhang) 
using TopHat and Cufflinks software, and alignment to the University of 
California, Santa Cruz mm9 reference genome. Differentially expressed 
transcripts were analyzed using in-house software. 
 
Real Time RT-PCR 
Placentas from C57BL/6 and Egfl7 knockout mice were dissected and flash 
frozen in liquid nitrogen. RNA was isolated using Trizol (Invitrogen) and reverse 
transcribed using qScript cDNA Synthesis Kit (Quanta Biosciences). Gene 
expression was measured quantitatively using PerfeCTa SYBR Green 
SuperMix for iQ (Quanta Biosciences) and specific primer sets for ß-actin, 
Egfl7 (as described in (24)). Additional primer sequences are listed in 
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Supplemental Table 4.1. Differences among target expression were 
quantified using the ∆∆CT method and normalized to ß-actin. 
 
For analysis of miR-126 expression, ten nanograms of E12.5 placenta RNA 
was reverse transcribed using TaqMan MicroRNA Reverse Transcription Kit 
(Life Technologies #4366596) with RT primers specific for miR126 (002228),  
miR126* (000451),  and control snoRNA234(0001234). Real Time PCR was 
performed using TaqMan Universal PCR Master Mix (Life Technologies 
#4324018) and TaqMan probes for miR126 (002228), miR126* (000451), and 
control snoRNA234 (0001234). 
 
Statistics 
Data are represented as mean ± SEM. The data were analyzed using a 
student’s t-test with statistical significance defined as *P < 0.05, **P<0.001 
unless otherwise noted. 
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SUPPLEMENTAL TABLE 4.1 Real Time RT-PCR primers.
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Chapter 5 – Conclusion and Future Perspectives 
 
5.1 – Summary  
 
The work described in this thesis demonstrates that Egfl7 plays a functional 
role during organogenesis. Using Egfl7 overexpressing and knockout mice, as 
well as a mouse model for preeclampsia, I have demonstrated that 
dysregulation of Egfl7 expression results in aberrant pancreatic and placental 
development and function. In the pancreas, endothelial EGFL7 regulates 
pancreatic progenitor cell proliferation and stem cell maintenance, and thus 
pancreatic size. In the placenta, EGFL7 affects vascular patterning and 
perfusion of the fetal labyrinth. Results of these studies have provided insight 
into the function of Egfl7 during organogenesis and its implications in 
pathological pancreatic and placental development. 
 
5.2 – Implications of Egfl7 signaling during pancreatic development 
 
Endothelial cells play a critical role in pancreatic growth and development (1-3). 
In chapter 2, I revealed that Egfl7 signaling from the endothelium influences the 
size of the developing pancreas in vivo by facilitating proliferation of pancreatic 
progenitor cells. The laboratory of Dr. Shuibing Chen demonstrated the stage-
dependent role of EGFL7 in pancreatic progenitor cell self-renewal in vitro 
using hESCs. Furthermore, collaborative studies with the Chen laboratory 
uncovered the functional consequences of Egfl7 overexpression and aberrant 
pancreatic development by revealing that adult Egfl7 overexpressing mice have 
impaired beta cell function. Taken together, these results provide insight into 
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understanding normal pancreatic development and have clinical implications 
for diseases of the pancreas, such as diabetes mellitus.  
 
Diabetes mellitus is a chronic health condition characterized by prolonged 
hyperglycemia resulting from defects in insulin production or insulin action (4), 
and is expected to reach a prevalence of 4.4% of the worldwide population by 
2030 (5). A promising strategy to treat diabetes involves the transplantation of 
mature, insulin-producing, glucose-responding beta cells derived from stepwise 
differentiation of human embryonic stem cells (hESC) in vitro for cell 
replacement therapy (6). The studies presented in chapter 2 suggest that 
EGFL7 can be used as a therapeutic tool for developing methods to increase 
the functional beta cell population in diabetic patients. 
 
5.3 –Implications of Egfl7 signaling during placental development 
 
Despite its critical role during pregnancy, the placenta remains under-studied. 
Many of the dynamic changes that occur in the placenta throughout gestation 
remain elusive. The lack of progress in understanding placental physiology and 
development is largely due to the difficulty in obtaining human placental tissue 
early in gestation, and a lack of animal and in vitro models that faithfully 
recapitulate human placental development. The mouse placenta, however, 
shares many structural, morphological, and genetic similarities to the human 
placenta, making it an excellent model for studying the development of this 
organ (7, 8). Indeed, several genetic mutant mice have elucidated much of 
what we know today about placental development (8). In this thesis, I have 
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utilized a mouse model of PE and developed a genetic knockout mouse of 
Egfl7 to study normal and pathological placental development.  
 
The studies described in chapter 3 provide much needed insight into the role of 
Egfl7 in placental development. Detailed characterization of the spatiotemporal 
expression profile in the placenta revealed a novel expression domain for Egfl7 
in trophoblast cells. Spongiotrophoblast cells of the junctional zone of the 
mouse placenta are known to play a structural role and to produce hormones, 
however, the molecular mechanisms underlying spongiotrophoblast function 
remain poorly characterized. Dissecting the trophoblast-specific role of Egfl7 
during placental development may shed insight into the function and physiology 
of this subset of spongiotrophoblast cells, as Egfl7 may mark a specialized, 
distinct group of trophoblast cells in the junctional zone of the placenta.  
 
Furthermore, communication between trophoblast and endothelial cells has 
been suggested as an important mechanism in fetal labyrinth formation and 
patterning (9). Consistent with these functions, Egfl7 has been shown to have 
both a paracrine and autocrine effect. It is plausible that Egfl7 may play distinct, 
non-overlapping roles in these two cell types. Ongoing and future studies 
dissecting the differential roles that Egfl7 plays in placental endothelial and 
trophoblast cell function and determining if Egfl7 is involved in interactive 
trophoblast and endothelial cell communication will elucidate the mechanisms 
by which Egfl7 affects normal and pathological placental development. 
Spongiotrophoblast-specific ablation of Egfl7 using a Tpbpa-Cre mouse, and 
endothelial-specific ablation of Egfl7 using a VE-cadherin-Cre mouse, will shed 
insight into the cell-specific functions of Egfl7 during placental development. 
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Furthermore, these studies can be complimented by in vitro studies using cells 
derived from C57BL/6 control and Egfl7 knockout mice, including trophoblast 
stem cells and isolated placental endothelial cells. 
 
The studies described in chapter 3 also have clinical implications for PE. 
Abnormal placental function underlies the maternal presentation of the disease, 
as PE resolves after delivery of the placenta and fetus (10-12). Although the 
clinical presentation of PE occurs in late gestation, studies suggest that the 
pathogenesis of the disease begins as early as implantation (13, 14). In 
chapter 3, I have shown that Egfl7 is downregulated in placentas of a PE 
mouse model preceding elevated blood pressure and proteinuria, suggesting a 
possible causative role in its pathophysiology. It is well established that a 
dysregulation of pro- and anti-angiogenic signaling factors is involved in PE, 
and it is likely that several signaling pathways are dysregulated, including 
signaling through EGFL7. With that, development of novel diagnostic and 
therapeutic tools will be needed for treatment of the disease. Indeed, studies 
are underway to diagnose PE using a panel of markers (15-17). Because Egfl7 
is downregulated in the BPH/5 mouse model of PE early in gestation, and 
downregulation of Egfl7 has been associated with human PE placentas, as well 
as in the serum of PE patients, utilizing Egfl7 in a diagnostic test for PE may 
prove beneficial. Future studies involve developing an ELISA test to detect 
EGFL7 in maternal serum of patients throughout pregnancy to determine if it is 
suitable for diagnostic use.   
 
Identifying the EGFL7 signaling pathway in the placenta will be important for 
understanding the functional role of Egfl7 during normal placental development 
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and potentially the pathogenesis of PE. In chapter 4 I have demonstrated that 
knockout of Egfl7 in mice results in altered placental vascular patterning and 
reduced placental perfusion. Together with results from transcriptome analysis,  
these studies provided insights into possible molecular mechanisms by which 
Egfl7 could be working in the placenta. It is evident that Egfl7 affects immune 
regulation and signaling, which play a critical role in immune tolerance during 
normal pregnancy and has been implicated in PE (18, 19). Interestingly, Notch 
signaling was largely unchanged in Egfl7 KO placentas at E12.5, despite its 
known modulation by Egfl7 in other vascular beds, as well as in human PE 
placentas and human trophoblast cells in vitro (20-22). Thus, it is likely that 
Egfl7 works through several signaling pathways to exert its effects on placental 
development, or that Egfl7 may function, in part, through modulating Notch 
signaling in the placenta in a stage-dependent manner.  
 
Understanding the cellular and molecular processes that underlie normal 
placentation will shed insight into the pathophysiology of PE and other 
placental pathologies, such as intrauterine growth restriction. To this end, 
future studies are underway to determine if Egfl7 knockout results in the 
presentation of PE-like symptoms of elevated blood pressure, proteinuria, and 
global endothelial dysfunction.  
 
5.4 –Conclusion 
 
Collectively, the studies presented in this thesis have elucidated novel roles for 
Egfl7 during organogenesis of the pancreas and the placenta. Studies 
presented here reveal that Egfl7 stimulates pancreatic progenitor proliferation 
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and pancreatic development in addition to regulating vascular patterning and 
perfusion in the placenta. These studies have carefully determined Egfl7-
specific function during development of endocrine organs by utilizing mouse 
models that maintain miR-126 expression, a microRNA embedded in the non-
coding region of the Egfl7 gene. Notably, these results reveal that 
dysregulation of Egfl7 has implications in common diseases such as diabetes 
and preeclampsia. Endothelial-derived EGFL7 increases the number of 
pancreatic progenitor cells produced during step-wise differentiation of hESC 
into functional beta cells. These findings enhance the strategy to produce 
sufficient numbers of functional beta cells for transplantation into diabetic 
patients. Furthermore, downregulation of Egfl7 early in gestation, its detection 
in maternal serum, and its function in fetoplacental vascular patterning and 
perfusion make it a candidate for diagnosing and/or treating PE. Future studies 
on Egfl7 function during pancreatic and placental development will reveal the 
potential of using Egfl7 for diagnostic and therapeutic purposes.  
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